Document:

EXHIBIT 10.65

 

		[***]	Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

Confidential

EXECUTION VERSION

 

DEVELOPMENT AND LICENSE AGREEMENT

 

This DEVELOPMENT AND
LICENSE AGREEMENT (together with the exhibits hereto, the “Agreement”) is entered into as of March 11, 2010
(the “Effective Date”) by and between Theraclone Sciences, Inc., a corporation organized and existing under
the laws of the State of Delaware, USA and having its principal office at 1124 Columbia Street, Suite 300, Seattle, Washington,
98104, USA (“Theraclone”) and Zenyaku Kogyo Co., Ltd., a corporation organized and existing under the laws of
Japan and having its principal office at 6-15 Otsuka, 5-Chome, Bunkyo-Ku, Tokyo 112-8650, Japan (“ZKC” or “Zenyaku”).

 

RECITALS

 

WHEREAS, Theraclone has
scientific expertise, proprietary information and biological materials related to identifying, cloning, and characterizing human
monoclonal antibodies from human tissues;

 

WHEREAS, ZKC has expertise
in developing and commercializing prophylactic and therapeutic products;

 

WHEREAS, Theraclone
and ZKC entered into the Exclusive Option Agreement dated September 29, 2009 (the “Option Agreement”), ZKC has
elected to exercise the option set forth in the Option Agreement, and the parties desire to further collaborate in the development
of prophylactic and therapeutic products for the prevention and treatment of influenza infection, as well as companion diagnostics
to such prophylactic and therapeutic products;

 

WHEREAS, in connection
with the Collaboration, Theraclone has agreed to license to ZKC in the territory described below certain intellectual property
rights related to the Licensed Products and Licensed Antibodies (as both terms are defined below), all as set forth in and subject
to the terms and conditions of this Agreement; and

 

WHEREAS, in addition,
Theraclone and Zenyaku wish to provide for a certain right of first refusal for Zenyaku for certain peptide mimetics operating
via the same targets as those of the Licensed Antibodies, as more particularly provided for below.

 

NOW, THEREFORE, for
and in consideration of the mutual observance of the covenants hereinafter set forth and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

    	1

    	 

    

 

AGREEMENT

 

1.                 
Definitions.

 

All references to particular
Exhibits, Articles and Sections shall mean the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise specified.
References to this “Agreement” include the Exhibits. For the purposes of this Agreement, the following words and phrases
shall have the following meanings and derivative forms (e.g., the singular shall be interpreted to be one of the items defined
in the plural and vice versa; provided, however, if a word or phrase does not have its first letter(s) capitalized then
it shall not have the following meaning) of them shall be interpreted accordingly:

 

“Additional
Technology” shall have the meaning set forth in Section 4.1(c).

 

“Affiliate”
of an entity that is a party to this Agreement means, for so long as one of the following relationships is maintained, any corporation
or other business entity owned by, owning, or under common ownership with such party to this Agreement to the extent of at least
fifty percent (50%) of the equity (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in
a particular jurisdiction) having the power to vote on or direct the affairs of the entity and any person, firm, partnership, corporation
or other entity actually controlled by, controlling or under common control with a party to this Agreement, where “control”
means majority ownership or the actual power to elect or direct the management or policies of the entity, whether by law, contract
or otherwise.

 

“BLA”
shall mean Biologics License Application.

 

“Clinical-and-Beyond
Licensed Antibodies” shall mean all Licensed Antibodies that have actually been in clinical development and are actually
commercialized, in each case as therapeutics and/or prophylactic products under this Agreement.

 

“Clinical
Regulatory Filings” means data, filings or materials relating to Licensed Antibody or Licensed Product submitted to the
United States Food and Drug Administration or other applicable Regulatory Authorities, including (a) data derived from clinical
trials, and (b) data, filings or materials relating to or contained in any CMC or DMF.

 

“Collaboration”
shall mean the joint collaboration of Theraclone and ZKC pursuant to the terms of this Agreement.

 

“Commercial
Launch” shall mean the first revenue-generating sale of Licensed Product after Regulatory Approval (determined on a Licensed
Product-by-Licensed Product basis) in the Territory by ZKC or an Affiliate of ZKC or a Sublicensee of ZKC.

 

“Commercially
Reasonable Efforts” shall mean the level of efforts required to carry out a task in a diligent and sustained manner without
undue interruption, pause or delay; which level is at least commensurate with the level of efforts that a biopharmaceutical company
of similar size and resources would devote to a product of similar potential and having similar commercial and scientific advantages
and disadvantages resulting from the company’s own research efforts, taking into account the product’s safety and efficacy;
the competitiveness of alternative products; the product’s proprietary position; pricing; reimbursement; scientific, technical
and regulatory matters; and all other relevant commercial factors.

 

    	2

    	 

    

 

“Control”
shall mean, with respect to any Know-How, Patent, or other materials as set forth herein, possession (other than pursuant to this
Agreement) by a party, directly or through an Affiliate controlled by such party (whether by ownership or license) of the ability
to grant a license, sublicense, or other rights as provided for in this Agreement without violating the terms of any written agreement
with any Third Party which written agreement exists as of the Effective Date, or, with respect to Third-Party Know-How, Patents
or other materials newly in-licensed after the Effective Date, which agreement was entered into in order to obtain rights to such
Third-Party Know-How, Patents or other materials newly in-licensed after the Effective Date (but excluding contracts with Other
Licensees and Sublicensees, because contracts with Other Licensees and Sublicensees must be consistent with the terms and conditions
of this Agreement and in particular must meet the requirements set forth in Sections 4.4 and 4.6 of this Agreement). This definition
of “Control” shall not be read to diminish Theraclone’s obligations to obtain rights from Other Licensees nor
Zenyaku’s obligations to obtain rights from Sublicensees as provided for elsewhere in this Agreement.

 

“Cover”
shall mean, with respect to a particular item and a particular Patent, that such Patent claims or covers (a) the composition of
such item, any of its ingredients or formulations or any product containing or that is made using such item (by virtue of such
product containing or being made using such item); (b) a method of making or using any of the foregoing things referred to in (a);
and/or (c) an item used or present in the manufacture of any of the foregoing things referred to in (a) (for example, with respect
to a biologic, any vector, plasmid or cell line used to manufacture such product or item or any ingredient in either of them).

 

“Damages”
shall have the meaning set forth in Section 16.1.

 

“Development
Plans” shall have the meaning set forth in Section 2.1.

 

“Diagnostic
Product” shall mean any Licensed Product that is not a pharmaceutical or biopharmaceutical composition.

 

“Distributor”
shall mean any Third Party that purchases Licensed Product from ZKC, its Affiliates or Sublicensees for further resale, which purchaser
(i) pays ZKC, its Affiliates or Sublicensee a transfer price (established at arms-length and in accordance with generally accepted
business practices in the industry in the Territory) for such Licensed Products that is independent of the price at which such
purchaser resells Licensed Products (i.e., such purchaser does not pay net sales royalties to ZKC, its Affiliates or Sublicensees
measured off of the resale price by such purchaser) and (ii) does not pay ZKC any other amounts or consideration in any way related
to the Licensed Products.

 

“Dollars”
or “$” shall mean U.S. Dollars.

 

“General Diagnostics”
shall mean any and all diagnostic uses and purposes, other than Therapeutic Drug Monitoring.

 

    	3

    	 

    

 

“Generic Version”
shall mean a product that has been Regulatorily Approved for sale based on a demonstration of biosimilarity or bio-equivalence
to a Licensed Product, including all products that actually do rely on or reference or refer to the efficacy or approval data of
the Licensed Product marketed by Zenyaku (or its Affiliate or Sublicensee). For clarity, a Generic Version must compete for binding
with a Licensed Antibody from a Licensed Product and the amino acid sequence of the Generic Version must be identical to the amino
acid sequence of the Licensed Antibody.

 

“HA”
shall mean any hemagglutinin as expressed on any Influenza Virus.

 

“ICH”
shall mean The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human
Use.

 

“Influenza
Virus” shall mean any of the influenza viruses in the family Orthomyxoviridae, including influenza A, influenza B, and
influenza C.

 

“Joint Commercialization
Committee” or “JCC” shall have the meaning set forth in Section 3.1(b).

 

“Joint Inventions”
shall have the meaning set forth in Section 9.

 

“Joint Patents”
shall mean all Patents that claim Joint Inventions. In no event shall Joint Patents include or be deemed to include Theraclone
Patents or ZKC Patents.

 

“Joint Steering
Committee” or “JSC” shall have the meaning set forth in Section 3.1(a).

 

“Know-How”
shall mean all technical information, materials and know-how, including inventions, discoveries, trade secrets, specifications,
instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids, strains, samples, analytical
tools, libraries, clones and the like), methods, protocols, and expertise and other technology applicable to formulations, compositions
or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes
for their manufacture, formulations containing them or compositions incorporating or comprising them, and including all biological,
biochemical, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing,
assay, preclinical and clinical data, instructions, processes, formula, and expertise, other than that which is set forth in a
published Patent.

 

“Licensed
Antibodies” shall mean (a) the human monoclonal antibodies identified in Exhibit A attached hereto, and (b) all
antibodies directed to, raised against or that bind to M2e and/or HA discovered by or for Theraclone (or its Affiliate) or the
Patents Covering which or Know-How pertaining to which are owned or Controlled by any of the foregoing, in each case at any time
(including prior to or as of the Effective Date or at any time during the term of this Agreement). To avoid doubt, the term “antibody”
as used in this definition and this Agreement includes both full-length antibodies, fragments thereof (that contain the complementarity-determining
region (or “CDR”), and chemically modified versions thereof (including pegylated versions and regardless of whether
containing amino acid substitutions)), all of the foregoing whether naturally occurring, artificially produced, raised in an artificial
system, or created through modification of an antibody produced in any of the foregoing ways or otherwise.

 

    	4

    	 

    

 

“Licensed
Field” shall mean the Licensed Therapeutic/Prophylactic Field and Therapeutic Drug Monitoring.

 

“Licensed
Product” shall mean a product that contains one (1) or more Licensed Antibodies.

 

“Licensed
Therapeutic/Prophylactic Field” shall mean treatment of and prophylaxis of infection (in humans and animals).

 

“License Agreement”
shall mean an agreement or arrangement between Theraclone (or its Affiliate) and any Third Party pursuant to which the Third Party
obtains rights of any kind with respect to Licensed Antibody(ies) or Licensed Product(s) in the Licensed Field for the Retained
Territory or any subset thereof (including license rights, assignment of intellectual property, covenant not to sue, or an option
for any of the foregoing). If an Affiliate that is not 100% owned by Theraclone (or does not 100% own Theraclone) is the marketing
party, then such Affiliate is, for purposes of this definition and all contexts where it is used, deemed to be a Third Party.

 

“Licensing
Proceeds” shall mean (i) all upfront payments received by Theraclone from a Third Party pursuant to a License
Agreement, (ii) all milestone payments received by Theraclone pursuant to such a License Agreement and (iii) all other
payments received by Theraclone pursuant to a License Agreement except excluding only: payments for supply of Licensed
Product and including in this exception up to a [***] markup on the fully
burdened costs of supply for bulk or vialed product (as more fully described in Section 8.1 below) (and any amounts in excess
of such [***] markup are specifically included in Licensing Proceeds), royalty
payments calculated as a percentage of product sales, payments for equity in Theraclone at then-current fair market value of
such equity (specifically excluding the amount of any premiums; the amount of any such premium shall be included in Licensing
Proceeds), loans (except to the extent forgiven; all forgiven amounts are included in Licensing Proceeds), bona fide research
and development funding at reasonable and customary rates, funding for then-future research and development expenses
(including fully loaded costs of personnel), and reimbursement of past or future patent prosecution and maintenance expenses,
and reimbursement of other, future (after execution of the applicable License Agreement) costs and expenses.

 

“M2e”
shall mean the ectodomain of M2 protein as expressed on Influenza Virus.

 

“Net Sales”
shall mean the amount invoiced by ZKC, its Affiliates or its Third Party Sublicensee(s), as applicable, for the sale to a Third
Party of a Licensed Product in the Territory, less the following deductions for amounts actually incurred related to such sale
and included in the gross amount invoiced: (a) normal, customary trade discounts (including volume discounts), credits, chargebacks,
reductions, and rebates; (b) allowances and adjustments for rejections, recalls, outdated products or returns (in each event whether
voluntary or required); (c) freight, shipping, insurance, sales, use, excise, value-added, consumption and similar tariffs, taxes
or duties imposed on such sale; (d) credits actually given or allowances actually made for wastage replacement, Medicare/Medicaid
or other government rebates, indigent patient, compassionate use and similar programs to provide Licensed Product on at-cost (or
lower) basis, to the extent actually deducted from the gross amount invoiced and either not required to be paid by or refunded
to the customer or other payor; and (e) allowances taken for bad debt and uncollectible accounts. If there is overlap between any
of deductions (a) through (e), each individual item shall only be deducted once in each Net Sales calculation.

 

*Confidential Treatment Requested.

 

    	5

    	 

    

 

“Net Sales”
amounts shall be determined in accordance with the generally accepted accounting principles commonly employed by ZKC and/or its
Affiliates with respect to the country of sales, consistently applied.

 

“Net Sales”
shall not include sales of Licensed Product between either ZKC and its Affiliates or between ZKC (and its Affiliates), on the one
hand, and Sublicensee(s) on the other hand, unless such Affiliate(s) or Sublicensee(s), as the case may be, do or does not use
the quantities of Licensed Product in one of the following ways: for clinical trials, for resale, as marketing samples, for stability
studies or other research use, or for indigent patient programs, compassionate use or other charitable purposes.

 

“Net Sales”
shall include sales by Zenyaku, its Affiliates and Sublicensees to Distributors (and any other monetary compensation paid by such
Distributors to Zenyaku, its Affiliates or Sublicensees), but shall not include amounts invoiced by Distributors to their customers.
“Net Sales” shall also include any monetary compensation not invoiced but received and related to the sale of Licensed
Products, except to the extent set forth otherwise in this Agreement.

 

To avoid doubt, “Net
Sales” shall not include the distribution of Licensed Product for compassionate use, indigent patient programs, use in
pre-clinical and clinical trials, or use in research performed in connection with the Development Plans, provided that ZKC does
not receive any monetary compensation for such use.

 

To avoid doubt, “Net
Sales” shall not include the distribution of samples without charge by ZKC (or its Affiliates or Sublicensees), regardless
of the purpose.

 

“Other Licensee”
shall mean the Third-Party counterparty to each License Agreement.

 

“Other Licensed
Antibodies” shall mean all Licensed Antibodies other than the Clinical-and-Beyond Licensed Antibodies.

 

“Other Licensed
Antibodies Available For General Diagnostics Licenses” shall mean Licensed Antibodies which cannot become Clinical-and-Beyond
Licensed Antibodies as determined in accordance with the mechanism set forth in Section 3.5 below.

 

“Patent”
shall mean any patent application or patent anywhere in the world, including all of the following kinds: provisional, utility,
divisional, continuation, continuation-in-part, and substitution applications; and utility, re-issue, re-examination, renewal and
extended patents, and patents of addition, and any Supplementary Protection Certificates, restoration of patent terms and other
similar rights.

 

    	6

    	 

    

 

“Pending Claim”
shall mean, subject in all cases to Section 4.1(h), a claim of an unissued, pending patent application included in the Theraclone
Patents, which claim is being prosecuted in good faith and claims a first priority of no more than five (5) years prior to the
date on which pendency is determined.

 

“Phase I Clinical
Trial” means human clinical trials, the principal purpose of which is preliminary determination of safety and pharmacokinetics
in healthy individuals or patients as required by 21 C.F.R. 312.21(a) or similar clinical study in a country other than the USA.

 

“Phase II
Clinical Trial” human clinical trials conducted in a limited number of patients for the purpose of preliminary evaluation
of clinical efficacy and safety, and/or to obtain an indication of dosage regimen required as more fully defined in 21 C.F.R. 312.21(b)
or similar clinical study in a country other than the USA.

 

“Phase III
Clinical Trial” means human clinical trials, the principal purpose of which is to establish safety and efficacy in patients
with or at risk for the disease being studied as required by 21 C.F.R. 312.21(c) or similar clinical study in a country other than
the USA. Phase III shall include any other human clinical trial intended as a pivotal trial for Regulatory Approval purposes whether
or not such trial is a traditional Phase III (e.g., a Phase II/II1 clinical trial).

 

“Product Inventions”
shall mean any and all patentable inventions that constitute, or that are necessary or useful for the manufacture, development
(including testing) or commercialization of, any Licensed Antibodies or Licensed Products, including (a) their composition, (b)
any method of manufacturing, using (including methods of administration) or testing (in the case of testing, of or for the presence
of) any of the foregoing, and/or (c) any article necessary or useful to practice (including those present during the practice of)
any method referred to in clause (b).

 

“Regulatory
Approval” means final regulatory approval (including, where applicable, pricing approval in the event that actual approvals
do not take place before such approval) required to market a Licensed Product for a disease or condition in accordance with the
applicable laws and regulations of a given country or territory.

 

“Regulatory
Authority(ies)” shall mean the United States Food and Drug Administration or any successor agency thereto (the “FDA”)
and its applicable foreign counterparts responsible for the review or licensure of Licensed Product(s).

 

“Retained
Territory” shall mean worldwide, but excluding the Territory.

 

“Returned
Royalty Territory” shall mean China, Hong Kong, India, South Korea, Taiwan, Indonesia, Thailand, the Philippines, Malaysia,
Singapore and Vietnam.

 

“Royalty Term”
shall have the meaning set forth in Section 5.8.

 

“Safety Data”
means adverse event information and other information (if any) required by one (1) or more Regulatory Authorities to be reported
to such Regulatory Authorities under applicable laws.

 

    	7

    	 

    

 

“Sublicense
Agreement” or “Sublicensing Agreement” shall mean a written sublicense agreement between ZKC (or its
Affiliate) and a Third Party pursuant to which ZKC grants to the Third Party rights to practice under the Theraclone Patents, the
Joint Patents, and/or the Theraclone Know-How rights granted to ZKC in Section 4.1, to research, develop, use, have used, sell,
offer for sale, have sold, keep and/or import the Licensed Product in the Licensed Field in the Territory. If an Affiliate that
is not 100% owned by ZKC (or does not 100% own ZKC) is the marketing party, then such Affiliate is, for purposes of this definition
and all contexts where it is used, deemed to be a Third Party.

 

“Sublicensee”
shall mean any Third Party with whom ZKC executes a Sublicense Agreement. The term “Sublicensee” always excludes, however,
an entity that meets the definition of “Distributor,” provided that the entity is not an Affiliate of Zenyaku.

 

“Sublicensing
Proceeds” shall mean (i) all upfront payments received by ZKC pursuant to a Sublicense Agreement, and (ii) all milestone
payments received by ZKC pursuant to a Sublicense Agreement to the extent in excess of the milestone payments that are otherwise
payable by ZKC to Theraclone pursuant to Article 5 of this Agreement, and (iii) all other payments received by ZKC pursuant to
a Sublicense Agreement except excluding only: (a) (x) to the extent that ZKC is purchasing the supply of Licensed Product from
Theraclone, the transfer price paid by ZKC to Theraclone for such Licensed Product (and explicitly excluding any markup over such
transfer price paid by Sublicensee to ZKC; such markups are specifically included in Sublicensing Proceeds), and (y) to the extent
that ZKC is manufacturing or controls the manufacture of Licensed Product, payment for supply of Licensed Product and including
in this exception up to a [***] markup on the fully burdened costs of supply for
bulk or vialed product (and any amounts in excess of such [***] markup are specifically
included in Sublicensing Proceeds), (b) royalty payments calculated as a percentage of product sales, (c) payments for equity
in ZKC at then-current fair market value of such equity (specifically excluding the amount of any premiums; the amount of any
such premium shall be included in Sublicensing Proceeds), (d) loans (except to the extent forgiven; all forgiven amounts are included
in Sublicensing Proceeds), (e) bona fide research and development funding at reasonable and customary rates, (f) funding for then-future
research and development expenses (including fully loaded costs of personnel), (g) reimbursement of past or future patent prosecution
and maintenance expenses, and (h) reimbursement of other, future (after execution of the applicable Sublicense Agreement) costs
and expenses.

 

“Supply Agreement”
shall have the meaning set forth in Section 8.1.

 

“Territory”
shall mean Japan.

 

“Theraclone”
shall mean Theraclone Sciences, Inc., more particularly identified in the opening paragraph of this Agreement.

 

“Theraclone
Development Plan” shall have the meaning given in Section 2.1.

 

“Theraclone
Inventions” shall have the meaning set forth in Section 9.

 

“Theraclone
Know-How” shall mean all Know-How Controlled by Theraclone or any of its Affiliates that is necessary or useful for the
manufacture, development (including testing) or commercialization of Licensed Antibody(ies) or Licensed Products. For the purpose
of clarity, notwithstanding any other provision in this Agreement, Theraclone Know-How shall not include Theraclone’s proprietary
methods for B cell activation in vitro and for antibody discovery.

 

*Confidential Treatment Requested.

 

    	8

    	 

    

 

“Theraclone
Listed Patents” shall mean (a) all Patents listed in Exhibit C; (b) all patent applications (including provisional and
utility applications) claiming priority to or common priority with or based on any of the foregoing, including all divisionals,
continuations, continuations-in-part, patents of addition and substitutions of any of the foregoing; (c) all patents issuing on
any of the foregoing, and all reissues, reexaminations, renewals and extensions of any of the foregoing; (d) all counterparts to
the foregoing in other countries; and (e) all Supplementary Protection Certificates, restoration of patent term and other similar
rights of Theraclone and its Affiliates based on any of the foregoing.

 

“Theraclone
Patents” shall mean (a) the Theraclone Listed Patents, (b) all Patents that claim Theraclone Inventions, and (c) all
other Patents Controlled by Theraclone or any of its Affiliates as of the Effective Date or at any time during the term of this
Agreement that Cover Licensed Antibody or Licensed Product. Theraclone Patents exclude ZKC Patents and Joint Patents.

 

“Therapeutic
Drug Monitoring” shall mean diagnostic uses limited solely to (a) patient qualification for treatment or prophylaxis
with Licensed Product (e.g., testing to see whether the patient is infected with a virus to which the Licensed Antibody of the
Licensed Product binds) and/or (b) patient monitoring in the course of treatment or prophylaxis with Licensed Product.

 

“Third Party(ies)”
shall mean any party other than a party to this Agreement or an Affiliate thereof.

 

“Valid Claim”
shall mean, subject in all cases to Section 4.1(h), a claim of an issued, unexpired patent included in the Theraclone Patents that
has not been (a) held invalid or unenforceable by a final decision of a court or governmental agency of competent jurisdiction,
which decision is unappealable or was not appealed within the time allowed therefor or (b) admitted in writing to be invalid or
unenforceable by the holder(s) by reissue, disclaimer or otherwise.

 

“ZKC”
or “Zenyaku” shall mean Zenyaku Kogyo Co., Ltd., more particularly identified in the opening paragraph of this
Agreement.

 

“Zenyaku Development
Plan” shall have the meaning given in Section 2.1.

 

“ZKC Inventions”
shall have the meaning set forth in Section 9.

 

“ZKC Know-How”
shall mean all Know-How Controlled by ZKC (or any of its Affiliates) that is necessary or useful for the manufacture, development
(including testing) or commercialization of Licensed Antibody(ies) or Licensed Products.

 

“ZKC Patents”
shall mean all Patents that claim ZKC Inventions. ZKC Patents exclude Theraclone Patents and Joint Patents.

 

    	9

    	 

    

 

The words “include,”
“includes,” “including” and other conjugations of “to include” shall be deemed followed by
“without limitation” regardless of whether written there (and drawing no implications from inconsistent usage).

 

2.                 
Development; Development Plans; Information Exchange.

 

2.1             
Commencing on the Effective Date, the parties shall collaborate in the development and commercialization of the
Licensed Products in the Licensed Field. The bulk of the initial activities and responsibilities for the development of the Licensed
Products in the Licensed Field are to be primarily performed by Theraclone, because Theraclone will be developing for the United
States (and other areas of the Retained Territory), and the parties intend that ZKC’s development of Licensed Product for
the Territory will follow in time and be based on the results obtained in Theraclone’s development for the United States
and/or in countries whose Regulatory Authorities subscribe to (and in accordance with the guidelines established by) the ICH. The
program of activities to be conducted by Theraclone during the term of the Agreement is set forth on Exhibit D-1 (the “Theraclone
Development Plan”). Zenyaku shall provide to Theraclone within three (3) months after Theraclone doses the first patient
in a Phase III Clinical Trial in a country whose Regulatory Authorities subscribe to (and in accordance with the guidelines established
by) the ICH, Zenyaku’s draft written plan for its program of development activities in the Territory (“Zenyaku Development
Plan”). This draft that Zenyaku provides shall be the version that Zenyaku plans to present to and discuss with the Japanese
Regulatory Authority. Promptly after such presentation and discussion, Zenyaku shall, based on the feedback (if any) from such
Regulatory Authority, update the Zenyaku Development Plan and share the updated version with Theraclone. The Zenyaku Development
Plan shall be reviewed at least on an annual basis by the Joint Steering Committee as set forth in Section 3.2. Prior to submitting
the Zenyaku Development Plan to Theraclone, ZKC shall use good faith efforts to provide an update at each JSC meeting regarding
ZKC’s potential development strategies for the Licensed Product in the Territory. For clarity, the Zenyaku Development Plan
(and in general, Zenyaku’s development activities) shall be limited to activities within the Territory. In addition, if Zenyaku’s
protocols or endpoints differ from those of the clinical trials of the Theraclone Development Plan, Zenyaku shall present to the
JSC Zenyaku’s proposed protocols and endpoints; the parties shall seek to reach consensus in the JSC; and in any event Zenyaku
shall be permitted to adopt protocols and endpoints as needed to meet regulatory requirements in the Territory or any requirements
of the Regulatory Authority in the Territory. The Theraclone Development Plan and the Zenyaku Development Plan are the “Development
Plans.” The Theraclone Development Plan includes a development plan setting forth the activities currently contemplated
by the parties to be performed in developing the Licensed Products for the U.S. Anything herein to the contrary notwithstanding,
the timelines included in the Theraclone Development Plan are non-binding and shall function as guidelines for the development
of Licensed Products and may be modified from time-to-time as set forth in Section 3.2. The parties agree that the end goal of
the Development Plans shall be the expeditious clinical development and regulatory approval of the Licensed Products as necessary
for the import, manufacture, marketing and/or sale thereof in the Territory in the Licensed Field consistent with each party’s
obligations in Article 7. No material deviation in the subject matter and scope of the Theraclone Development Plan shall be made
without the mutual written agreement of both parties except as set forth in this Agreement.

 

    	10

    	 

    

 

2.2             
ZKC shall have the right, subject to the terms and conditions of this Agreement, including, without limitation,
Section 3 and Article 7, to determine the non-clinical, preclinical and clinical development and commercialization plan for the
Licensed Antibodies and Licensed Products in the Territory. For purposes of clarity, Zenyaku has the right to develop a combination
product (i.e., a product that includes more active ingredients than one Licensed Antibody), but if Zenyaku chooses to do so, and
Theraclone (or its licensee, sublicensee or Affiliate) is not developing such combination product for the Retained Territory, then
the costs and activities associated with clinical development, manufacturing development, formulation, and pre-clinical testing
for use and/or sale of such combination Licensed Product for the Territory shall be solely borne by ZKC and be ZKC’s sole
responsibility. Any cost of additional manufacturing requirements and testing that must be performed to meet specific and unique
requirements in the Territory for the use and/or sale of the Licensed Products in the Territory shall be solely borne by ZKC (provided
that these have been pre-approved in writing by Zenyaku).

 

2.3             
Theraclone shall provide ZKC access to Theraclone Know-How (to avoid doubt, including manufacturing, non-clinical
and clinical data, and regulatory filings Controlled by Theraclone) that are necessary or useful for the Licensed Product in the
Licensed Field, and shall cause its Affiliates and, to the extent required (whether in writing or orally) by the Japanese Regulatory
Authorities, any Third Party(ies), including, but not limited to, Theraclone’s additional partner(s) other than ZKC (i.e.,
all Other Licensees) for the Licensed Products in the Licensed Field controlling any such manufacturing, non-clinical and clinical
data and regulatory filings to make such access available to ZKC, subject to the confidentiality obligations set forth in Section
11, as more particularly provided for in Sections 2.6-2.9. ZKC shall reimburse Theraclone for all out-of-pocket costs (to be clear,
specifically excluding any internal costs such as personnel time) associated with providing such assistance. In addition, on an
ongoing basis as requested by ZKC, Theraclone shall provide ZKC with regular reports of Theraclone’s performance of the activities
assigned to it in the Development Plans, and access to any Theraclone Controlled underlying raw data, case report forms, laboratory
notebooks or other original documents regarding such reports if requested by ZKC, for use by ZKC to determine if ZKC wishes to
continue making the research and development funding payments set forth in Section 5.1(b). These regular reports shall be written
summaries, in a form reasonably acceptable to ZKC. The frequency of such reports shall be determined by the JSC, and in any event
shall be at least quarterly.

 

2.4             
ZKC shall provide Theraclone access to ZKC Know-How (to avoid doubt, including manufacturing, non-clinical and
clinical data, and regulatory filings Controlled by ZKC that are necessary or useful for the Licensed Product in the Licensed Field),
and shall also cause its Affiliates and any Sublicensees controlling any such manufacturing, non-clinical, and clinical data and
regulatory filings to make such access available to Theraclone, subject to the confidentiality obligations set forth in Section
11, as more particularly provided for in Sections 2.6-2.9. Theraclone shall reimburse ZKC for all out-of-pocket costs (to be clear,
specifically excluding any internal costs such as personnel time) associated with providing such assistance.

 

2.5             
In addition to its performance of the activities assigned to it in the Development Plans, Theraclone shall perform
(or have performed by the contractors identified in the following plans) the M2e and HA mimetic research activities outlined in
Exhibit E-1 and Exhibit E-2. On an ongoing basis as requested by ZKC, Theraclone shall provide ZKC with regular reports
of Theraclone’s performance of such activities. These reports shall be written summaries in a form reasonably acceptable
to ZKC. The frequency of such reports shall be determined by the JSC, but in any event at least quarterly. Theraclone shall, to
the extent Controlled by Theraclone (and Theraclone shall use commercially reasonable efforts to gain Control of all such data,
reports, notebooks, and documents) provide ZKC access to any underlying raw data, research reports from contractors, laboratory
notebooks or other original documents regarding such reports if requested by ZKC, at no additional cost to ZKC, for use by ZKC
to determine if ZKC wishes to exercise its right of first refusal set forth in Section 4.2. To avoid doubt, ZKC has the right to
receive all data resulting from the research plans (to the extent Controlled by Theraclone) set forth on Exhibits E-1 and E-2 at
no additional cost.

 

    	11

    	 

    

 

2.6             
Sharing of Clinical and Other Data. Once clinical development has been initiated by either party, from
time to time (but no less frequently than annually, in advance of the Joint Steering Committee meeting(s) closest to September)
each of ZKC and Theraclone shall disclose to the other a written summary, in a form reasonably acceptable to both parties, of clinical
data with respect to Licensed Antibodies in the Licensed Field and Licensed Products in the Licensed Field generated by or under
authority of such party since the last such disclosure. It is understood that ZKC’s and Theraclone’s obligation to
provide summaries under this Section 2.6 can be fulfilled by providing a copy of the annual report describing clinical development
with respect to Licensed Antibodies in the Licensed Field and Licensed Products in the Licensed Field conducted by or on behalf
of such party, including any that such party (or others acting under its authority, including Sublicensees and Other Licensees)
is requested to provide to Regulatory Authorities in its territory (each an “Annual Regulatory Report”). Upon
the request of ZKC or Theraclone, the other shall provide prompt and complete access to and the right to use for purposes of the
activities for which such requesting party is licensed under this Agreement any Clinical Regulatory Filings and Safety Data generated
by such party, its Affiliates, its Sublicensees and its Other Licensees; provided that in any such case the requesting party
provides notice to the other party reasonably in advance and reimburses the other party for any reasonably incurred costs of satisfying
the request. (To be clear, this regards costs of providing access, not costs of generating the clinical data.) Each party must
include its Sublicensees’ Clinical Regulatory Filings data (in the case of Zenyaku) and its Other Licensees’ Clinical
Regulatory Filings data (in the case of Theraclone) in such party’s Annual Regulatory Reports (but only to the extent that
such data is required (whether in writing or orally) to be provided by the relevant Regulatory Authorities for such party’s
territory) (or cause the Sublicensee or Other Licensee to provide such a report to Zenyaku or Theraclone, as the case may be),
and provide access to its Sublicensees’ or Other Licensees’ Clinical Regulatory Filings on the same basis as if the
Sublicensees or Other Licensees were such party. If requested by either party, the Joint Steering Committee shall discuss such
Annual Regulatory Reports. In addition to the Annual Regulatory Report, Clinical Regulatory Filings and Safety Data required to
be shared as stated above in this Section 2.6, if necessary (because it is required (whether in writing or orally) by the applicable
Regulatory Authority(ies)) for a party or its Affiliate, Sublicensee or Other Licensee to have access to certain of the underlying
raw data, case report forms or other original documents (including laboratory notebooks) generated by or on behalf of the other
party (or its Affiliates, Sublicensees and Other Licensees (collectively with such other party, the “Possessing Entities”)),
then, to the extent required (whether in writing or orally) by such Regulatory Authority(ies), the Possessing Entities shall provide
copies, or if required, access to the originals, of such items. The requesting party shall reimburse the providing party for all
out-of-pocket costs (to be clear, specifically excluding any internal costs such as personnel time) associated with providing such
assistance.

 

    	12

    	 

    

 

2.7             
Records. Each of ZKC and Theraclone shall maintain complete and accurate records of all work (including
research, development, clinical, manufacturing and commercialization) it conducts (itself or through its Affiliates or Third Parties
(including in Theraclone’s case Other Licensees and in Zenyaku’s case Sublicensees)) under this Agreement and all results,
data and developments made pursuant to its efforts under this Agreement. Each of ZKC and Theraclone shall use commercially reasonable
efforts to gain Control of all such reports, results, data and developments of its Other Licensees (in Theraclone’s case)
and Sublicensees (in Zenyaku’s case). Such records shall be complete and accurate and shall fully and properly reflect all
work done and results achieved in the performance of this Agreement in sufficient detail and in good scientific manner appropriate
for Patent and regulatory purposes.

 

2.8             
Access to Records. Each of ZKC and Theraclone shall have the right to review and copy the records of the
other party (that are Controlled by such other party) described in Section 2.7 (including raw data and scientific notebooks, to
the extent provided for under Section 2.7) at reasonable times to the extent necessary for it to conduct its activities in its
respective territory or exercise its rights under this Agreement and at the reviewing party’s expense (including compensating
the other party for reasonable associated out-of-pocket costs and expenses). With respect to filings made to a Regulatory Authority
(including applications for INDs, Regulatory Approval applications and the like), both parties shall make available to the other
original documentation of such records in connection therewith. Each of Theraclone and Zenyaku shall have the right to use such
records of the other party for purposes of the development or commercialization of any Licensed Product or Licensed Antibody (including
the filing of Regulatory Approval applications) in its respective territory during the Term. In general, both in this Section and
in relation to all other Sections under which Zenyaku provides documents and information under this Agreement, Zenyaku shall not
be required to translate such documents and information into English (or into any other language), except solely that Zenyaku shall
provide a courtesy, unofficial English version of the following: (i) meeting minutes with the Japanese Regulatory Authority and
an integrated summary of safety and efficacy data, and (ii) ZKC’s (or its Affiliate’s or Sublicensee’s) Annual
Regulatory Report, Clinical Regulatory Filings and Safety Data. Such translation shall be at no cost to Theraclone. In general,
both in this Section and in relation to all other Sections under which Theraclone provides documents and information under this
Agreement, Theraclone shall not be required to translate such documents and information into Japanese (or into any other language),
except solely that Theraclone shall provide a courtesy, unofficial English version of the following: (i) meeting minutes with any
and all Retained Territory Regulatory Authorities and an integrated summary of safety and efficacy data, and (ii) Theraclone’s
(or its Affiliate’s or Other Licensee’s) Annual Regulatory Report, Clinical Regulatory Filings and Safety Data. Such
translation shall be at no cost to Zenyaku.

 

2.9             
Communications with Regulatory Authorities. Each of ZKC and Theraclone shall keep the other party informed
on an ongoing basis at Joint Steering Committee meetings regarding its (or its Affiliate’s, Sublicensee’s or Other
Licensee’s) regulatory strategy, planned regulatory submissions and material communications with Regulatory Authorities with
respect to all Licensed Antibodies and Licensed Products in its respective territory. Subject to Zenyaku’s rights below in
this paragraph, Zenyaku, its Affiliates and Sublicensees, on the one hand, and Theraclone, its Affiliates and Other Licensees on
the other hand, shall not, during the term of this Agreement, communicate with Regulatory Authorities of the other party’s
territory regarding any Licensed Antibody or Licensed Product without such party’s advance written consent, such consent
not to be unreasonably withheld, delayed or conditioned. However, each party shall provide the other party with reasonable advance
notice of any meeting or pre-scheduled, material, substantive telephone conference with any Regulatory Authority relating to any
Licensed Product or Licensed Antibody. Each party may request, and, only with permission of the party who is conducting the meeting
or teleconference with the Regulatory Authority of its respective territory, shall have the right to attend and observe (but not
participate actively in) any material meeting or material conference call with any Regulatory Authority regarding any of the other
party’s (or its Affiliate’s, Sublicensee’s, or Other Licensee’s) Licensed Products or Licensed Antibody.
In addition, each party shall promptly furnish to the other party copies of all correspondence that the furnishing party (or its
Affiliate, Sublicensee or Other Licensee) receives from, or submits to, any Regulatory Authority (including contact reports concerning
conversations or substantive meetings) relating to any Licensed Product or Licensed Antibody. The furnishing party shall also provide
to the other party any meeting minutes that reflect material communications with any Regulatory Authority regarding a Licensed
Product or Licensed Antibody. Minutes of material communications with the Japanese Regulatory Authority will be translated into
English, but materials actually corresponded with the Japanese Regulatory Authority are not required to be translated into English.

 

    	13

    	 

    

 

Each of Theraclone
and ZKC shall allow the other to attend all of their clinical investigators’ meetings, and will use commercially reasonable
efforts in good faith to cause the Other Licensees and Sublicensees, as appropriate, to allow the parties to attend all of such
Other Licensees’ and Sublicensees’, as appropriate, clinical investigators’ meetings. By way of background, it
is anticipated that through joint meetings of the JSC of this Agreement and the steering committees that each party may have with
its Sublicensees and Other Licensees, that the worldwide development program for Licensed Antibodies and Licensed Products will
be conducted in such a manner that allows for all developing parties worldwide to confer with each other and have an opportunity
to reach consensus as to clinical development worldwide.

 

2.10         
Regulatory Assistance. Beyond the information sharing provided for above in this Article, at Zenyaku’s
request, Theraclone shall provide advice and reasonable assistance to Zenyaku with respect to Zenyaku’s filings with Regulatory
Authorities for the Territory. This advice and assistance shall be provided free of charge -- as regards internal or personnel
costs -- up to four (4) Theraclone person hours per calendar month. To be clear, time spent by Theraclone personnel to support
an audit of Theraclone’s (or its manufacturers’) facilities by Zenyaku or the Regulatory Authority in the Territory
shall not be counted toward the foregoing allotment of Theraclone person hours. All (a) external costs of providing such advice
and assistance (e.g., travel and lodging expenses of any Theraclone personnel who travel to Japan under this Section), and (b)
personnel costs for Theraclone person hours exceeding the free-of-charge hours described above, shall be reimbursed to Theraclone
by Zenyaku within 30 days after invoiced by Theraclone to Zenyaku.

 

    	14

    	 

    

 

3.                 
Joint Steering Committee.

 

3.1             
As set forth below, the parties will establish a Joint Steering Committee and a Joint Commercialization Committee.
Each of the Joint Steering Committee and the Joint Commercialization Committee shall have no power to amend, modify or waive compliance
with this Agreement. Each such committee shall have only such powers as are specifically set forth in this Agreement for such committee
to perform. The minutes of the Joint Steering Committee and the Joint Commercialization Committee, regardless of whether signed
by representatives of both parties, shall not be deemed to amend, modify or waive compliance with this Agreement.

 

(a)              
A Joint Steering Committee (the “Joint Steering Committee” or “JSC”) shall
be established within thirty (30) days after the Effective Date. During the period beginning on the Effective Date and ending on
the earlier of (i) the date on which all Regulatory Approvals have been obtained in the Territory, and (ii) a date mutually agreed
by the parties if they reach mutual written agreement for a later date (the “Development Period”), the Joint
Steering Committee shall consist of four (4) members, two (2) individuals appointed by Theraclone and two (2) individuals appointed
by ZKC. The Joint Steering Committee shall meet quarterly in person or via teleconference or video conference as set forth in Section
3.2. During the Development Period, the Joint Steering Committee shall be responsible for, among other things, facilitating ongoing
cooperation and information exchange between the parties, discussing potential coordination of activities under the Development
Plans and communicating each party’s direction of all research activity related to the Licensed Products by the parties.

 

(b)              
Upon the timing set forth in Section 3.3, a Joint Commercialization Committee (the “Joint Commercialization
Committee” or “JCC”) shall be established and maintained. The Joint Commercialization Committee shall
consist of five (5) members, three (3) individuals appointed by ZKC and two (2) individuals appointed by Theraclone, and shall
be chaired by an individual from ZKC. The Joint Commercialization Committee shall meet on the frequency as set forth in Section
3.3. The Joint Commercialization Committee shall be responsible for, among other things, allowing the parties an opportunity for
regular coordination in the Territory and the Retained Territory of: reimbursement policies, product positioning and marketing
and such other related and ancillary activities as may be agreed. The Joint Commercialization Committee provides an opportunity
for the parties to coordinate and share ideas in these areas, but does not have decision making authority regarding the matters
that come before it.

 

3.2             
Development Reports. To facilitate coordination during the Development Period, all reports and data generated
under the Development Plans by or for each of ZKC and Theraclone shall, subject to the limitations set forth in Article 2, be shared
with each other on a prompt and regular basis at meetings of the Joint Steering Committee, to be held every three (3) months either
in person, alternatively in Seattle, Washington or Tokyo, Japan, or via teleconference or video conference as may be determined
by the Joint Steering Committee taking into account the desire for both parties to manage travel expenses. At least one (1) JSC
meeting per year shall be in person, alternating between Seattle, Washington and Tokyo, Japan.

 

The Joint Steering
Committee shall review the Development Plans at least annually. The Joint Steering Committee may make recommendations related to
possible Development Plan extensions and/or expansions to the respective senior management teams of each party. The Joint Steering
Committee shall be responsible (subject to the qualification at the end of this sentence) for all development decisions (including,
but not limited to the initiation and termination of specific projects) with respect to the Retained Territory, that affect activities
up to and including dosing of the first patient in a Phase III Clinical Trial of Licensed Product in a country whose Regulatory
Authorities subscribe to (and in accordance with the guidelines established by) the ICH, if the decision involves a material change
to the Theraclone Development Plan, as it exists at signing of this Agreement, or as it may be updated by the Joint Steering Committee
or otherwise with Zenyaku’s consent. This includes selection of one or more Licensed Antibody(ies) for clinical development
directed against M2e (the first such antibody selected for development, and any back-up or replacement such antibody selected for
development, the “Lead M2e Candidate Antibody”) and one or more Licensed Antibody(ies) for clinical development
directed against HA (the first such antibody selected for development, and any back-up or replacement such antibody selected for
development, the “Lead HA Candidate Antibody”) and the authority to determine if and when to cease clinical
development of such Lead M2e Candidate Antibody and such Lead HA Candidate Antibody. It is understood and agreed that, subject
to Section 7.2, Theraclone shall conduct activities at least commensurate with those set forth in the Theraclone Development Plan
as of the Effective Date, and the fact that JSC consensus is needed for any material update to the Theraclone Development Plan
as results are obtained (for example, positive and negative results or any results that may cause a back-up or replacement antibody
to become the new Lead M2e Candidate Antibody or Lead HA Candidate Antibody) shall not be used as a means for Theraclone by withholding
consensus or consent to conduct less development work than what is set forth in the Theraclone Development Plan as of the Effective
Date. Also, nothing in this Section is intended to suggest that the JSC cannot approve a combination product Licensed Product (for
example, one combining an anti-M2e Licensed Antibody and an anti-HA Licensed Antibody) for development by Theraclone under an updated
Theraclone Development Plan approved by the JSC; this is permitted if the JSC reaches consensus as to the matter. ZKC shall have
sole discretion over all decisions with respect to the development and commercialization of Licensed Products in the Territory,
including all aspects of the Zenyaku Development Plan, without any need for approval or further action by the Joint Steering Committee,
but, to be clear, without lessening Zenyaku’s obligations in Article 7; provided, however that the Zenyaku Development Plan
(and in general, Zenyaku’s development activities) shall be limited to activities within the Territory and shall be at ZKC’s
cost and expense. If Zenyaku desires to start development activities in the Territory prior to the Start Time (as defined below
in Section 7.1), then Zenyaku may do so in its sole discretion provided that it has discussed in advance the ZKC Development Plan
with the JSC.

 

    	15

    	 

    

 

All actions by the
Joint Steering Committee shall require the approval by a majority of its members, and approval of any and all actions shall require
participation of a majority of all members of the Joint Steering Committee, and approval by majority shall require the affirmative
vote of at least one member appointed by each of the parties. In the event any actions of the Joint Steering Committee are not
approved within a reasonable period of time, the Chief Executive Officers of the parties (or his designee) shall enter into good
faith discussion on any such actions by the Joint Steering Committee and seek to reach an amicable decision or outcome, as soon
as is practicable. The availability of these CEO (or designee) discussions as a way of finding consensus shall not expand the decisionmaking
authority of the JSC, nor prevent either party from ultimately invoking dispute resolution under Article 12, nor subject to dispute
resolution any decisions that are reserved to a party or the parties (such as, but not limited to, development decisions regarding
development for the Territory, provided that Zenyaku makes such decisions in compliance with its obligations in Article 7; another
example is development decisions for the Retained Territory by Theraclone affecting only activities after dosing of the first patient
in a Phase III Clinical Trial in a country whose Regulatory Authorities subscribe to (and in accordance with the guidelines established
by) the ICH, provided that Theraclone makes such decisions in compliance with its obligations in Article 7).

 

    	16

    	 

    

 

3.3             
Commencing in the year prior to the first anticipated commercial launch anywhere in the world for the first Licensed
Product, and continuing until two (2) years after the last Commercial Launch in the Territory, the Joint Commercialization Committee
shall meet at least once every twelve (12) months and at any other time reasonably requested by ZKC, at a mutually agreed location,
or via teleconference or video conference, to review and discuss the commercialization progress and plans with respect to the Licensed
Product(s) in the Territory (by or for ZKC) and in the Retained Territory (by or for Theraclone). In conjunction with the foregoing
meetings, each party shall provide the other party with annual written summary reports on the progress of commercialization, including
activities related to the marketing and the Commercial Launch of the Licensed Product(s) in the Territory (by or for ZKC) and activities
related to the marketing and the commercial launch of the Licensed Product(s) in the Retained Territory (by or for Theraclone).
All such information shall be subject to the confidentiality provisions of Section 11 of this Agreement. The Joint Commercialization
Committee has no decision making authority. It will serve as a forum in which the parties may coordinate and explore the possibility
of consensus between the parties in commercial matters (to the extent permitted by law), but it is not empowered to make decisions
or to take actions.

 

3.4             
Theraclone shall use commercially reasonable efforts to make arrangements such that the joint committee(s) under
its collaboration(s) (whether current or future) with Other Licensees shall meet in joint session with the JSC of this Agreement,
at least annually, and more frequently if mutually agreed by all of the relevant entities.

 

3.5             
Theraclone may submit a list of Licensed Antibodies to the JSC and/or to ZKC which Therelone proposes cannot
become Clinical-and-Beyond Licensed Antibodies and therefore would be designated as Other Licensed Antibodies Available For General
Diagnostics License. If such a list is submitted to the JSC at least thirty (30) days prior to the next JSC meeting then the JSC
shall discuss which of such Licensed Antibodies should be designated as Other Licensed Antibodies Available For General Diagnostics
License and try to agree on which Licensed Antibodies should be designated as such. If, after the later of (i) two (2) quarterly
JSC meetings at which the matter is discussed, and (ii) nine (9) months after such list of Licensed Antibodies is submitted by
Theraclone to ZKC (the “Parties’ Deadline”), the parties have not reached agreement regarding which of
the Licensed Antibodies on such list should be designated as Other Licensed Antibodies Available For General Diagnostics License,
then the parties shall engage an independent person with at least fifteen (15) years in senior management positions in the biopharmaceutical
industry, including positions with responsibility for development and commercialization of diagnostics. Such person (the “Technology
Expert”) shall not be affiliated with or be an advisor to either of the parties. If the parties cannot agree as to who
the Technology Expert shall be within twenty (20) days after the expiration of the Parties’ Deadline, then the mechanism
for selecting such person shall be the same as that used with the Patent Expert in Section 4.1(c). The Technology Expert is instructed
not to designate as Other Licensed Antibodies Available For General Diagnostics License any Licensed Antibodies that are
reasonable back-up candidates for the Licensed Therapeutic/Prophylactic Field. The parties shall accept the Technology Expert’s
determination (which shall be binding on the parties) as to which of the listed Licensed Antibodies should be designated as Other
Licensed Antibodies Available For General Diagnostics License, and the standard that the Technology Expert shall apply in making
the decision shall be: If it is beyond a reasonable doubt that a Licensed Antibody will not become a Clinical-and-Beyond Licensed
Antibody then such Licensed Antibody will be designated as a Other Licensed Antibodies Available For General Diagnostics License.
Except as set forth in this Section 3.5, the procedures that shall be used with the Technology Expert shall be the same as those
used with the Patent Expert in Section 4.1(c).

 

    	17

    	 

    

 

4.                 
License Grants; Rights Of First Negotiation.

 

4.1             
License.

 

(a)              
Subject to the terms and conditions of this Agreement, including, without limitation, Sections 5 and 6 hereof,
Theraclone hereby grants to ZKC an exclusive, royalty-bearing (as in Article 5) license (with the right to grant sublicenses through
one or multiple tiers in accordance with Sections 4.3 and 4.6) under the Theraclone Patents, Theraclone Know-How and Theraclone’s
interest in the Joint Patents to research, develop, use, sell, have sold, offer to sell, import and export:

 

(i)                
Licensed Antibodies and Licensed Products in the Territory for the Licensed Therapeutic/Prophylactic Field;

 

(ii)              
Clinical-and-Beyond Licensed Antibodies and Diagnostic Products containing them in the Territory for Therapeutic
Drug Monitoring and General Diagnostics; and

 

(iii)            
Other Licensed Antibodies and Diagnostic Products containing them in the Territory for Therapeutic Drug Monitoring.

 

Notwithstanding the above, the immediately
foregoing license in clause (iii) (immediately preceding this sentence) shall be non-exclusive. In addition, Zenyaku hereby covenants
that it and its Affiliates and the Sublicensees shall not practice the license with respect to Clinical-and-Beyond Licensed Antibodies
and Diagnostic Products containing them, in each case, for General Diagnostics. Furthermore, Theraclone hereby covenants that it
and its Affiliates and the Other Licensees shall not seek a label (i.e., Regulatory Approval) of any Diagnostic Product based on
an Other Licensed Antibody, for Therapeutic Drug Monitoring of or in connection with therapeutic and/or prophylactic Licensed Products
of this Agreement.

 

Subject to the terms
and conditions of this Agreement, Theraclone also hereby grants to ZKC during the term of this Agreement, an exclusive license,
with the right to grant sublicenses (through one or more tiers in accordance with Sections 4.3 and 4.6) in the Territory, to use
and display any trademarks under Theraclone’s sole Control in the Territory with regard to Licensed Antibodies (including
Licensed Products) in connection with activities licensed in the first paragraph of this Section.

 

    	18

    	 

    

 

Theraclone acknowledges
that ZKC may, in its sole discretion, register its exclusive license rights under this Agreement with applicable governmental authorities
in the Territory and Theraclone agrees that, if requested by ZKC, it shall cooperate with ZKC to register such license rights.
All costs, fees, and expenses (including compensating Theraclone of its time spent in connection with such activities at Theraclone’s
then standard rates) associated with any such registration, whether incurred by ZKC or Theraclone, shall be borne by ZKC.

 

For avoidance of doubt,
once a Licensed Antibody has been designated an Other Licensed Antibodies Available For General Diagnostics Licenses under Section
3.5 then (notwithstanding any provisions of this Agreement) thereafter ZKC has no General Diagnostic rights in or to such Other
Licensed Antibodies Available For General Diagnostics Licenses.

 

(b)              
Subject to the terms and conditions of this Agreement, including Section 5.6, ZKC hereby grants to Theraclone
during the term of this Agreement a non-exclusive, fully paid-up (with the exception of patent costs for which Theraclone is responsible
under Section 10.1 as regards the ZKC Patents in the Retained Territory), royalty-free license, with the right to grant sublicenses
through one or multiple tiers in accordance with Sections 4.4 and 4.6, under the ZKC Patents and ZKC Know-How to research, develop,
use, have used, sell, offer for sale, have sold, keep, import, export, make and have made Licensed Antibodies and Licensed Products
for the Licensed Field in the Retained Territory or to make and have made Licensed Antibodies and Licensed Products anywhere in
the world for supply to Zenyaku and Theraclone’s Other Licensees, all to the extent that ZKC has the right to grant licenses
thereunder on the terms and conditions of this Agreement.

 

(c)               
Without making any admission as to the Coverage or lack of Coverage of the Patents licensed hereunder, and without
indicating any concern or making any admission regarding any given Third-Party intellectual property known to the parties as of
the Effective Date, if Theraclone or ZKC believes that technology related to the subject matter hereof is controlled by a Third
Party, which technology may be valuable to the commercialization of the Licensed Products hereunder (“Additional Technology”;
Additional Technology may include formulation, use, dosing regimen, manufacturing or other intellectual property), Theraclone or
ZKC as appropriate shall present such Additional Technology to the Joint Steering Committee. All Joint Steering Committee discussions
of Additional Technology shall be conducted with legal counsel (whether from the party’s in-house legal department or outside
counsel to such party, as elected by such party) present, so as to maintain legal privilege for the discussions, and the parties
shall reasonably cooperate to take such other reasonable measures as may be advised by counsel in order to maintain such privilege
(such as, but not limited to, entering into a customary common interest/joint defense agreement prior to commencing any such discussions,
or refraining from stating opinions regarding Patent Coverage, validity and enforceability in writing). The Joint Steering Committee
shall then determine whether licenses to, and/or acquisitions of, such Additional Technology should be made for the Territory,
the party that shall approach and negotiate with any such Third Party(ies) and the terms of any agreement(s) with any such Third
Party(ies). All costs and expenses to be incurred in connection with obtaining such a license or acquisition for the Territory
shall be subject to approval of the JSC, irrespective of which party is selected to negotiate with such Third Party(ies). No such
Third Party license and/or acquisition shall be effective with respect to ZKC or Theraclone, as the case may be, unless and until
ZKC or Theraclone, as the case may be, specifically agrees in writing to abide by the applicable terms and conditions of any such
license and/or acquisition (which terms are consistent with this Agreement), and to make such payments and/or royalties as are
mutually agreed by the parties. Nothing set forth in this Section 4.1(c) shall limit the ability of either party to procure technology
for their own account or for license to Third Parties, provided, however, that in the case of Additional Technology the parties
shall first have completed the determination set forth above and determined that such Additional Technology will not be licensed
or acquired pursuant to this Section.

 

    	19

    	 

    

 

Notwithstanding the
foregoing, for Third-Party Patent or Know-How licenses or acquisitions signed within three (3) years after the Effective Date
(“First-3-Years Additional Technology”) (i) the parties hereby agree that ZKC shall be solely responsible for
the first [***] of Third Party royalties that are payable on annual Net Sales of
a Licensed Product (determined on a Licensed Product-by-Licensed Product basis) in the Territory for First-3-Years Additional
Technology, and Theraclone shall be solely responsible for Third Party royalties that are payable on annual Net Sales of a Licensed
Product in the Territory for First-3-Years Additional Technology in excess of such [***]
(determined on a Licensed Product-by-Licensed Product basis), (ii) in the event that any such agreements include upfront
payments, milestone payments, or any other form of payments (other than royalties), then all such payments and the party responsible
for making such payments shall need to be approved by the JSC prior to entering into any agreement for such Additional Technology,
and (iii) notwithstanding the above, ZKC shall be free from (and Theraclone shall solely bear) such royalty payment for additional
Third Party technology which is obtained after the third anniversary of the Effective Date (i.e., all Additional Technology other
than First-3-Years Additional Technology).

 

The mechanism set forth
in the following paragraph shall only be applicable if the JSC cannot agree as to obtaining a license to some Additional Technology
in connection with the commercialization of a Licensed Product in the Territory. If, after at least two (2) quarterly meetings
at which the matter is discussed, the JSC cannot agree as to whether any item of Additional Technology should be licensed for the
Territory, then they shall engage an experienced patent attorney mutually acceptable to the parties -- and who does not otherwise
perform work for either party or any of its Affiliates and is not affiliated with them -- (a “Patent Expert”)
to advise the parties and make the decision. They shall engage such Patent Expert within thirty (30) days after the second such
quarterly meeting at which consensus is not reached, if requested in writing by either party. (If the parties cannot agree as to
who such attorney shall be within such time period, then the total of two (2) nominees of the parties (one from each party) shall
select a third Patent Expert who shall be the attorney to resolve the dispute. If such two (2) people cannot agree on the third
person, then the arbitral body referred to in Article 12 shall select the Patent Expert who shall be the attorney to advise the
parties and make the decision.) The parties shall share equally the expenses incurred for the services of such Patent Expert. The
parties shall manage the engagement of the Patent Expert in a manner so as best to protect the privilege of the advice rendered
by the Patent Expert and the parties’ communications with the Patent Expert. Within fifteen (15) days after engaging the
Patent Expert, the parties shall each submit up to twenty (20) pages of documentation to the Patent Expert. Within five (5) business
days thereafter, the parties shall convene a discussion with the Patent Expert during which each party may orally present its position
as to the desirability of licensing the Additional Technology for no more than two (2) hours. The parties shall require the Patent
Expert to render his or her guidance as to the desirability of licensing the Additional Technology within five (5) business days
after the oral presentations. No party shall engage in any communications with the Patent Expert in which the other party is not
included or copied. The parties shall accept and follow the Patent Expert’s guidance on the desirability of licensing the
Additional Technology. The Patent Expert shall also decide which party shall be the licensing party for Additional Technology that
the Patent Expert advises and decides should be licensed. The standard that the Patent Expert shall apply in making the decision
whether any item of Additional Technology should be licensed shall be: If a license under Additional Technology is reasonably required
in order to avoid claims of patent infringement that are reasonably likely not to be discussed at a preliminary summary judgment
stage, then the Additional Technology should be licensed.

 

*Confidential Treatment
Requested.

 

    	20

    	 

    

 

(d)              
Without limiting or altering subsection (c), prior to in-licensing any Additional Technology for the Territory,
Zenyaku shall confer with Theraclone in order to learn from Theraclone whether Theraclone desires rights for the Retained Territory.
If Theraclone does, and agrees to pay all financial obligations for the Retained Territory, then Zenyaku (if it is the licensing
party) shall use commercially reasonable efforts to try to include in the in-license rights for Theraclone’s use for the
Retained Territory.

 

(e)               
Each sublicense or license under Additional Technology granted by a party to the other party under this Agreement
shall be subject to the terms and conditions of the in-licensing or acquiring party’s agreement with the Third Party governing
the in-licensing or other acquisition of the rights, provided such terms and conditions are consistent with this Agreement.

 

(f)               
If the JSC has decided to license any Additional Technology, or the Patent Expert has decided that the parties
shall license any Additional Technology, and that Theraclone shall be the licensing party, then: Theraclone shall obtain Control
of such Additional Technology for at least the Territory in the form of an agreement reviewed and approved by Zenyaku prior to
signing (such approval not to be unreasonably withheld, delayed or conditioned); if such Additional Technology falls within the
First-3-Years Additional Technology and within the [***] limit stated in paragraph
(c), then Zenyaku shall be responsible for royalties under the license for such Additional Technology up to the cap of [***]
of Net Sales in the Territory aggregated across all First-3-Years Additional Technology (“Zenyaku Additional Technology
Costs”) and shall reimburse Theraclone promptly on a quarterly basis for such Net Sales royalties for which Zenyaku
is responsible; and Theraclone shall be responsible for all other payments to the licensor. If Theraclone fails to license the
Additional Technology as decided by the JSC or the Patent Expert within six (6) months after the decision, then Zenyaku is entitled
to take the license for the Territory and to credit all payments to the licensor thereunder, other than the Zenyaku Additional
Technology Costs, against payments due Theraclone under this Agreement.

 

(g)              
If the JSC has decided to license any Additional Technology, or the Patent Expert has decided that the parties
shall license any Additional Technology, and that Zenyaku shall be the licensing party, then Zenyaku shall in-license the Additional
Technology for the Territory and shall be entitled to credit all payments to the licensor under the in-license, other than the
Zenyaku Additional Technology Costs, against payments due Theraclone under this Agreement.

 

*Confidential Treatment Requested.

 

    	21

    	 

    

 

(h)              
Even if Theraclone is the licensing party, the claims of Patents in Additional Technology are never considered
Valid Claims or Pending Claims under this Agreement and are not royalty-bearing to Theraclone under this Agreement.

 

4.2             
Right of First Refusal Regarding Mimetic Research. With respect to all Know-How, and all Patents on inventions
in each case developed or invented in connection with the M2e and HA mimetic research as described in Section 2.5, or any product
candidate or product discovered or suggested in such research or in any research funded by the research extension payments in subsection
(b) below (“Mimetics IP/Candidates”), Zenyaku shall have a right of first refusal as follows:

 

(a)              
A “Potential Mimetics Transaction” is a transaction for the grant of a license, sublicense
or covenant not to sue; sale; assignment; or other transfer to a Third Party (or grant to a Third Party of an option for any of
the foregoing rights) with respect to any Mimetics IP/Candidate(s) in the Territory.

 

(b)              
The “ROFR Period” is the time from Zenyaku’s receipt of the final report of data from
the research under Section 2.5 until [***]. Up to [***]
times, Zenyaku may extend the ROFR Period by one year by paying Theraclone an additional [***]
in research and development funding for M2e Mimetics IP/Candidates or HA Mimetics IP/Candidates (or both) for each extension (so
that the longest the ROFR Period may become is [***] for either M2e Mimetics IP/Candidates
or HA Mimetics IP/Candidates, or both). To be clear, Zenyaku may elect to extend the ROFR Period with respect to (i) Potential
Mimetics Transactions pertaining to M2e Mimetics IP/Candidates (in which case Zenyaku would pay [***]
per extension), (ii) Potential Mimetics Transactions pertaining to HA Mimetics IP/Candidates (in which case Zenyaku would pay [***]
per extension), or (iii) Potential Mimetics Transactions pertaining to both M2e Mimetics IP/Candidates and HA Mimetics IP/Candidates
(in which case Zenyaku would pay [***] per extension). To avoid doubt, Theraclone
shall provide ZKC with any and all updates to the data regarding Mimetics/IP Candidates.

 

(c)               
During the ROFR Period, Theraclone shall not grant any rights outside the Territory as part of or in connection
with a Potential Mimetics Transaction (i.e., shall not mix Territory and ex-Territory rights in the same transaction), whether
or not having followed the procedures in the remainder of this Section first, notwithstanding anything implied to the contrary
below.

 

(d)              
If during the ROFR Period, Theraclone decides, intends, or will negotiate terms (including responding to inquiries
initiated by another) of a Potential Mimetics Transaction, Theraclone shall first notify ZKC in writing. Without limiting Section
5.5, Theraclone shall state in such notice the following items regarding such Potential Mimetics Transaction: identify the product
candidate(s), the licensed field, and the economics so that ZKC may evaluate the Potential Mimetics Transaction. ZKC shall have
sixty (60) days to determine if ZKC wishes to negotiate with Theraclone the terms of the Potential Mimetics Transaction.

 

(e)               
Prior to the end of such 60 days, Theraclone and its Affiliates shall not discuss the Potential Mimetics Transaction
(including negotiating terms) with any Third Party, unless Zenyaku earlier indicates in writing it declines to discuss the Potential
Mimetics Transaction with Theraclone.

 

*Confidential Treatment Requested.

 

    	22

    	 

    

 

(f)               
If Zenyaku timely notifies Theraclone in writing that Zenyaku chooses to negotiate the terms of any given Potential
Mimetics Transaction, then the parties shall negotiate in good faith, and exclusively with each other, such terms for a period
of one hundred twenty (120) days. During this time, both parties shall be reasonably available for discussion, both parties shall
respond in a reasonably time to term sheets and drafts, and Theraclone shall not discuss or negotiate terms for such Potential
Mimetics Transaction with any Third Party.

 

(g)              
If the parties reach agreement during such one hundred twenty (120) days, then they shall sign the definitive
written agreement (which shall be substantially in the form of this Agreement, excepting the economics and other non-relevant provisions
-- e.g., this Section 4.2) for the potential Mimetics Transaction within that one hundred twenty (120) days.

 

(h)              
If the parties fail to reach written agreement within such one hundred twenty (120) days, then Theraclone shall
be entitled to discuss such Potential Mimetics Transaction with Third Parties, and in the following twelve (12) months may conclude
an agreement with a Third Party for such Potential Mimetics Transaction provided that Theraclone shall not enter into any agreement
with any Third Party on terms more favorable to the Third Party than the terms in Theraclone’s notice in subsection (d) or
the last proposal by Theraclone in the negotiations in subsection (f), nor less favorable to Theraclone than Zenyaku last offered
to Theraclone in the negotiations of subsection (f) in all cases, for such Potential Mimetics Transaction. If Theraclone does not
sign the definitive agreement with the Third Party within such twelve (12) months, then, during the remainder of the ROFR Period,
Zenyaku’s rights under this Section shall again apply to such Potential Mimetics transaction.

 

(i)                
Subsections (d) - (h) apply individually to each and every Potential Mimetics Transaction.

 

After the ROFR Period,
Zenyaku shall have a right of first notice as to all Potential Mimetics Transactions as follows: If Theraclone decides, intends,
or will negotiate terms (including responding to inquiries initiated by another) of a Potential Mimetics Transaction, Theraclone,
thirty (30) days prior to negotiating with any Third Party with respect to such transaction, shall first notify ZKC in writing
(providing in such notice the identity of the product candidate(s) and the licensed field(s) and the economics that Theraclone
would propose to ZKC). Thereafter, if ZKC wishes to negotiate with Theraclone as to such transaction, then Theraclone agrees to
negotiate in good faith with ZKC regarding such transaction. After the ROFR Period, Theraclone is not required to sell Territorial
rights separately from extra-Territorial rights to Mimetics IP/Candidates.

 

4.3             
Sublicenses by ZKC in the Territory. In any Sublicense to a Third Party for the grant of rights under
this Article 4 ZKC will to the fullest extent applicable, (i) include provisions at least as favorable to Theraclone for the protection
of Theraclone’s rights and the limitation of Theraclone’s liability exposure as the terms of this Agreement, including
without limitation with respect to limitation of liability and indemnification, and (ii) contain provisions for the Sublicensee
to accommodate all rights and obligations due to Theraclone by ZKC contained in this Agreement with respect to record-keeping,
Theraclone’s audit rights and the grant of further sublicenses of the Sublicensed rights. ZKC shall ascertain, calculate,
audit, and collect all royalties and other payments that become payable in relation to Sublicensee hereunder and take or not take
(as determined in ZKC’s sole discretion) applicable enforcement action against such Sublicensee for any failure to pay or
to properly calculate payments, or for any other material breach of such Sublicense Agreement. No Sublicense shall relieve ZKC
of its obligations hereunder, including, but not limited to, ZKC’s obligation to pay Theraclone the milestone payments, royalty
payments, share of Sublicensing Proceeds, patent expenses payments, and other payments set forth herein, on the same terms set
forth herein such that Theraclone will receive at least what would have been due to Theraclone as if ZKC had completed the applicable
milestones, or made sales of Licensed Product(s) or Licensed Antibodies, as were completed and made under the Sublicense Agreement
by the Sublicensee. Any purported Sublicense in violation of this Section 4.3 shall be void. ZKC shall furnish Theraclone a copy
of each Sublicense Agreement within fifteen (15) days of entering into such agreement for Theraclone’s records; provided
that ZKC may appropriately redact such Sublicense Agreement to remove information not directly relevant to determining compliance
with Theraclone’s rights under this Section.

 

    	23

    	 

    

 

4.4             
Sublicenses by Theraclone Outside the Territory. In any sublicense to a Third Party by Theraclone for
the grant of rights by ZKC to Theraclone under this Article 4, Theraclone will, to the fullest extent applicable (i) include provisions
at least as favorable to ZKC for the protection of ZKC’s rights and the limitation of ZKC’s liability exposure as the
terms of this Agreement, including without limitation with respect to limitation of liability and indemnification, and (ii) contain
provisions for the sublicensee to accommodate all rights and obligations due to ZKC by Theraclone contained in this Agreement with
respect to record- keeping, ZKC’s audit rights and the grant of further sublicenses of the sublicensed rights. Any purported
sublicense in violation of this Section 4.4 shall be void. Theraclone shall furnish ZKC a copy of each sublicense agreement within
fifteen (15) days of entering into such agreement for ZKC’s records; provided that Theraclone may appropriately redact such
sublicense agreement to remove information not directly relevant to ZKC’s rights under this Section. To avoid doubt, this
Section applies mutatis mutandis to all License Agreements.

 

4.5             
If during the term of this Agreement Theraclone creates a partnership outside the Territory with a company that
shows interest in the Territory, and if ZKC is interested in discussing with such company regarding Sublicensing the Licensed Product
in the Territory, then ZKC may enter into such discussions in good faith with such company and Theraclone shall fully assist ZKC.
Zenyaku shall have no obligation to grant or discuss a Sublicense to any Third Party.

 

4.6             
Coordination of Sublicenses and Rights of Other Licensees with this Agreement.

 

(a)              
Zenyaku shall ensure that its agreements with Sublicensees are consistent with and impose obligations consistent
with the terms and conditions regarding Sublicensees set forth in this Agreement, including Sections 2.4, 2.6, 2.7, 2.8, 2.9, 4.1(a),
4.3, 4.6, 11.2 and 15.8. Without limiting the generality of the foregoing, Zenyaku shall in particular require its Sublicensees
to make available Clinical Regulatory Filings, Safety Data, and underlying detailed data as required by Section 2.6. In addition
to the foregoing, in any Sublicense Agreement Zenyaku shall obtain ownership of or a sublicenseable license that is exclusive in
the Territory (including the right of sublicensees to further sublicense) to: (i) all Patents claiming inventions developed by
or for the Sublicensee in Licensed Product and/or Licensed Antibody related activities that if invented by Zenyaku would be Zenyaku
Product Inventions (and for purposes of this Agreement they shall be deemed to be Zenyaku Product Inventions); and (ii) all Know-How
developed in such activities that if owned or Controlled by Zenyaku would be Zenyaku Know- How. Information provided by a Sublicensee
(or of a Sublicensee provided by Zenyaku) to Theraclone and its Other Licensees under this Section 4.6(a) shall be the Confidential
Information of Zenyaku licensed to Theraclone in accordance with this Agreement.

 

    	24

    	 

    

 

(b)              
Similarly, Theraclone shall ensure that its agreements with Other Licensees are consistent with and impose on
its Other Licensees obligations consistent with the terms and conditions set forth in this Agreement, including Sections 2.3, 2.6,
2.7, 2.8, 2.9, 3.4, 4.1(a), 4.4, 4.6, 11.2 and 15.9. The last two (2) sentences of Section 4.6(a) shall apply mutatis mutandis
to describe the obligations of Theraclone to obtain intellectual property and data rights from Other Licensees for the Territory.
To avoid doubt, and without limiting the generality of the foregoing, this means that Theraclone must obtain ownership of or a
fully sublicensable license that is exclusive in the Territory under any antibodies directed to, raised against or that bind M2e
and/or HA, discovered by or for the Other Licensee in Licensed Antibody-related or Licensed Product-related activities, including
all of the kinds of antibodies referred to in the definition of Licensed Antibody, including fragments and chemically modified
versions of the types as described in such definition.

 

(c)               
Both parties shall use Commercially Reasonable Efforts to obtain ownership or license rights and Control of all
Know-How generated and all Patents on inventions invented by service providers performing research and/or development for such
party with respect to Licensed Antibodies and/or Licensed Products, which Know-How and Patents would be included in the party’s
Zenyaku Know-How or Theraclone Know-How and ZKC Patents or Theraclone Patents if the applicable Know-How or invention claimed in
such Patent had been generated or invented by such party. Such license rights and Control may be on an exclusive or a non-exclusive
basis.

 

4.7             
Trademarks. Theraclone shall be responsible for the selection, registration and maintenance of the primary,
product-specific trademarks which will be employed in connection with the Licensed Products in the Territory, which product-specific
trademarks shall be the local (in the Territory) version of the worldwide trademarks for the commercialized Licensed Products.
Theraclone shall own and/or Control any such trademarks and shall ensure that such trademarks and use thereof by ZKC in the Territory
does not infringe any rights of Third Parties, provided that prior to selection of such trademarks, Theraclone shall provide ZKC
an opportunity to review and comment on any such trademark together with the results of Theraclone’s non- infringement searches
and analysis related to such trademark and Theraclone shall, in good faith, take ZKC’s comments into consideration in Theraclone’s
selection of such trademarks. Theraclone shall have all trademark infringement liability for trademark infringement by use of the
trademarks referred to above in this Section. In addition to the trademarks referred to above in this Section, it is understood
and agreed that the label for each Licensed Product may include the trademarks and company names of the marketing entity (whether
Zenyaku, its Affiliate, or a Sublicensee or Distributor), and shall -- if requested by Theraclone and legally permitted -- contain
Theraclone’s name or logo (as determined by Theraclone), in a type font or size no smaller (unless otherwise agreed by Theraclone)
and no larger (unless otherwise agreed by Zenyaku) than 50% of the size of the type font in which the marketing entity’s
name is written or size in which such marketing entity’s logo appears, or if smaller, the maximum percentage allowed by applicable
law in the Territory. If a local version of the global Licensed Product-specific trademark is not available or appropriate in Japan
(or would infringe a Third-Party trademark in Japan), then after discussion with Theraclone through the JCC, Zenyaku as the local
company with marketing expertise in Japan shall be entitled to select and own the local Licensed Product trademark, and shall have
any liability for Third Party trademark infringement by such local Licensed Product trademark selected by Zenyaku.

 

    	25

    	 

    

 

5.                 
Payments.

 

The parties agree to make the following
payments to each other in US Dollars by wire transfer of immediately available funds:

 

5.1             
License Fee and Research and Development Funding and Phase I Clinical Trial Funding.

 

(a)              
Within ten (10) business days after the Effective Date, ZKC shall pay to Theraclone a non-creditable, non-refundable
licensing fee of [***] to be made via wire transfer of immediately available funds.

 

(b)              
In addition, ZKC may make the following non-refundable research and development funding payments in the following
amounts in accordance with the progress of development of the Licensed Product and this Section 5.1(b). Without limiting Theraclone’s
reporting obligations under Section 2.3, in order for ZKC to review the progress of development (and to examine the potential of
Licensed Product in the Licensed Field and to evaluate the feasibility in Zenyaku’s opinion of the development and commercialization
program contemplated by this Agreement), commencing on the Effective Date and during the research and development funding payments,
Theraclone shall provide ZKC with a summary report at least forty-five (45) days prior to each payment’s expected date summarizing
the progress of development of the Licensed Product. If ZKC wishes to continue funding Theraclone’s research and development
efforts under the Development Plans, then ZKC shall notify Theraclone within such forty-five (45) day period whether Zenyaku will
make the corresponding research and development funding payment provided in the table below or whether it chooses instead to terminate
its rights to Licensed Antibodies and Licensed Products under this Agreement pursuant to Section 15.3 (which termination is required
if Zenyaku chooses not to make the scheduled payment). If Zenyaku has chosen to continue funding, then it shall make the scheduled
payment within an additional fifteen (15) days. Failure to make the payment under such circumstance shall be actionable by Theraclone
under Section 15.4.

 

*Confidential Treatment Requested.

 

    	26

    	 

    

 

Research and Development Funding
Payments

 

	EXPECTED PAYMENT DATE	AMOUNT (US $) IF ZKC WISHES TO

CONTINUE FUNDING
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

If ZKC wishes to continue
funding as set forth above, the payment amounts set forth above shall be paid directly to Theraclone. [***]
of each of the expected payments for [***] shall be creditable to the payments
due from ZKC for Theraclone’s mimetic research as set forth in Section 5.4. Except as may be passed through to ZKC by means
of the potential ZKC payments as described above, Theraclone shall be responsible for bearing all clinical and development costs
in the United States (and all other costs for the Retained Territory) and ZKC will be responsible for bearing all clinical and
development costs in the Territory.

 

5.2             
Milestone Payments.

 

In addition to the
amounts payable pursuant to Section 5.1 above, ZKC also agrees to pay Theraclone the following milestone payments for the first
Licensed Product to reach each of the following milestones (for purposes of clarity each of the milestone payments shall only be
made once), to be made via wire transfer of immediately available funds, within thirty (30) days following (i) in the event such
milestone is achieved outside of the Territory (by or for Theraclone), ZKC’s receipt of a written notice as well as documentary
evidence of achievement of each of the following milestones, or (ii) in the event such milestone is achieved in the Territory (by
or for Zenyaku or its Affiliate or Sublicensee), achievement of such milestone:

 

	DEVELOPMENT MILESTONES FOR THE FIRST LICENSED PRODUCT TO REACH SUCH MILESTONE	PAYMENT (US $)
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

[***].
Accordingly, a maximum of [***] United States dollars is payable under this Section
5.2.

 

5.3             
Sharing of Sublicensing Proceeds by ZKC.

 

In addition to the
amounts payable pursuant to Sections 5.1 and 5.2 above, ZKC also agrees to pay Theraclone for each Licensed Product, a share of
all Sublicensing Proceeds received by ZKC in connection with Sublicensing Agreements, the amount of which shall be dependent upon
the stage of development of the Licensed Product at the time of execution of the Sublicensing Agreement pursuant to which the Sublicensing
Proceeds are paid, as follows:

 

*Confidential Treatment Requested.

 

    	27

    	 

    

 

	STAGE OF DEVELOPMENT OF LICENSED PRODUCT (ANYWHERE IN THE WORLD) AT TIME OF EXECUTION OF SUBLICENSING AGREEMENT	SHARE OF

SUBLICENSING

PROCEEDS
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

All such payments
shall be made by ZKC to Theraclone via wire transfer of immediately available funds within thirty (30) days of ZKC’s receipt
of the corresponding Sublicensing Proceeds.

 

5.4             
Research Funding for Structured Mimetic of M2e and of HA. By [***],
ZKC shall pay to Theraclone a research funding payment of [***] to cover the research
costs for Theraclone to engage in the research outlined in Exhibit E-1, unless ZKC has made the expected payment for [***]
as set forth in Section 5.1 above, in which case such expected payment shall be fully creditable to the foregoing research funding
payment. By [***], ZKC shall pay to Theraclone a research funding payment of [***]
to cover the research costs for Theraclone to engage in the research outlined in Exhibit E-2, unless ZKC has made the expected
payment for [***] as set forth in Section 5.1 above, in which case such expected
payment shall be fully creditable to the foregoing research funding payment. It is understood and agreed that these payments will
be fully paid by the credits described in Section 5.1 unless this Agreement earlier terminates.

 

5.5             
Milestone Payments for Structured Mimetic of M2e and HA. In the event that ZKC enters into a license agreement(s)
with Theraclone for the structured mimetic for M2e and/or for HA, pursuant to Section 4.2 above (i.e., the parties sign a definitive
agreement for a Potential Mimetics Transaction), then Theraclone hereby agrees that such license agreement(s) will, similar to
Section 5.2 above, limit the milestone payments such that ZKC will only be obligated to make a single milestone payment for each
milestone reached, by the first licensed product to reach it, and no milestone payments shall be due if subsequent licensed products
reach the applicable milestones.

 

5.6             
Payments by Theraclone with respect to the Retained Territory.

 

(a)              
Licensing Proceeds. Theraclone shall pay to Zenyaku a share of Theraclone’s and its Affiliates’
Licensing Proceeds based on the time of receipt by them of the Licensing Proceeds as follows:

 

	TIME OF RECEIPT OF

LICENSING PROCEEDS	PERCENTAGE OF LICENSING

PROCEEDS TO BE PAID TO

ZENYAKU
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

*Confidential Treatment Requested.

 

    	28

    	 

    

 

All such payments
for Licensing Proceeds shall be made by Theraclone to ZKC via wire transfer of immediately available funds within thirty (30)
days of Theraclone’s receipt of such Licensing Proceeds. Theraclone shall provide to Zenyaku, at the time of each such payment,
a report reasonably detailing the nature and calculation of the Licensing Proceeds being paid. Notwithstanding the foregoing,
for Licensing Proceeds in the form of a markup in excess of a [***] markup on the
fully burdened costs of supply for bulk or vialed product (as more fully described in Section 8.1 below), such Licensing Proceeds
shall be reportable and payable on a quarterly basis, within forty-five (45) days after the end of each calendar quarter in which
this form of Licensing Proceeds is received.

 

(b)              
Share of Net Sales Royalties. With respect to royalties on net sales of Licensed Product solely in the
Licensed Field in the Returned Royalty Territory, Theraclone shall pay to Zenyaku [***]
of such royalties received by Theraclone and/or its Affiliates. The mechanics of payment for reporting and payment of such
royalties shall be the same as in Section 6.1, applied mutatis mutandis.

 

(c)               
Licensing Proceeds and Share of Net Sales Royalties Under Certain Assignments of This Agreement. Without
limiting Article 13, if Theraclone (in one or a series of related transactions) sells all or substantially all of its assets to
a Third Party (including any Other Licensee), or enters into any merger or consolidation with or into a Third Party (including
any Other Licensee) other than a merger or consolidation in which the holders of more than fifty percent (50%) of the shares of
capital stock of Theraclone outstanding immediately prior to such transaction continue to hold (either by the voting securities
remaining outstanding or by their being converted into voting securities of the surviving entity) more than fifty percent (50%)
of the total voting power represented by the voting securities of Theraclone or such surviving entity outstanding immediately after
such transaction (the initially mentioned merger or consolidation, an “Acquisition” and the acquiring party,
the “Acquiror”), or such surviving entity enters into an Acquisition, Theraclone shall include as a condition
of such Acquisition that Zenyaku shall receive the following: (i) if the Acquiror is an Other Licensee for all of the Retained
Territory and the License Agreement to which the Other Licensee is a party provides for Licensing Proceeds and royalties on net
sales for which Zenyaku is entitled to receive a share pursuant to subsections (a) and (b) above, Zenyaku shall receive at least
what would have been due to Zenyaku as if such License Agreement had remained in place and all Licensing Proceeds and royalties
had been paid under it, even if as a result of the Acquisition the underlying License Agreement is terminated (e.g., if a big-pharma
Acquiror cancels the License Agreement after acquiring rights through a License Assignment in the form of an acquisition of Theraclone);
and (ii) in all cases other than that of clause (i), if Theraclone at the time retains rights to sell Licensed Products for the
Licensed Field in the Returned Royalty Territory (and thus the Acquiror obtains access to such rights through the Acquisition),
then Theraclone shall require, as part of such Acquisition, that the Acquiror pay to ZKC royalties on annual Net Sales of Licensed
Product (calculated on a Licensed Product-by-Licensed Product and country-by-country basis) for sales in countries in the Returned
Royalty Territory during the applicable Royalty Term and at the base rates set forth in Section 5.7 and subject to the reductions,
adjustments, and Royalty Terms as set forth in Sections 5.7 and 5.8 applied mutatis mutandis, and the mechanics of payment
for reporting and payment of such royalties shall be the same as in Section 6.1, applied mutatis mutandis.

 

*Confidential Treatment Requested.

 

    	29

    	 

    

 

(d)              
Clarification Regarding Assignment. For the sake of clarity with regard to Section 5.6(c)(i) and as a
non-limiting clarification and example, the parties acknowledge that if Theraclone assigns this Agreement, the Patents related
to this Agreement or any interest hereunder, such assignment meets the definition of a License Agreement giving rise to Licensing
Proceeds, and the assigned Patents shall remain wholly subject to the terms and conditions of this Agreement, including the licenses
to Zenyaku.

 

5.7             
Royalties for Licensed Product.

 

(a)              
Base Rates. Royalties on annual Net Sales of Licensed Product (calculated on a Licensed Product-by-Licensed
Product and country-by-country basis during the applicable Royalty Term in each country) in the Territory shall be paid to Theraclone
by ZKC on the timing stated in Section 6.1 as follows:

 

	ANNUAL NET SALES OF LICENSED PRODUCT IN THE TERRITORY	ROYALTY
	[***]	[***]
	[***]	[***]
	[***]	[***]

The royalty rates under
this Section are incremental with respect to the annual Net Sales of the Licensed Product sold in the Territory. For example, by
way of illustration, if annual Net Sales of a Licensed Product in the Territory is [***],
ZKC will owe Theraclone [***], which is equal to: [***].
The royalty rates under this Section shall be subject to reduction in accordance with this Section 5.7.

 

(b)              
Up-to-[***] Reduction for Patent Expiry or Generic or
Biosimilar Competition. Either of the following that is applicable, but not both as to royalties on the same Net Sales, shall
apply:

 

(i)                
Patent Expiry. If there is no Valid Claim due to a Theraclone Patent or Pending Claim due to a Theraclone
Patent Covering a given Licensed Product in the country of sale, the royalty rates under this Section shall be reduced by [***]
of the amounts otherwise payable with respect to Net Sales of such Licensed Product in such country for the remainder of
the Royalty Term in such country.

 

(ii)              
Generic or Biosimilar Competition. If a Generic Version of a Licensed Product enters the market in the Territory,
the royalty rates under this Section shall be reduced by [***] for such Licensed
Product in the Territory for the remainder of the Royalty Term for such Licensed Product in the Territory.

 

(c)               
Combination Product Proportional Adjustment. If any Licensed Product contains one or more active ingredients
(including adjuvants) other than Licensed Antibody(ies) (such other active ingredients, “Other Active Ingredients”
and such a product, a “Combination Product”), then [***]. In the
first instance, [***] shall be as determined reasonably and in good faith by Zenyaku.
Zenyaku shall disclose its determination of these values to Theraclone. Theraclone shall respond within thirty (30) days whether
Theraclone agrees. If Theraclone disagrees, then the parties shall negotiate and either agree on such values in good faith, or,
if thirty (30) additional days after Zenyaku’s original disclosure the parties have not agreed in writing, then they shall,
within thirty (30) days thereafter, engage an independent person with at least fifteen (15) years in senior management positions
in the biopharmaceutical industry, including positions with responsibility for sales and marketing and/or finance. Such person
(the “Valuation Expert”) shall not be affiliated with or be an advisor to either of the parties. If the parties
cannot agree as to who the Valuation Expert shall be within such time period, then the mechanism for selecting such person shall
be the same as that used with the Patent Expert in Section 4.1(c). The procedures that shall be used with the Valuation Expert
shall be the same as those used with the Patent Expert in Section 4.1(c). The Valuation Expert’s findings as to the appropriate
values for A and B shall be binding on both parties absent proven fraud and shall apply retroactively. The standard that the Valuation
Expert shall apply to determine A and B shall be that each should represent the fair market value contribution of the Licensed
Antibody and the Other Active Ingredient(s), respectively, to the value and selling price of the Combination Product.

 

*Confidential Treatment Requested.

 

    	30

    	 

    

 

Royalties on Combination
Products shall be due only on adjusted (as in this subsection) Net Sales, not actual Net Sales; provided, however, in no event
shall adjusted (as in this subsection) Net Sales be less than [***] of actual Net
Sales for purposes of determining royalty payments due under this Agreement.

 

5.8             
Royalty Term. Subject to Section 5.11 of this Agreement and the second sentence of this Section, royalties
shall be earned and paid to Theraclone until the later to occur, on a country-by-country and Licensed Product-by-Licensed Product
basis, of (i) the date the last Valid Claim or Pending Claim Covering such Licensed Product expires (or otherwise ceases to be
a Valid Claim or Pending Claim) in such country, determined on a Licensed Product-by-Licensed Product and country-by-country basis,
and (ii) expiration of ten (10) years from Commercial Launch of such Licensed Product in such country, determined on a Licensed
Product-by-Licensed Product and country-by-country basis (such period, the “Royalty Term” for that Licensed
Product in that country). All Licensed Products containing the same Licensed Antibody(ies) are considered to be a single Licensed
Product for purposes of this Section. In addition, if a Licensed Product is later incorporated into a Combination Product, this
shall not restart the 10-year time period under clause (ii) of this Section.

 

5.9             
Currency. Except as provided in Section 5.10 below regarding currency transfer restrictions, all amounts
payable to Theraclone under this Agreement shall be payable in United States Dollars by wire transfer of immediately available
funds to a bank account designated by Theraclone. Net Sales during a month shall be translated on a monthly basis from Japanese
Yen to US Dollars by using an average rate of exchange of such month. This average shall be computed using the closing Telegraphic
Transfer Selling (TTS) Rate of exchange quoted by the Tokyo-Mitsubishi Bank in Tokyo (or if it no longer exists its successor,
or if no successor to it exists then a similarly reputable financial institution) as of the end of such month plus the rate as
of the end of the prior month and dividing by two (2). A similar exchange mechanism shall be used for sales in other countries
in the Territory.

 

*Confidential Treatment Requested.

 

    	31

    	 

    

 

5.10         
Currency Transfer Restrictions. If payment or transfer of funds out of a country in the Territory shall
be prohibited by law or regulation, the parties hereto shall confer regarding the possibility of payment of royalties to Theraclone
in local currency to a bank account in the prohibited country or the renegotiation of royalties for such sales, and in the absence
of any other agreement by the parties, such funds payable to Theraclone shall be deposited in whatever currency is allowable by
ZKC in an accredited bank in that country that is reasonably acceptable to Theraclone.

 

5.11         
Royalty Payments Upon Termination. The parties’ obligations with respect to payment of royalties
after expiration or termination of this Agreement are set forth in Article 15 below.

 

5.12         
Withholding Tax. All payments made by ZKC under this Agreement shall be made to Theraclone with the deduction
of withholding tax (if any) imposed upon such payment. If requested by Theraclone, ZKC shall cooperate with Theraclone regarding
the accurate characterization of payments so that it may take advantage of any and all benefits under any Japan-US Tax Treaty (or
similar tax treaty for other countries in the Territory) and any filing fees or other governmental fees shall be at the cost and
expense of Theraclone.

 

5.13         
Past Due Amounts. Any past due payments under this Agreement shall accrue interest until paid at the
greater of [***]. Notwithstanding the foregoing, if such rate is greater than the
maximum rate permitted by law, then such rate will be reduced to the maximum rate permitted by law.

 

6.                 
Reports, Payments and Accounting.

 

6.1             
Payments and Reports.

 

(a)              
Beginning with the quarter of the first Commercial Launch in the Territory, ZKC agrees to make written reports
(in a reasonable format) regarding the payments set forth in Section 5.7, to Theraclone within forty-five (45) days after the close
of each calendar quarter during the term of this Agreement until the last Royalty Term expires. These reports shall show for such
calendar quarter sales by ZKC, its Affiliates and Sublicensees of Licensed Product, the aggregate amount of gross invoices, the
aggregate amount of deductions in each category (a)-(e) in the definition of Net Sales in Section 1, Net Sales and the royalties
due to Theraclone pursuant to Section 5.7 and royalties due for Additional Technology pursuant to Section 4.1(c) and Section 4.1(f).
Concurrently with the making of each such report, ZKC shall make payment to Theraclone of (i) amounts payable under Section 5.7
for the period covered by such report and (ii) all other amounts accrued under this Agreement which have not been previously paid
as required, unless otherwise provided hereunder. All payments due to Theraclone by ZKC under this Agreement that are subject to
withholding tax under the laws of Japan shall, in accordance with Section 5.12, be made net of Japanese (or other countries within
the Territory, as applicable) withholding tax.

 

(b)              
Theraclone agrees to submit a detailed statement of account to ZKC within thirty (30) days after the close of
each calendar quarter for any costs or expenses incurred during such calendar quarter related to patents and other expenses agreed
to be paid or reimbursed by ZKC. The costs and expenses of patent filings shall be as set forth in Section 10.

 

*Confidential Treatment Requested.

 

    	32

    	 

    

 

(c)               
Each party shall report quarterly to the other party within forty-five (45) days after the end of the calendar
quarter on Licensing Proceeds or Sublicensing Proceeds received by the reporting party during such calendar quarter.

 

6.2             
Termination Report. ZKC also agrees to make a written report (in a reasonable format) within ninety (90)
days after the date on which ZKC, its Affiliates or Sublicensees sell the last Licensed Product on which a royalty is due under
this Agreement, stating in such report the same information required for quarterly reports provided under Section 6.1 hereof.

 

6.3             
Accounting. ZKC agrees to keep clear, accurate and complete records for a period of at least three (3)
years for each reporting period in which sales of Licensed Product occur on which a royalty is due under this Agreement, in sufficient
detail to determine amounts payable pursuant to Sections 5.7, 4.1(c) and 4.1(f) hereof. ZKC further agrees to permit such records
to be examined from time to time (but not more than once a year or one time with respect to the same set of records) by an independent
accounting firm selected and paid by Theraclone and reasonably satisfactory to ZKC. Such examination shall occur only on reasonable
prior notice during regular business hours during the term of this Agreement and for three (3) years thereafter, provided, however,
that such examination shall not (i) be of such records for more than the prior three (3) years, (ii) take place more often than
once a year, or (iii) cover any such records which date prior to the date of the last examination, and provided further that such
accountants shall report to Theraclone only as to the accuracy of the royalty statements and payments. Copies of such reports
shall be supplied to ZKC. In the event the report demonstrates that ZKC has underpaid Theraclone, ZKC shall pay the amount of
such underpayment immediately upon request of Theraclone and to the extent such underpayment is more than [***]
otherwise due for the audited period, ZKC shall reimburse Theraclone for the expense of the audit. This Section shall apply
mutatis mutandis with respect to Theraclone’s obligation to keep (and ZKC’s right to audit) records regarding
the amounts payable by Theraclone to ZKC pursuant to Section 5.6.

 

6.4             
Confidentiality of Reports. Each party agrees that the information set forth in (i) the reports required
by Sections 6.1 and 6.2 and (ii) the records subject to examination under Section 6.3, shall be subject to Section 11 hereof and
maintained in confidence by the receiving party and the applicable independent accounting firm, shall not be used by such party
or such accounting firm for any purpose other than verification of the payments due under this Agreement, and shall not be disclosed
by the receiving party or such accounting firm to any other person except for purposes of enforcing this Agreement, and except
as allowed under Section 11.

 

7.                 
Commercial Development.

 

7.1             
Diligence by ZKC. Prior to the Start Time, and until and unless the Start Time occurs, Zenyaku shall have
no diligence obligations express or implied under or in connection with this Agreement, at law or in equity. Beginning as of the
Start Time (defined below in this Section), ZKC shall use Commercially Reasonable Efforts to develop and commercialize at least
one (1) Licensed Product for the Licensed Field in the Territory. The scope of such development and commercialization activities
shall include clinical development, seeking Regulatory Approval as warranted by the data, and providing for a reasonable Commercial
Launch if Regulatory Approval is obtained in the Territory. The activities and achievements of any Affiliates and Sublicensee(s)
shall be counted towards ZKC’s satisfaction of its diligence obligations under this Agreement. The clinical work performed
by or for Zenyaku under this Agreement shall be in accordance with the then-current Zenyaku Development Plan shared with Theraclone
as described in Article 2. It is understood and agreed that, because Zenyaku’s development program for the Territory will
likely commence after the results of successful Phase II Clinical Trials in a country whose Regulatory Authorities subscribe to
(and in accordance with the guidelines established by) the ICH (by or for Theraclone) are known and Phase III Clinical Trials commence
in a country whose Regulatory Authorities subscribe to (and in accordance with the guidelines established by) the ICH: (a) other
than JSC participation, Zenyaku is not required to commence development under this Agreement until after the first patient is dosed
in a Phase III Clinical Trial of Licensed Product (“Start Time”) (although Zenyaku may choose to do so); (b)
Zenyaku shall disclose its initial Development Plan to Theraclone on the timeline as stated in Section 2.1; and (c) review and
discussion of the Zenyaku Development Plan shall be as provided for in Article 3 (with Zenyaku retaining decision making authority
as provided for in that Section).

 

 

*Confidential Treatment Requested.

 

    	33

    	 

    

 

7.2             
Diligence by Theraclone. Theraclone shall use Commercially Reasonable Efforts to (i) develop the Lead
M2e Candidate Antibody and the Lead HA Candidate Antibody to the extent set forth in the original Theraclone Development Plan attached
to this Agreement at signing through Phase I Clinical Trials, (ii) take either the Lead M2e Candidate Antibody or the Lead HA Candidate
Antibody (or another Licensed Antibody or combination product as agreed to by the JSC) past Phase I Clinical Trials, and (iii)
seek Regulatory Approval for either the Lead M2e Candidate Antibody or the Lead HA Candidate Antibody (or another Licensed Antibody
or combination product as agreed to by the JSC) for the U.S. market or other country whose Regulatory Authorities subscribe to
(and in accordance with the guidelines established by) the ICH. The activities within the scope of the foregoing diligence obligation
include preclinical testing, Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, and seeking Regulatory
Approval in the U.S., or other country whose Regulatory Authorities subscribe to (and in accordance with the guidelines established
by) the ICH, each to the extent reasonably supported by the data from clinical testing. Subject to the foregoing, Theraclone’s
efforts in accordance with this Section shall include performing activities at least commensurate with the activities set forth
in the Theraclone Development Plan as of the Effective Date. For purpose of clarity, Theraclone is only obligated to use Commercially
Reasonable Efforts to take a total of one (1) product candidate past Phase I Clinical Trials.

 

7.3             
Theraclone Development Plan Timeline. If Theraclone fails to meet the timing for any of the timing goals
set forth in the Theraclone Development Plan, the parties shall meet to discuss the reason for this, and how Theraclone may overcome
any impediments that have prevented Theraclone from meeting such timing, and a revised timeline for Theraclone to achieve the events
described in the Theraclone Development Plan as soon as is reasonably practicable by the application of Commercially Reasonable
Efforts. Within 30 days after the meeting, Theraclone shall submit a written plan (including a revised timeline) to do so to Zenyaku.
If Zenyaku has any comments or questions, Zenyaku may request (and both parties shall promptly participate in) another meeting,
and Theraclone shall provide within 15 days after such meeting a revised version of the plan, reasonably addressing Zenyaku’s
comments. The timeline set forth in the thus-revised plan shall from that point forward be the timeline that Theraclone is required
to use Commercially Reasonable Efforts to try to meet.

 

    	34

    	 

    

 

8.                 
Supply; Distribution of Sample Product.

 

8.1             
Theraclone shall be responsible for supplying the Licensed Products in bulk or vialed unlabelled form to ZKC,
and ZKC shall pay Theraclone for such Licensed Product at a rate equal to Theraclone’s Fully Burdened Manufacturing Cost
(as defined in the Supply Agreement) [***], all as set forth in more detail and
pursuant to the terms and conditions of a Supply Agreement in the form attached hereto as Exhibit F (“Supply Agreement”)
and subject to reductions as set forth therein. ZKC shall use all materials provided to ZKC by Theraclone hereunder or under the
Supply Agreement in compliance with all applicable foreign, federal, state or local laws and regulations. In creating the scaled
up commercial manufacturing process for bulk Licensed Product, Theraclone shall use Commercially Reasonable Efforts to achieve
a commercially reasonable manufacturing cost for Licensed Product.

 

8.2             
Without limiting the licenses and other rights granted to ZKC under this Agreement, ZKC may transfer Licensed
Product to a Third Party according to the following.

 

(a)              
Prior to Commercial Launch, ZKC may request that Theraclone (and Theraclone shall), or ZKC may itself, transfer
reasonable amounts of Licensed Product to academic researchers outside the Territory in connection with the performance of non-clinical
studies related to the Development Plans, subject to Joint Steering Committee approval and execution of a material transfer agreement
as agreed to by the Joint Steering Committee.

 

(b)              
Prior to Commercial Launch, ZKC may transfer Licensed Product for use in clinical trials in the Licensed Field
in the Territory or for other purposes in furtherance of Licensed Product development.

 

(c)               
Subject to all terms and conditions set forth in this Agreement, following Regulatory Approval of commercial
sales in the Territory, there is no restriction on ZKC’s right to transfer Licensed Product to Third Parties in the Territory.

 

(d)              
ZKC may transfer amounts of Licensed Product to Affiliates and Sublicensees at any time.

 

9.                 
Inventions.

 

Product Inventions
that arise from the performance of Licensed Antibody and/or Licensed Product development and that are made by Theraclone solely
or jointly (other than with an employee or agent of ZKC) (“Theraclone Inventions”) shall be owned by Theraclone.

 

Product Inventions
which are made jointly by employees or agents of Theraclone and ZKC during the term of this Agreement shall be jointly owned by
Theraclone and ZKC and treated as joint inventions (collectively, “Joint Inventions”). The nature of such joint
ownership shall be that each party having the rights of co-inventors named on U.S. Patents under U.S. patent laws in the absence
of a written agreement (including the right to practice the invention without having to obtain consent from and without having
any duty of accounting to the other party; and including the right to license others to do the same, without having to obtain consent
from and without have any duty of accounting to the other party), except solely to the extent explicitly provided to the contrary
in this Agreement (including without limitation Section 10.1).

 

*Confidential Treatment
Requested.

 

    	35

    	 

    

 

Product Inventions
that arise from the performance of Licensed Antibody and/or Licensed Product development and that are made by an employee or agent
of ZKC during the term hereof, solely or jointly, other than with an employee or agent of Theraclone, shall be owned by ZKC (collectively,
“ZKC Inventions”).

 

For purposes of this
Section, “made by” shall mean, with respect to a party, that such party has (meaning that it or its Affiliate it employs
or has engaged as a consultant) at least one (1) person who would be a properly named inventor on the U.S. Patent claiming such
Product Invention, and “made jointly by” shall mean that Theraclone and ZKC each have (meaning that each employs or
has engaged as a consultant, or its Affiliate has done so) at least one (1) person who would be a properly named inventor on the
U.S. Patent claiming such Product Invention.

 

Except as otherwise
set forth in this Agreement, ZKC and Theraclone shall retain their respective unrestricted rights to all inventions and discoveries
that are owned by them.

 

10.             
Patents; Prosecution and Litigation.

 

10.1         
Prosecution.

 

(a)              
Theraclone Patents. Theraclone shall have the right to prosecute and maintain all Theraclone Patents
as provided in this Section 10 and shall do so in a timely manner. Theraclone shall promptly disclose in writing to ZKC the complete
texts of all Theraclone Patents as well as promptly provide ZKC with, and promptly notify ZKC of, all information and material
correspondence given or received concerning the institution or possible institution of any interference, opposition, re-examination,
reissue, revocation, nullification or any official proceeding involving any Patent licensed herein. Theraclone agrees to keep
ZKC promptly (in any event at least thirty (30) days in advance of any submission by Theraclone) and fully informed of the course
of Patent prosecution or other proceedings with the applicable patent offices regarding the Patents licensed herein, including
by providing ZKC with copies of all communications, search reports and Third Party observations submitted to or received from
such patent offices. ZKC shall have the right to review all such Patents, communications and other proceedings (and, where such
Patents, material communications and other proceedings are submitted by Theraclone, Theraclone shall allow for such review to
be reasonably in advance of their submission) and make recommendations to Theraclone concerning them and their conduct in the
Territory (and Theraclone shall incorporate such comments, to the extent reasonably practicable, in its communications and filings
with such patent offices). ZKC shall hold all information disclosed to it under this Article 10 as Confidential Information under
Article 11. ZKC shall reimburse Theraclone, within forty-five (45) days of receipt of invoice, for (a) reasonable and documented
costs incurred prior to the Effective Date up to [***] and (b) reasonable and documented
costs incurred after the Effective Date, in each case of (a) and (b) for the filing, prosecution and maintenance of the Theraclone
Patents in the Licensed Field in the Territory that contain claim(s) directed to the Licensed Antibodies and/or Licensed Products
in the Licensed Field. To be clear, such reasonable and documented costs shall be only those costs applicable to filing, prosecution
and maintenance of the Theraclone Patents for the Territory (i.e., costs representing a fair and proper allocation in consideration
of the market size of the Territory relative to the Retained Territory). In addition, ZKC shall pay Theraclone, within forty-five
(45) days of receipt of invoice, an amount equal to [***] of the reasonable and
documented costs incurred by Theraclone for the filing, prosecution, and maintenance of (a) Patent Cooperation Treaty patent applications
and (b) if a Patent Cooperation Treaty patent application that designates Japan claims priority to a provisional patent application
filed with the United States Patent and Trademark Office, then such provisional patent application filed with the USPTO; in the
case of each (a) and (b), only if they contain claim(s) directed to the Licensed Antibodies and/or Licensed Products. Reimbursement
under the foregoing sentence shall not exceed [***] per patent family. All expenses
to be paid or reimbursed by ZKC pursuant to this Section shall be obligations that are separate and apart from other payment obligations
described in this Agreement and shall be invoiced and paid separately.

 

*Confidential Treatment Requested.

 

    	36

    	 

    

 

(b)              
Joint Patents. Each party shall have the right but not the obligation to file, prosecute and maintain
the Joint Patents in such party’s territory. Each party shall bear its own cost in connection therewith. The parties shall
mutually agree which party shall file the first priority filing for each Joint Patent.

 

(c)               
Zenyaku Patents. If Theraclone requests on a case-by-case basis with respect to each ZKC Patent, Theraclone
shall have the right to prosecute the ZKC Patents in the Retained Territory. Zenyaku shall have an approval right over such prosecution.
Otherwise, the procedures shall be as provided in Section 10.1(a). All costs incurred by Theraclone with respect to such prosecution
shall be at Theraclone’s sole expense and not subject to reimbursement by Zenyaku.

 

10.2         
Abandonment. In the event Theraclone wishes to finally abandon any Theraclone Patent, or part of a Theraclone
Patent, in either case in the Territory, then it shall notify ZKC at least thirty (30) days before the deadline upon which the
Theraclone Patent would otherwise go abandoned if action were not taken, and ZKC shall have the right at its own expense to assume
(and Theraclone shall assign to ZKC) all rights to any such Patent or part thereof in the Territory; provided, however,
ZKC’s rights under this Section 10.2 shall in all respects be subject to the rights of Theraclone’s Third Party licensor(s)
of such Patent or part of a Patent (if any). In the event ZKC wishes to finally abandon any ZKC Patent, or part of a ZKC Patent,
in either case in the Retained Territory, then it shall notify Theraclone at least thirty (30) days before the deadline upon which
the ZKC Patent would otherwise go abandoned if action were not taken, and Theraclone shall have the right at its own expense to
assume (and ZKC shall assign to Theraclone) all rights to any such Patent or part thereof in the Retained Territory.

 

10.3         
Accused Infringement of Third-Party Patents. In the event of the initiation of any suit or claim by a
Third Party against Theraclone, ZKC or any Affiliate of either for patent infringement with respect to the manufacture, use, sale,
distribution or marketing of the Licensed Products in the Licensed Field in the Territory, the party sued or claimed shall promptly
notify the other party in writing. The party sued has the right to defend itself Each party shall assist and cooperate with the
other party, in any such litigation, at the defending party’s request and expense, as applicable.

 

 

 

    	37

    	 

    

 

Theraclone shall not
enter into any settlement with respect to such suit or claim without ZKC’s written consent, which consent shall not be unreasonably
withheld, delayed, or conditioned. ZKC shall not enter into any settlement with respect to such suit or claim without Theraclone’s
consent, which consent shall not be unreasonably withheld, delayed, or conditioned.

 

Each party shall be
responsible to pay its costs in connection with these suits, except to the extent any particular costs (such as a settlement involving
a license for Additional Technology) are allocated to a given party elsewhere in this Agreement or a party has an obligation to
indemnify for breach of a representation and warranty under Article 14.

 

If a party wishes to
bring a claim for patent infringement of a Theraclone Patent or a Joint Patent as a defense to a claim by a Third Party of patent
infringement (as described in the foregoing paragraph), then the procedure of Section 10.4 must be followed first.

 

This Section 10.3 shall
in no way limit a party’s indemnification rights or obligations in Article 16, including a party’s rights to tender
defense of a Third Party Claim for which such party is entitled to be indemnified and defended under such Article.

 

10.4         
Infringement of Parties’ Patents by Third Parties.

 

(a)              
Notification. Each party shall promptly notify the other party in writing if the notifying party reasonably
believes that any Theraclone Patent or Joint Patent is being or has been infringed or misappropriated by a Third Party (such infringement,
together with any that may be imminently threatened to occur by any potential Generic Version of a Licensed Product arising under
the implementing procedures of 35 U.S.C. 271(e)(2) or ex-U.S. equivalent, “Infringement”).

 

(b)              
License-Competitive Infringement of Theraclone Patents or Joint Patents.

 

(i)                
First Right. ZKC shall have the first right, but not the obligation, to enforce the Theraclone Patents and
Joint Patents against Infringement through activities or conduct of a Third Party in the Licensed Field in the Territory that if
conducted by ZKC would be within the scope of the licenses granted to ZKC in Section 4.1(a) (“License-Competitive Infringement”).
ZKC shall reasonably consider Theraclone’s comments on any such enforcement activities. Except as provided in subsection
(d) (regarding settlement) or in subsection (g) (regarding allocation of proceeds), ZKC shall bear all costs and expenses for enforcement
under this Section 10.4(b)(i) (including the costs of Theraclone’s cooperation as required under subsection (e)).

 

(ii)              
Back-up Right for License-Competitive Infringement of Theraclone Patents or Joint Patents. If ZKC does not
bring action to prevent or abate License-Competitive Infringement within one hundred twenty (120) days (or twenty (20) days in
the case of an action brought under any ex-U.S. equivalent of the Hatch-Waxman Act in the Territory) after notification thereof
to or by ZKC pursuant to Section 10.4(a), then Theraclone shall have the right, but not the obligation, to bring, at its own expense,
an appropriate action against any person or entity engaged in such License-Competitive Infringement directly or contributorily.
However, Theraclone shall not initiate legal action without first conferring with ZKC and considering in good faith ZKC’s
reasons for not bringing any such action.

 

    	38

    	 

    

 

(iii)            
Proceeds. Recoveries on suits under this Section 10.4(b) will be handled as provided in Section 10.4(g).

 

(c)               
Participation of the other Party with Respect to Infringement Suits. If a party brings an action against
infringement under Section 10.4(b), the other party shall be entitled to separate representation in such matter by counsel of its
own choice and at its own expense, and such party shall cooperate fully with the party bringing such action including by being
joined as a party plaintiff if necessary to obtain standing for such action (all at the expense on a pass-through basis of the
prosecuting party).

 

(d)              
Settlement. Theraclone shall not settle a claim brought under this Section 10.4 in a manner that would
limit or restrict the ability of ZKC to sell Licensed Products for use in the Licensed Field, impair the exclusivity of ZKC’s
license rights under this Agreement, or otherwise limit or restrict the ability of ZKC to fully enjoy the benefits of the exclusive
licenses to ZKC in this Agreement, in each case without the prior written consent of ZKC (which consent shall not be unreasonably
withheld, conditioned or delayed). ZKC shall not settle a claim brought under this Section 10.4 involving Theraclone Patents or
Joint Patents in a manner that would limit or restrict the ability of Theraclone to sell, practice, license and fully enjoy the
benefits of the Theraclone Patents or Joint Patents outside the scope of the exclusive licenses to ZKC in this Agreement or that
shortens the life of the Theraclone Patents or Joint Patents or that would narrow their scope, in each case without the prior written
consent of Theraclone (which consent shall not be unreasonably withheld, conditioned or delayed).

 

(e)               
Cooperation. Each party shall reasonably cooperate with the other party in any and all suits under Section
10.4(b), at the expense of the party bringing suit (on a purely pass-through basis), including being joined in name as a party
plaintiff if needed to maintain standing.

 

(f)               
Clarification. Notwithstanding anything express or implied in this Agreement, Theraclone shall not have
any right to enforce the ZKC Patents except to the extent set forth in Section 10.4(h).

 

(g)              
Allocation of Proceeds. If monetary damages are recovered from any Third Party in an action brought by
a party under Section 10.4(b), such recovery shall be allocated first to the reimbursement of any costs and expenses incurred by
the party controlling such litigation (including, for this purpose, a reasonable allocation of expenses of internal counsel or
other personnel acting in such capacity (i.e., coordination of litigation matters and the like)), to the extent not previously
reimbursed, and then the same costs and expenses of the non- controlling party (to the extent not previously reimbursed by the
controlling party), and any remaining amounts shall be split as follows:

 

    	39

    	 

    

 

(i)                
if ZKC exercised its first right to bring the suit, then the rest of the remaining recovery (1) to the extent not
representing treble or punitive damages shall be allocated to Theraclone in an amount equal to the royalty that would have been
payable to Theraclone under Section 5.7 if ZKC had made Net Sales equivalent to the actual sales that underlie the remaining recovery,
with the remaining portion of the remaining recovery that does not represent treble or punitive damages being allocated to ZKC;
and (2) to the extent representing treble or punitive damages shall be allocated [***]
to Theraclone and [***] to ZKC;

 

(ii)              
if instead Theraclone exercised its back-up right to enforce, then the rest of the remaining recovery shall be allocated
to Theraclone in the same amount as under subsection (i) ZKC would have received if ZKC had brought the suit, with the remainder
under this subsection (ii) being allocated to ZKC; provided, however that in such case the allocation under Section 10.4(g)(i)(2)
shall be [***] to Theraclone and [***]
to ZKC; and

 

(iii)            
the portion of any remaining amounts that represents recoveries for Infringement of Joint Patents shall be split
[***] to the party that controlled the suit and [***]
to the other party.

 

(h)              
Sections 10.4(b)-(g) shall apply mutatis mutandis to the enforcement of the ZKC Patents and Joint Patents
in the Retained Territory, except that Theraclone shall have the first right to enforce such Patents in the Retained Territory.

 

(i)                
The parties shall keep one another informed of the status of their respective activities regarding any litigation
or settlement thereof concerning a Licensed Product or Licensed Antibody.

 

(j)                
Only the enforcement rights specifically set forth in this Section 10.4 are granted. No other rights to enforce
Patents licensed under this Agreement, express or implied, are granted or available under this Agreement.

 

10.5         
Patent Term Extensions. If requested by Zenyaku, Theraclone shall use its Commercially Reasonable Efforts
and cooperate with ZKC to extend the term of Theraclone Patents and Joint Patents in the Territory, including by providing necessary
information and assistance as ZKC may reasonably request. If requested by Theraclone, ZKC shall use its Commercially Reasonable
Efforts and cooperate with Theraclone to extend the term of ZKC Patents, including by providing necessary information and assistance
as Theraclone may reasonably request.

 

11.             
Confidentiality; Publicity; Publications.

 

11.1         
Disclosure of Inventions. To the extent not already provided for elsewhere in this Agreement, each party
shall promptly report to the other party (no less frequently than quarterly) as to all Theraclone Product Inventions, Joint Product
Inventions, or ZKC Product Inventions invented by or for the disclosing party and not previously disclosed to the other party under
this Agreement. Additional data and other Know-How disclosure requirements are as set forth elsewhere in this Agreement.

 

*Confidential Treatment Requested.

 

    	40

    	 

    

 

11.2         
Adverse Drug Events. The parties recognize that each may be required to submit information and file reports
to various governmental agencies on compounds under clinical investigation, compounds proposed for marketing, or marketed drugs.
In this regard, information must be submitted at the time of initial filing for investigational use in humans and at the time of
a request for market approval of a new drug. In addition, supplemental information must be provided on compounds at periodic intervals
and adverse drug experiences must be reported at more frequent intervals depending on the severity of the experience. Consequently,
each party agrees to: (a) provide to the other party for initial and/or periodic submission to government agencies significant
information on the Licensed Products from preclinical laboratory, animal toxicology and pharmacology studies, as well as adverse
drug experience reports from clinical trials and commercial experiences with the Licensed Products; (b) in connection with investigational
use of the Licensed Products, report to the other party within fifteen (15) calendar days of the initial receipt of a report of
any related, unexpected serious adverse event with the Licensed Products or concurrently with the reporting of such experience
to a regulatory agency, if sooner than fifteen (15) calendar days, or sooner if required for any party to comply with regulatory
requirements; and (c) in connection with commercial use of the Licensed Products, report to the other party within fifteen (15)
calendar days of the initial receipt of a report of any adverse experience with the Licensed Products that is serious and unexpected
or sooner if required for any party to comply with regulatory requirements. Serious adverse experiences mean any experience that
is fatal or life-threatening, is permanently disabling, requires or prolongs inpatient hospitalization, or is a congenital anomaly.
Other important medical events may be considered serious if medical or surgical intervention is required to prevent one of the
outcomes listed above. An unexpected adverse experience is one not identified in nature, specificity, severity or frequency in
the current investigator brochure or the United States labeling for the Licensed Products. Each party also agrees that if it contracts
with a Third Party for research to be performed by such Third Party on the Licensed Products, that party agrees to require such
Third Party to report to the contracting party the information set forth in subparagraphs (a), (b) and (c) above, and such contracting
party shall provide this information to the other party. This applies equally to the parties’ Affiliates, Sublicensees and
Other Licensees.

 

In any event, notwithstanding
anything express or implied in this Agreement, the parties shall report to each other on safety data and safety information on
a timetable and within a scope that is sufficient to allow both parties to satisfy their reporting obligations to Regulatory Authorities
having jurisdiction over such party’s activities under this Agreement. If the foregoing paragraph does not provide for sufficiently
broad or sufficiently rapid disclosures so as to allow for this, then the parties shall enter into a separate pharmacovigilance/safety
agreement that does meet such standard. The parties shall work mutually and in good faith to finalize such agreement well in advance
of both parties sponsoring human clinical trials of Licensed Product at the same time. If they are unable to agree on the details,
then they shall engage a regulatory expert not affiliated with either company, and such person shall prepare the final protocol
for the data exchange addressed by this Section, and this shall be the protocol that the parties shall use, and shall replace the
first paragraph of this Section. The parties shall share 50:50 the fees of such expert. Both parties recognize that such a protocol
might provide for electronic transfer of data (which may be in a then-standard format for such exchanges prevailing in the industry
now or at the time), and for disclosure to occur more quickly than provided for in the foregoing paragraph.

 

    	41

    	 

    

 

As of the Effective
Date, each party shall maintain its own safety database. The parties shall discuss in good faith, and may mutually agree, for either
party to maintain a single global safety database for Licensed Product. If they reach subsequent written agreement for such a single
global safety database, then that agreement shall be the agreement that will be followed by the parties. Any such agreement will
provide all relevant details as to operational and financial responsibilities for maintaining such database, as well as each parties’
rights to access, and to maintain a “shadow” copy of the global safety database. In addition, such agreement will provide
for a cost sharing arrangement for such database.

 

Each party shall have
the right to report Confidential Information of the other party to the Regulatory Authority in the reporting party’s territory
in furtherance of activities for which the reporting party is licensed under this Agreement.

 

11.3         
Confidential Information. During the term of this Agreement and for five (5) years thereafter, irrespective
of any termination earlier than the expiration of the term of this Agreement, the party receiving Confidential Information of the
other party (such recipient, the “Receiving Party” and such discloser, the “Disclosing Party”)
shall not use or reveal or disclose to any Third Party any proprietary or confidential information received from the Disclosing
Party or otherwise developed by the Disclosing Party in the performance of activities in furtherance of this Agreement that by
its nature or content, or the context of disclosure, might reasonably be expected to be confidential (“Confidential Information”),
without first obtaining the written consent of the Disclosing Party, except as may be otherwise provided herein, or for the purpose
of exercising the Receiving Party’s rights or performing its obligations under this Agreement, or to the Disclosing Party’s
investors or potential investors, consultants, contractors, accountants, and legal counsel who are bound by confidentiality and
limited use obligations commensurate to the ones in this Agreement, or for securing essential or desirable authorizations, privileges
or rights from governmental agencies, or as may be required to be disclosed to a governmental agency, or as necessary to file or
prosecute patent applications concerning the Licensed Products or as otherwise required by applicable law and/or regulations. This
confidentiality obligation shall not apply to such Confidential Information of the Disclosing Party which is or becomes a matter
of public knowledge through no act or omission of the Receiving Party, or is already in the possession of the Receiving Party without
obligation of confidentiality, or is disclosed to the Receiving Party by a Third Party having the right to do so without obligation
of confidentiality to the Disclosing Party, or is subsequently and independently developed by employees of the Receiving Party
who had no knowledge of the Confidential Information disclosed. The parties shall take at least commercially reasonable measures
to assure that no unauthorized use or disclosure is made by those to whom access to such Confidential Information is granted.

 

Disclosures by a party’s
Affiliate, Sublicensee or Other Licensee shall for purposes of this Article be deemed to be disclosures by the corresponding party
to this Agreement.

 

11.4         
Permitted Disclosures. Nothing herein shall be construed as preventing ZKC from disclosing any Confidential
Information received from Theraclone to any ZKC Affiliate, Sublicensee, distributor, contractor, consultant or permitted manufacturer
of ZKC, provided such entity is bound in writing by obligations of confidentiality and limited use with respect to the Confidential
Information commensurate to those in this Agreement. Nothing herein shall be construed as preventing Theraclone from disclosing
any Confidential Information received from ZKC related to the Development Plans, the Theraclone Patents and the Joint Patents,
or otherwise, to any Theraclone Affiliate, permitted manufacturer, consultant, contractor, distributor, or Theraclone’s additional
partners for the development, manufacturing, and commercialization of Licensed Products in the Licensed Field outside of the Territory,
provided that such Affiliate or partner are bound in writing by confidentiality and limited use obligations with respect to such
Confidential Information commensurate to those of this Agreement.

 

    	42

    	 

    

 

A Receiving Party shall
be entitled to disclose Confidential Information of a Disclosing Party to the extent required by law, regulation or court order.
First, however, the Receiving Party must notify the Disclosing Party in writing of the disclosure obligation, and if requested
by the Disclosing Party, seek confidential treatment or a protective order within a commercially reasonable timeframe to maintain
the confidentiality of the applicable Confidential Information (or assist the Disclosing Party in seeking such confidential treatment
or protective order). Public filing of this Agreement, however, shall be per Section 11.5, not this Section 11.4.

 

11.5         
Terms of Agreement. The terms of this Agreement shall be treated as the Confidential Information of both
parties. If a party is legally required to file publicly a copy of this Agreement, then it shall seek confidential treatment of
the competitively sensitive terms of this Agreement, and no later than 30 days prior to the intended filing date, that party shall
share with the other party what redactions the filing party intends to make from the upcoming filing. If the non-filing party requests
additional redactions within three (3) weeks, then the filing party shall make such additional redactions, unless confidential
treatment is manifestly unavailable based on advice from the filing party’s outside counsel. If the securities regulatory
authority will not permit all the redactions, or has comments, then the filing party shall work with the non- filing party to seek
to justify or obtain the confidential treatment by answering the comments, if requested by the non-filing party.

 

11.6         
Bankruptcy Procedures. All Confidential Information disclosed by one party to the other shall remain the
intellectual property of the Disclosing Party. In the event that a court or other legal or administrative tribunal, directly or
through an appointed master, trustee or receiver, assumes partial or complete control over the assets of a party to this Agreement
based on the insolvency or bankruptcy of or any other similar insolvency event with respect to such party, the bankrupt or insolvent
party shall promptly notify the court or other tribunal (i) that Confidential Information received from the other party under this
Agreement remains the property of the other party and (ii) of the confidentiality obligations under this Agreement. In addition,
the bankrupt or insolvent party shall, to the extent permitted by law, take all commercially reasonable steps necessary or desirable
to maintain the confidentiality of the other party’s Confidential Information and to insure that the court, other tribunal
or appointee maintains such Confidential Information in confidence in accordance with the terms of this Agreement.

 

11.7         
Publicity.

 

(a)              
The parties to this Agreement may disclose the nature and general terms of the Agreement in a mutually agreed
upon press release following signature after due consultation with the other party. The wording of any press release must be agreed
by both parties in advance of its release; provided that such agreement is not unreasonably withheld or delayed by either party.
Notwithstanding the foregoing, each party shall have the right to issue press releases immediately and without prior consent of
the other to the extent required by the rules and regulations of the Securities and Exchange Commission or similar federal, state
or foreign authorities, as determined in good faith by the disclosing party with advice from outside counsel, and subject at all
times to the confidentiality obligations in Section 11.3 and working with the other party to arrive at a mutually acceptable text
(such acceptance shall not be unreasonably withheld or delayed).

 

    	43

    	 

    

 

(b)              
Neither party shall publish or provide public disclosure of information or inventions arising from the performance
of the Development Plans or otherwise related to the activities contemplated by this Agreement (a “Dissemination”)
without at least ninety (90) days prior written notice of such planned publication or disclosure sent to the other party. In the
event any such Dissemination is reasonably determined by the other party to include its Confidential Information or affect its
intellectual property position, the disseminating party shall delay such publication for a period sufficient, but in no event greater
than an additional sixty (60) days, to allow the other party to take the steps necessary to protect such Confidential Information
or intellectual property position, including the filing of any patent applications and/or deletion of its Confidential Information.
Nothing in this Section 11.7(b) shall diminish a party’s rights to make legally required disclosures as provided for in Section
11.4.

 

12.             
Governing Law; Arbitration.

 

This Agreement shall
be governed by the laws of the State of New York, USA, without regard to conflicts of law principles. Prior to engaging in any
formal dispute resolution with respect to any dispute, controversy or claim arising out of or in relation to this Agreement or
the breach, termination or invalidity thereof (each, a “Dispute”), the designated officers of the parties (for
ZKC, an officer at the level of Vice President or above; for Theraclone, its CEO) shall attempt for a period of not less than sixty
(60) days to resolve such Dispute. Any Dispute that cannot be settled amicably by agreement of the parties pursuant to the preceding
sentence, shall be finally settled by arbitration in accordance with the arbitration rules of the American Arbitration Association
(“AAA”), then in force, as modified by this Section, by a panel of three arbitrators if the amount alleged to
be in controversy exceeds [***] and otherwise by a single arbitrator. The arbitrator
or arbitrators shall be appointed in accordance with said rules, provided that the appointed arbitrators shall have appropriate
experience in the biopharmaceutical industry. The language of the arbitration shall be in English, and the place of arbitration
shall be New York, New York, USA. The award rendered shall be final and binding upon both parties. Each party shall pay its own
costs incurred in participating in the arbitration, except that the parties shall split 50:50 the administrative costs of the arbitration;
provided, however, that the judgment rendered by the arbitrator(s) may include costs of arbitration, reasonable attorneys’
fees and reasonable costs for any expert and other witnesses. The arbitrators in such proceeding may expressly consider the amounts
paid or payable pursuant to this Agreement in considering any claim of damages. Nothing in this Agreement shall be deemed as preventing
either party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the parties
and the subject matter of the dispute as necessary to protect either party’s name, proprietary information, trade secrets,
know-how or any other proprietary rights. Judgment upon the award may be entered in any court having jurisdiction, or application
may be made to such court for judicial acceptance of the award and/or an order of enforcement as the case may be.

 

*Confidential Treatment Requested.

 

    	44

    	 

    

 

13.             
Assignment.

 

Neither this Agreement nor any interest
hereunder shall be assignable by either party without the written consent of the other; provided, however, that either party
may assign this Agreement and all of such party’s Patents related to this Agreement to any of such party’s Affiliates
(for so long as such Affiliate remains Affiliated with such party) or to any corporation or other entity with which such party
may merge or consolidate (regardless of who is the surviving entity of such merger or consolidation), and/or to any corporation
or other entity to which such party may transfer all or substantially all of such party’s assets to which this Agreement
relates or all or substantially all of such party’s stock, without obtaining the consent of the other party. Transfer in
contravention of this Section 13 shall be considered a material breach of this Agreement pursuant to Section 15.4 below. Subject
to other provisions of this Section 13, all rights and obligations under this Agreement and the licenses herein granted shall be
binding upon and inure to the benefit of the successors in interest of the respective parties. Any assignment in violation of the
foregoing shall be null and void.

 

To avoid doubt, this Section 13 shall not
limit a party’s ability to extend to its Affiliates, Sublicensees and Other Licensees the benefits of this Agreement in the
territory applicable to that entity (including the right to attend JSC and JCC meetings, to comment on patent prosecution, to receive
supply and reports directly, and the like).

 

14.             
Warranties, Representations and Covenants.

 

14.1         
Each party represents and warrants that it has the right to enter into this Agreement, and that this Agreement
is a legal and valid obligation binding upon such party and enforceable in accordance with its terms, and that it has been authorized
by all requisite corporate action within such party.

 

14.2         
Theraclone represents and warrants that (i) to the best of its knowledge as of the Effective Date Theraclone’s
issued patents within the Theraclone Patents existing as of the Effective Date hereof are valid and enforceable and the practice
of them does not and will not infringe the intellectual property rights of others, (ii) to the best of its knowledge as of the
Effective Date Theraclone’s patent applications within the Theraclone Patents existing as of the Effective Date (x) contain
patentable subject matter and (y) the practice of their subject matter does not and will not infringe the intellectual property
rights of others, (iii) Theraclone owns or has the right to license to ZKC (and hereby covenants that it will continue to have
such right throughout the term of this Agreement) on the terms and conditions of this Agreement the Theraclone Listed Patents,
the other Theraclone Patents on and the Theraclone Know-How free and clear of any liens, restriction on use or encumbrances of
any nature whatsoever, (iv) no Third Party has any right to research, develop, use, have used, sell, offer for sale, have sold,
keep and import the Licensed Products in the Licensed Field in the Territory, (v) to the best of its knowledge as of the Effective
Date, the distribution, sale, marketing, and import of the Licensed Products by ZKC in the Territory does not infringe the intellectual
property rights of Third Parties, (vi) there are no pending infringement actions or other litigation actions, either actual or
threatened, relating to the Licensed Products, Theraclone Patents or Theraclone Know-How, (vii) other than as set forth on Exhibit
G, Theraclone and its Affiliates are not parties to any agreement with any Third Party under which Theraclone or its Affiliate
will owe the Third Party money with respect to this Agreement, Zenyaku’s payments under this Agreement, or the development
or commercialization of Licensed Antibody(ies) or Licensed Product(s) under this Agreement, including Third Party(ies) holding
intellectual property rights relating to or Covering the manner in which any Licensed Antibody was discovered, (viii) as of the
Effective Date, other than the Patents listed in Exhibit G, all Theraclone Patents are owned by Theraclone and no Theraclone Patent
has been in-licensed, (ix) Theraclone’s arrangements entered into as of the Effective Date for the research provided for
in Section 5.4 grant Theraclone ownership or other Control of all Know-How generated, and all Patents on inventions generated,
pursuant to such research (and Theraclone hereby covenants to use commercially reasonable efforts so that the same shall be true
with respect to its future research and development arrangements entered into in connection with the research provided for in Section
5.4), and (x) with respect to those agreements set forth in Exhibit G, Theraclone has not received any notice of being in breach
of any such agreement and knows of no reason why it would receive such a notice.

 

    	45

    	 

    

 

Theraclone hereby covenants
that (1) both as to the agreements listed in Exhibit G and if the Theraclone Patents in the future include Patents with respect
to which Theraclone or its Affiliate has acquired (including licensing) rights from any Third Party, then Theraclone shall (and
shall cause its Affiliates to) use Commercially Reasonable Efforts to comply fully with and maintain in full force and effect the
agreement with the Third Party(ies) governing such acquisition (including licenses), not take any action that would allow the Third
Party(ies) to terminate such an agreement, and disclose within five (5) days to Zenyaku any notice of breach received by Theraclone
or its Affiliate (and if not cured by Theraclone by one half of the way through the cure period then Zenyaku shall have the right
to cure on Theraclone’s behalf, and in such event Zenyaku shall be entitled to credit the costs of such cure against payments
otherwise due Theraclone under this Agreement), and (2) Theraclone shall not (and shall cause its Affiliates not to) during the
term of this Agreement enter into any conflicting agreement or arrangement with any Third Party or any agreement or arrangement
with any Third Party that would impair or diminish Zenyaku’s rights under this Agreement.

 

14.3         
TO THE EXTENT PERMITTED BY APPLICABLE LAW, THERACLONE MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,
OTHER THAN THOSE EXPRESSLY SET FORTH ABOVE IN THIS SECTION 14. ZKC MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,
OTHER THAN THOSE EXPRESSLY SET FORTH ABOVE IN THIS SECTION 14.

 

14.4         
Limited Liability.

 

EXCEPT WITH RESPECT TO A PARTY’S
INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT OR BREACH OF THE CONFIDENTIALITY OBLIGATIONS IN SECTION 11, IN NO EVENT WILL EITHER
PARTY HERETO BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES SUFFERED BY THE OTHER PARTY ARISING IN ANY
WAY OUT OF THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN IF THE PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

 

    	46

    	 

    

 

15.             
Term and Termination.

 

15.1         
General. This Agreement may not be terminated by either party except in accordance with this Article 15.
To be clear, there shall be no, and ZKC shall have no obligation to pay any, termination fee to Theraclone if ZKC or Theraclone
terminates this Agreement under this Article 15.

 

15.2         
Term. Unless otherwise terminated in accordance with this Article 15, this Agreement shall expire upon
the expiration of the Royalty Term. Without limiting Section 15.10, if ZKC requests, after expiration of this Agreement under this
Section 15.2, that any agreement should be entered into between the parties hereto in connection with the subject hereof, Theraclone
shall enter into good faith negotiations with ZKC for such purpose.

 

15.3         
Termination by ZKC for Convenience. If ZKC determines in good faith for bona fide scientific or clinical
reasons not to proceed with development of the Licensed Products, for any reason or no reason, ZKC may terminate this Agreement
at its option, without any charge to, or obligation of indemnification by, ZKC in connection with any Damages arising on or after
the date of such termination, by providing thirty (30) days prior written notice at any time to Theraclone. To be clear, such termination
may be for any reason or no reason and shall not be subject to the resolution procedure set forth in the remainder of this paragraph.
In addition, if ZKC desires to terminate this Agreement for convenience for commercial reasons then ZKC shall notify Theraclone
of such desire and Theraclone shall agree or disagree within thirty (30) days of receipt of such notice (the “Response
Deadline”). If Theraclone disagrees, then the parties shall engage an independent person with at least fifteen (15) years
in senior management positions in the biopharmaceutical industry, including positions with responsibility for finance and sales
and/or marketing. Such person (the “Commercial Expert”) shall not be affiliated with or be an advisor to either
of the parties. If the parties cannot agree as to who the Commercial Expert shall be within twenty (20) days after the expiration
of the Response Deadline, then the mechanism for selecting such person shall be the same as that used with the Patent Expert in
Section 4.1(c). The parties shall accept the Commercial Expert’s determination (which determination shall be binding on the
parties) as to whether ZKC may terminate this Agreement for convenience due to commercial reasons and the Commercial Expert’s
determination shall be based on (i) the likelihood of a Licensed Product receiving Regulatory Approval in the Territory in a commercially
reasonable timeframe, and the (ii) market opportunity as compared to ZKC’s other products. Except as set forth in this Section
15.3, the procedures that shall be used with the Commercial Expert shall be the same as those used with the Patent Expert in Section
4.1(c).

 

15.4         
Termination for Uncured Material Breach. If either party is in material breach of any material provision
of this Agreement and if such breach is not cured within ninety (90) days (or in the case of non-payment of undisputed amounts,
thirty (30) days) after receiving written notice from the other party with respect to such breach detailing the alleged breach
and stating explicitly that the writing is a notice under this Section 15.4, the non-breaching party shall have the right to terminate
this Agreement by giving written notice to the party in breach. The parties agree and acknowledge that any material breach by ZKC
or Theraclone of their respective diligence obligations in Section 7 shall be deemed to be a material breach of a material provision
of this Agreement. Termination under this Section 15.4, if disputed by the non-terminating party, shall not be effective until
the dispute or contest is resolved under Article 12, and then only if the arbitrator finds that the termination is proper.

 

    	47

    	 

    

 

15.5         
Termination for Insolvency; Rights under Bankruptcy Code. Either party may terminate this Agreement by
written notice to the other party if, at any time, the other party files in any court or agency pursuant to any statute or regulation
of the United States or of any individual state or foreign country, a petition in bankruptcy or insolvency or for reorganization
or for an arrangement or for the appointment of a receiver of trustee of the party or of its assets or for any other similar proceedings,
or if the other party is served with an involuntary petition against it, filed in any of such insolvency proceedings, and such
petition is not be dismissed with sixty (60) days after the filing thereof, or if the other party proposes or is a party to any
dissolution or liquidation, or if the other party makes an assignment for the benefit of creditors, or if the other party’s
license, registration, approval or the like granted by any official or governmental agency is rescinded, canceled or suspended.
All rights and licenses granted under or pursuant to this Agreement by Theraclone and ZKC are, and shall be deemed to be, for purposes
of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section
101 of the U.S. Bankruptcy Code. The parties agree that the parties as licensees of such rights under this Agreement, shall retain
and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code. The parties further agree that, in the
event of the commencement of a bankruptcy proceeding by or against Theraclone under the U.S. Bankruptcy Code, then ZKC shall be
entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments
of such intellectual property, and the same, if not already in ZKC’s possession, shall be promptly delivered to ZKC upon
any such commencement of a bankruptcy proceeding upon its written request therefor. The foregoing sentence shall apply mutatis
mutandis to allow Theraclone to receive duplicates, access and the like in the same manner, if Zenyaku undergoes a bankruptcy
event as outlined in the foregoing sentence.

 

15.6         
Termination by Theraclone due to ZKC Material Breach of Supply Agreement. If Theraclone terminates the
Supply Agreement for the uncured material breach of that agreement by Zenyaku, then Theraclone has the right to terminate this
Agreement by written notice to Zenyaku and the effect of such termination of this Agreement shall be the same as provided for in
Section 15.8.

 

15.7         
Effect of Termination or Expiration on Certain Joint Inventions. Upon expiration or termination of this
Agreement for any reason, each party shall retain its respective rights in all Joint Inventions not covered by the Joint Patents
in existence as of the expiration or termination effective date without obligation to the other party, provided that the parties
agree to cooperate with each other with respect to any patenting activities related to such Joint Inventions. In the event either
party wants to obtain a license to the other party’s interest in such Joint Inventions, the parties agree to negotiate the
terms of such license in good faith at such time.

 

15.8         
Effect of Termination By ZKC for Convenience; Effect of Termination by Theraclone for ZKC’s Uncured
Material Breach or Insolvency. If (a) ZKC terminates this Agreement pursuant to Section 15.3 (for convenience), or (b) Theraclone
terminates this Agreement pursuant to Section 15.4 (for ZKC’s uncured material breach) or pursuant to Section 15.5 (for ZKC’s
insolvency) then: (i) subject to the maintenance of rights held by Sublicensees as of the effective date of a termination pursuant
to this Section 15.8, all rights and licenses granted to ZKC pursuant to this Agreement with respect to the Licensed Products and
Licensed Antibodies, including, without limitation, rights and licenses granted to ZKC under the Theraclone Patents, Theraclone
Know-How and Theraclone’s interest in the Joint Patents, shall revert to Theraclone and ZKC shall retain no license rights
therein, (ii) the license granted to Theraclone pursuant to Section 4.1(b) shall become exclusive, fully-paid up, royalty free,
and worldwide with respect to all Licensed Antibodies and all Licensed Products in each case originating with and proprietary to
Theraclone, to the extent that ZKC has the right to grant licenses under the intellectual property of such Section on the terms
and conditions of this Agreement, (iii) ZKC shall use good faith efforts and cooperate with Theraclone to transfer to Theraclone
ZKC’s Licensed Product Regulatory Approvals and/or Clinical Regulatory Filings, as the case may be, for Licensed Antibodies
and all Licensed Products in each case originating with and proprietary to Theraclone, (iv) ZKC shall pay all sums accrued hereunder
which are due as of the effective date of termination, (v) the Supply Agreement shall automatically terminate with no further action
required by the parties, (vi) for purpose of clarity, any obligations Theraclone had to pay a portion of its Licensing Proceeds
to ZKC shall immediately cease as of such termination date, and (vii) all Sublicensees that elect in writing within thirty (30)
days to retain rights shall automatically become directly licensed by Theraclone within the same scope of sublicense that they
had from Zenyaku and shall owe royalties and Sublicensing Proceeds to Theraclone at the same rates as set forth in Article 5.

 

    	48

    	 

    

 

In addition, ZKC hereby
agrees that in the event of any such termination, unless Theraclone shall otherwise be in material breach of the licenses granted
pursuant to this Section or ZKC shall obtain any right to the Licensed Products, ZKC shall promptly disclose in physical or other
tangible form to Theraclone all data, regulatory filings, and product licenses with respect to all Licensed Antibodies and all
Licensed Products in each case originating with and proprietary to Theraclone, each to the extent necessary to allow Theraclone
to exercise the licenses granted pursuant to this Section. Following any such termination described in this Section, Theraclone
shall be responsible for any and all costs and liabilities in connection with its or its sublicensee’s holding and/or exercise
of the licenses granted pursuant to this Section.

 

Furthermore, in the
event of any such termination of this Agreement, ZKC shall notify Theraclone of the amount of Licensed Product ZKC and its Affiliates,
Sublicensees and distributors have on hand as of the effective date of such termination, the sale of which would be subject to
royalty payments under this Agreement. ZKC and its Affiliates, Sublicensees and distributors shall have the right to sell that
amount of Licensed Product, provided that ZKC shall pay to Theraclone the royalty amounts payable thereon at the time of the effective
date of such termination, which amounts shall be due within forty-five (45) days after such sale:

 

15.9         
Effect of Termination by ZKC for Theraclone’s Uncured Material Breach or Insolvency. If ZKC terminates
this Agreement pursuant to Section 15.4 (for Theraclone’s uncured material breach) or pursuant to Section 15.5 (for Theraclone’s
insolvency) then: (i) all rights and licenses granted to ZKC pursuant to Section 4.1(a) of this Agreement under the Theraclone
Patents, Theraclone Know-How and Theraclone’s interest in the Joint Patents shall remain in full force and’effect and
ZKC shall continue to have the obligation to pay royalties in accordance with Section 5.7 with respect to Licensed Products thereafter
commercialized; provided, however, that the applicable royalty rate(s) set forth in Section 5.7 shall thereafter be reduced by
one-third (1/3), (ii) subject to the maintenance of rights held by Other Licensees as of the effective date of a termination pursuant
to this Section, all rights and licenses granted to Theraclone pursuant to Section 4.1(b) shall revert to ZKC and Theraclone shall
retain no license rights therein, (iii) ZKC shall be released from any and all obligations hereunder (including the diligence obligations
in Section 7) arising after the effective date of such termination, (iv) Theraclone’s supply obligations under this Agreement
(including those in Section 8) and the Supply Agreement shall continue in full force and effect but ZKC’s covenant not to
practice its manufacture and have manufactured rights under the Supply Agreement shall immediately expire, (v) ZKC shall have the
right to elect in its sole discretion to terminate the Supply Agreement, or reduce the amount of its requirements that it satisfies
under the Supply Agreement, upon written notice to Theraclone or to continue the Supply Agreement (in any event for at least two
(2) years after the effective date of termination of this Agreement, if elected by ZKC), and (vi) ZKC agrees that any sublicenses
at that time in effect between Theraclone and Other Licensees under the license to Theraclone in Section 4.1(b), shall become direct
licenses between Zenyaku and the Other Licensees for the practice, use, licensing, manufacturing, marketing, sale, or distribution
by such Other Licensees of the Licensed Antibodies and Licensed Products that originated with and were proprietary to Zenyaku,
to avoid doubt, solely in the Retained Territory and solely to the extent within or more narrow than the scope of the license to
Theraclone in Section 4.1(b). In the case of (vi), this only applies with respect to those Other Licensees who were not in breach
of any provision of the agreement by which they obtained rights from Theraclone, and to avoid doubt, the flow-through of rights
from such Other Licensees to Zenyaku in accordance with Section 4.6 shall remain in full force and effect as a condition of obtaining
such direct license from Zenyaku.

 

    	49

    	 

    

 

15.10     
Effect of Expiration. Upon expiration of the Royalty Term of this Agreement, the license granted to ZKC
in Section 4.1(a) shall thereafter become irrevocable and royalty-free except for the following royalty payments: (i) if there
is a cell line within the Theraclone Know-How that is the production cell line for the Licensed Product, then ZKC shall pay the
royalties due under Section 5.7 at the rate of [***] and (ii) if ZKC uses Theraclone’s
product trademarks in connection with the Licensed Product, then the trademark license granted to ZKC by Theraclone in Section
4.1(a) shall survive for this purpose and ZKC shall pay additional royalties on Net Sales of Licensed Product at the rate of [***].
In addition, ZKC shall be fully released from its covenant and commitment not to practice its manufacture and have manufactured
rights under the Supply Agreement. To be clear, the right of Theraclone to be identified on the label of Licensed Products shall
not survive expiration unless required by law.

 

15.11     
Survival. Expiration or early termination of this Agreement shall not relieve either party of its obligations
incurred prior to such expiration or early termination. In addition, Sections 5.9, 5.12 and 5.13 (with respect to payments due
for sales during the term of this Agreement); 6.3 (with respect to audit rights); 6.4; 10.1(b); 11.3; 11.4; 11.5; 11.6; 11.7; 15.7;
15.8; 15.9; 15.10; and 15.11; and Articles 9, 12, 13, 14, 16 and 17 shall survive any expiration or early termination of this Agreement.

 

16.             
Indemnification.

 

16.1         
By ZKC. Subject to Section 16.3 hereof, from and after the Effective Date, except as otherwise herein
specifically provided, ZKC shall defend, indemnify and hold harmless Theraclone and its Affiliates and their successors and assigns,
Other Licensees, and the respective officers, directors, shareholders, partners, and employees of each of the foregoing entities
(each a “Theraclone Indemnified Party”) from and against all losses, damage, liability, and expense including
legal fees (“Damages”) incurred thereby or caused thereto arising out of or relating to any demand, claim, action
or proceeding brought or initiated by a Third Party (each a “Third Party Claim”) against any Theraclone Indemnified
Party to the extent that such Third Party Claim arises out of (i) any breach or violation of, or failure to properly perform, any
covenant or agreement made by ZKC in this Agreement or the Supply Agreement, unless waived in writing by the Theraclone Indemnified
Party; (ii) any breach or alleged breach of any of the representations or warranties made by ZKC in this Agreement or the Supply
Agreement; (iii) the gross negligence or willful misconduct of ZKC; (iv) the First-3-Years Additional Technology costs to the extent
that Zenyaku is responsible for them under Section 4.1(c) and Section 4.1(f); or (v) any claim arising from the manufacture (to
be clear, other than by Theraclone under the Supply Agreement), storage, handling, use, sale, offer for sale, import, export or
distribution of Supply Products by ZKC, in each case except to the extent arising from the failure of the delivered quantities
of Supply Product to conform to the Specifications upon delivery pursuant to Section 2.4 of the Supply Agreement, such exception
including, to be clear, Latent Defects present in the delivered quantities of Supply Product upon delivery pursuant to Section
2.4 of the Supply Agreement (and, to avoid any doubt, this item (v) excludes Damages and Third Party Claims arising out of or relating
to item (v) in Section 16.2); provided, however, that such indemnity as provided for in items (i) - (v) shall not apply
to the extent Theraclone has an indemnification obligation pursuant to Section 16.2 for such Damages. “Supply Products,”
“Specifications” and “Latent Defects” shall have the meanings given to them in the Supply Agreement.

 

*Confidential Treatment
Requested.

 

    	50

    	 

    

 

16.2         
By Theraclone. Subject to Section 16.3 hereof, from and after the Effective Date, except as otherwise
herein specifically provided, Theraclone shall defend, indemnify and hold harmless ZKC, its Affiliates and their successors and
assigns, Sublicensees, and the respective officers, directors, shareholders, partners, and employees of each of the foregoing entities
(each a “ZKC Indemnified Party”) from and against all Damages incurred thereby or caused thereto arising out
of or relating to any Third Party Claim against any ZKC Indemnified Party to the extent that such Third Party Claim arises out
of (i) any breach or violation of, or failure to properly perform, any covenant or agreement made by Theraclone in this Agreement
or the Supply Agreement (including, to be clear, with respect to any Latent Defects (as defined in the Supply Agreement) present
in the delivered quantities of Supply Product (as defined in the Supply Agreement) upon delivery pursuant to Section 2.4 of the
Supply Agreement), unless waived in writing by the ZKC Indemnified Party; (ii) any breach or alleged breach of any of the representations
or warranties made by Theraclone in this Agreement or the Supply Agreement (including, to be clear, with respect to any Latent
Defects (as defined in the Supply Agreement) present in the delivered quantities of Supply Product (as defined in the Supply Agreement)
upon delivery pursuant to Section 2.4 of the Supply Agreement); (iii) the research and development activities performed by Theraclone
under this Agreement, (iv) the gross negligence or willful misconduct of Theraclone, or (v) all costs of Additional Technology
and/or infringement thereof, other than those First-3-Years Additional Technology costs to the extent that Zenyaku is responsible
for them under Section 4.1(c) and Section 4.1(f); provided, however, that such indemnity as provided for in items (i) -
(v) shall not apply to the extent ZKC has an indemnification obligation pursuant to Section 16.1 for such Damages.

 

    	51

    	 

    

 

16.3         
Mechanics. If any Theraclone Indemnified Party or ZKC Indemnified Party (in each case an “Indemnified
Party”), receives any written claim which it believes is the subject of indemnity hereunder by either Theraclone or ZKC,
as the case may be (in each case an “Indemnifying Party”), the Indemnified Party shall, as soon as reasonably
practicable after forming such belief, give notice thereof to the Indemnifying Party, including full particulars of such claim
to the extent known to the Indemnified Party; provided, however, that the failure to give timely notice to the Indemnifying
Party as contemplated hereby shall release the Indemnifying Party from any liabilities caused by such failure but shall not release
the Indemnifying Party from any liability to the Indemnified Party other than any liabilities caused by such failure. The Indemnifying
Party shall have the right, by prompt notice to the Indemnified Party, to assume the defense of such claim with counsel reasonably
satisfactory to the Indemnified Party, and at the cost of the Indemnifying Party. If the Indemnifying Party does not so assume
the defense of such claim, the Indemnified Party may assume such defense with counsel of its choice at the sole expense of the
Indemnifying Party. If the Indemnifying Party so assumes such defense, the Indemnified Party may participate therein through counsel
of its choice, but the cost of such counsel shall be borne solely by the Indemnified Party. The party not assuming the defense
of any such claim shall render all reasonable assistance to the party assuming such defense, and all out-of-pocket costs of such
assistance shall be borne solely by the Indemnifying Party. No such claim shall be settled other than by the party defending the
same, and then only with the consent of the other party, which shall not be unreasonably withheld or delayed; provided, however,
that the Indemnified Party shall have no obligation to consent to any settlement of any such claim which imposes on the Indemnified
Party any liability or obligation which cannot be assumed and performed in full by the Indemnifying Party.

 

17.             
Miscellaneous.

 

17.1         
Force Majeure. If the performance of any part of this Agreement by either party, or of any obligation
under this Agreement, is prevented, restricted, interfered with or delayed by reason of any cause beyond the reasonable control
of the party liable to perform, the party so affected shall, upon giving written notice to the other party, be excused from such
performance to the extent of such prevention, restriction, interference or delay, provided that the affected party shall use its
Commercially Reasonable Efforts to avoid or remove such causes of nonperformance and shall continue performance with the utmost
dispatch whenever such causes are removed. When such circumstances arise, the parties shall discuss what, if any, modification
of the terms of this Agreement may be required in order to arrive at an equitable solution. Notwithstanding anything to the contrary,
this Section shall not be interpreted to diminish Zenyaku’s rights in Section 5.2 of the Supply Agreement or to excuse Theraclone
from the consequences under such section.

 

17.2         
Severability.

 

(a)              
In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portions
hereof shall remain in full force and effect.

 

(b)              
If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law,
then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to
be modified to conform with such statute or rule of law.

 

    	52

    	 

    

 

17.3         
Entire Agreement. This Agreement and all Exhibits hereto, entered into as of the date first written above,
together with the Supply Agreement, constitutes the entire agreement between the parties relating to the subject matter hereof
and supersedes all previous writings and understandings (and any and all information exchanged by the parties under their Confidential
Information and Non Disclosure Agreement dated as of June 23, 2006 shall be deemed Confidential Information exchanged under this
Agreement and subject to the obligations with respect thereto contained in this Agreement). No terms or provisions of this Agreement
shall be varied or modified by any prior or subsequent statement, conduct or act of either of the parties, except that the parties
may mutually amend this Agreement by written instruments specifically referring to and executed in the same manner as this Agreement.

 

17.4         
Notices. Any notice required or permitted under this Agreement shall be deemed given if delivered in writing
(i) personally, (ii) by facsimile transmission (receipt verified), (iii) by registered or certified mail (return receipt requested),
postage prepaid, (iv) by electronic mail (receipt verified), or (v) sent by express courier service (receipt verified), to the
following addresses of the parties or such other addresses as the parties may provide notice of pursuant to this Section. Any notice
required or permitted to be given pursuant to this Agreement shall be effective upon receipt by Theraclone or ZKC, as the case
may be.

 

IF TO THERACLONE:

Theraclone Sciences, Inc.

1124 Columbia Street, Suite 300

Seattle, WA 98104

USA

Attention: Chief Executive Officer with
a copy to Chief Financial Officer

Telephone: +1 (206) 805-1600

Facsimile: +1 (206) 805-1699

 

WITH A REQUIRED COPY (which shall not
constitute notice) to:

Beacon Law Advisors, PLLC

801 2nd Ave., Suite 614

Seattle, WA 98104

Attention: Noel C. Howe

Telephone: +1 (206) 264-3071

Facsimile: +1 (206) 749-9261

 

IF TO ZKC:

Zenyaku Kogyo Co., Ltd

5-6-15, Otsuka, Bunkyo,

Tokyo 112-8650

Attention: Director, Product Development

Telephone: +(03) 3946-1113

Facsimile: +(03) 3946-1202

 

    	53

    	 

    

 

WITH A REQUIRED COPY (which shall not
constitute notice) to:

Morrison & Foerster LLP

425 Market Street

San Francisco, CA 94105

 

17.5         
Independent Contractors. Theraclone and ZKC shall be independent contractors and shall not be deemed to
be partners, joint venturers or each other’s agents or involved in any fiduciary relationship. Nothing in this Agreement
shall be construed to be inconsistent with the parties’ relationship or status as independent contractors.

 

17.6         
Unenforceable Provisions. If any provision of this Agreement is finally held to be invalid, illegal or
unenforceable by a court of competent jurisdiction, the validity, legality and enforceability of the remaining provisions shall
not be affected or impaired in any way.

 

17.7         
Waiver. Any delay in enforcing a party’s rights under this Agreement or any waiver as to a particular
default or other matter shall not constitute a waiver of a party’s right to the future enforcement of its rights under this
Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time
executed by an authorized officer of the waiving party.

 

17.8         
Construction. This Agreement has been prepared jointly and shall not be strictly construed against either
party. Ambiguities, if any, in this Agreement shall not be construed against any party, irrespective of which party may be deemed
to have authored the ambiguous provision.

 

17.9         
Headings. The headings for each article and section in this Agreement have been inserted for convenience
of reference only and are not intended to limit or expand on, nor to be used to interpret, the meaning of the language contained
in the particular article or section.

 

17.10     
Counterparts. This Agreement may be signed in counterparts, each of which shall be deemed an original
and all of which together shall constitute one instrument. In addition, signatures may be exchanged by facsimile or PDF.

 

[Signature page follows]

 

    	54

    	 

    

 

 

IN WITNESS WHEREOF, each of the parties hereto
has caused this Agreement to be executed by its duly authorized officer as of the date first written above.

 

	 	THERACLONE SCIENCES, INC.
	 	 
	 	By:	/s/ David Fanning
	 	 	David Fanning
	 	 	President and Chief Executive Officer
	 	 	 
	 	 	 
	 	ZENYAKU KOGYO CO., LTD.
	 	 
	 	By:	/s/ Kazuhiro Hashimoto
	 	 	Kazuhiro Hashimoto
	 	 	President and Representative Director

 

    	55

    	 

    

 

EXHIBIT A

 

LICENSED ANTIBODIES

 

The antibodies with the following reference
numbers: [***]. The compositions of such antibodies can be found in the patents listed
on Exhibit C hereto.

 

 

 

*Confidential Treatment Requested.

 

    	56

    	 

    

 

EXHIBIT B

 

[Intentionally left blank.]

 

    	57

    	 

    

 

 

EXHIBIT C

 

PATENT EXHIBIT

THERACLONE PATENT APPLICATIONS

 

[***]

 

 

 

 

*Confidential Treatment Requested.

 

    	58

    	 

    

 

EXHIBIT D-1

 

ANTI-INFLUENZA M2E MAB DEVELOPMENT
PLAN OUTLINE

PROJECT ROLES AND RESPONSIBILITIES

 

[***]

 

Development Plan Outline

 

The activities below are to be performed
by Theraclone.

 

[***]

 

 

*Confidential Treatment Requested.

 

    	59

    	 

    

 

 

EXHIBIT E-1

 

RESEARCH PLAN OUTLINE TO IDENTIFY
A STRUCTURED MIMETIC

OF THE M2E NATIVE CONFORMATION THAT MAY BE USED AS A VACCINE

ANTIGEN

 

[***]

 

 

 

*Confidential Treatment Requested.

 

    	60

    	 

    

 

EXHIBIT E-2

 

RESEARCH PLAN OUTLINE TO IDENTIFY
A STRUCTURED MIMETIC

OF THE HA NATIVE CONFORMATION THAT MAY BE USED AS A VACCINE

ANTIGEN

 

[***]

 

 

 

*Confidential Treatment Requested.

 

    	61

    	 

    

 

EXHIBIT F

 

FORM OF SUPPLY AGREEMENT

 

    	62

    	 

    

 

SUPPLY AGREEMENT

 

This Supply Agreement (this “Supply
Agreement”) is made as of ____________ (the “Effective Date”) by and between Theraclone Sciences,
Inc., a corporation organized and existing under the laws of the State of Delaware, USA and having its principal office at 1124
Columbia Street, Suite 300, Seattle, Washington, 98104, USA (“Theraclone”) and Zenyaku Kogyo Co., Ltd., a corporation
organized and existing under the laws of Japan and having its principal office at 6-15 Otsuka, 5-Chome, Bunkyo-Ku, Tokyo 112-8650,
Japan (“ZKC” or “Zenyaku”).

 

RECITALS

 

A. ZKC and Theraclone have entered into
a Development and License Agreement dated as of the date hereof (the “License Agreement”), pursuant to which
Theraclone licensed to ZKC certain intellectual property rights related to the development of prophylactic and therapeutic products
for the prevention and treatment of disease, including influenza infection in humans.

 

B. In connection with, and in accordance
with the terms and conditions of, Section 8.1 of the License Agreement, Theraclone is willing to supply to ZKC, and ZKC agrees
to purchase from Theraclone upon the terms and subject to the conditions set forth in this Supply Agreement, certain preclinical
and clinical grade human monoclonal antibodies as set forth in this Supply Agreement.

 

NOW THEREFORE, in consideration of the premises
and the mutual covenants herein set forth, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree
as follows:

 

1.                 
DEFINITIONS.

 

Capitalized terms used herein shall have
the respective meanings set forth in the License Agreement unless otherwise defined herein. All references to particular Exhibits,
Articles and Sections shall mean the Exhibits to, and Articles and Sections of, this Supply Agreement, unless otherwise specified.
References to this “Supply Agreement” include the Exhibits. For the purposes of this Supply Agreement, the following
words and phrases shall have the following meanings and derivative forms (e.g., the singular shall be interpreted to be one of
the items defined in the plural and vice versa; provided, however, if a word or phrase does not have its first letter(s)
capitalized then it shall not have the following meaning) of them shall be interpreted accordingly:

 

“cGMP” means current good
manufacturing practices as defined in (a) the FDA rules and regulations, 21 CFR Part 211 for finished pharmaceuticals, (b) the
counterparts to these regulations in the Territory, and/or (c) International Conference on Harmonization guidelines relating to
the same subject matter, whatever is the most stringent.

 

“FDA” shall mean the U.S.
Food and Drug Administration or any successor agency thereof.

 

    	1

    	 

    

 

“Fully Burdened Manufacturing Cost”
or “FBMC” means the actual fully burdened costs and expenses of manufacturing for the Supply Product in the
Territory, which costs and expenses include, without limitation, the costs of all raw materials and labor (including all allocable
benefits) used or consumed in such manufacture, the costs of storage, Third Party contract manufacturing costs (but excluding any
costs with respect to manufacturing development by a Third Party and/or facility expansion and/or build-out; all of the foregoing
are handled as provided in Section 2.2(a)), packaging costs and expenses, all quality assurance and quality control related
expenses, all other regulatory costs and expenses, and all overhead amounts specifically allocable to such manufacturing (but explicitly
excluding executive management and related overhead relating to executive management with broader responsibility than solely manufacturing;
capital equipment costs and start-up costs, whether or not amortized; and costs of excess capacity), and all royalty amounts payable
by Theraclone to any Third Party due to the manufacture of Supply Product, all of the foregoing as calculated in accordance with
US generally accepted accounting principles consistently applied.

 

“Specifications” means
written specifications related to the manufacture (including, to avoid doubt, manufacturing methods and processes and assay procedures)
of the Supply Product that will be developed (and may be amended) pursuant to Section 3.1 and shall be attached hereto and
made a part hereof as Exhibit B. Whether or not separately referenced in Exhibit B, compliance with cGMP
shall be deemed to be required by the Specifications and by this Supply Agreement.

 

“Supply Failure” has the
meaning given in Section 5.2.

 

“Supply Product” shall
mean the monoclonal antibody or monoclonal antibodies, or products containing the foregoing, set forth on Exhibit A
attached hereto, as amended from time-to-time by mutual written agreement by the parties; provided that, with respect to any composition
that is a Licensed Antibody that Zenyaku requires after JSC review under the License Agreement, if Theraclone does not agree to
manufacture such composition as a Supply Product under this Supply Agreement, Zenyaku shall have the right to manufacture or have
manufactured such composition for the Territory (and ZKC shall be released with respect to such composition from its covenant not
to practice its manufacture and have manufactured rights set forth below in Section 5.4).

 

The words “include,” “includes,”
“including” and other conjugations of “to include” shall be deemed followed by “without limitation”
regardless of whether written there (and drawing no implications from inconsistent usage).

 

2.                 
PRODUCT SUPPLY.

 

2.1             
Purchase and Sale. Upon the terms and subject to the conditions of this Supply Agreement, Theraclone shall
sell and supply to ZKC all of its requirements of the Supply Product, in accordance with this Supply Agreement. ZKC agrees, for
itself, its Affiliates and Sublicensees, to satisfy solely through ZKC’s purchase of the Supply Product under this Supply
Agreement [***] of ZKC’s, its Affiliates’ and Sublicensees’ reasonable
requirements of the Supply Product (“Requirements”), except as provided for otherwise in this Supply Agreement
(for example, in Article 5). The parties agree that Theraclone shall have the right in connection with the supply of Supply
Product hereunder to contract with respect to manufacture of the Supply Product with such Third Parties that (i) are fully
accredited by the Regulatory Authority in the Territory, (ii) as Theraclone deems advisable, and (iii) are an entity
for whom ZKC has given its prior written approval (including with respect to the terms of Theraclone’s agreement with such
Third Party manufacturer), which approval shall not be unreasonably withheld, delayed, or conditioned; provided, however, that
Theraclone shall remain fully responsible for all of its obligations hereunder. ZKC may specify that certain of the orders that
it places under this Supply Agreement shall be delivered by the carrier directly to ZKC’s Affiliates and ZKC’s and
its Affiliates’ Sublicensees and Distributors, in which case Theraclone shall fully permit and facilitate this.

 

*Confidential Treatment Requested.

 

    	2

    	 

    

 

2.2             
Purchase Price, Price Adjustments and Payment.

 

(a)               
For Supply Product supplied by Theraclone to ZKC pursuant to this Supply Agreement, ZKC shall pay a purchase price
equal to the Fully Burdened Manufacturing Cost of the Supply Product plus [***] mark
up over FBMC for bulk or vialed unlabeled Supply Product (the “Purchase Price”). Additional costs of (a) manufacturing
development to develop processes that are unique to the Territory and are not being used to manufacture for the Retained Territory
shall be included in the calculation of FBMC of the Supply Products for supply to ZKC for the Territory, (b) manufacturing
development occurring after the Phase I Trials of Supply Product to develop manufacturing processes used to produce worldwide supply
shall be allocated to the products for worldwide supply, (c) any costs to develop manufacturing processes to meet the specific
requirements of any subset of the Retained Territory that will not be used to produce worldwide supply shall be absorbed by the
product for such Retained Territory and not included in FBMC under this Supply Agreement; provided however that the foregoing costs
included in (a) and (b) shall not be charged immediately and instead shall be absorbed or amortized into the commercial supply
price of Supply Product over a period of years mutually agreed after commercial launch; and provided, further, that,
notwithstanding the first sentence of this Section 2.2(a), the [***] markup
over FBMC to arrive at the Purchase Price shall be calculated excluding the particular cost elements (a) and (b) described in this
sentence, and there shall be no markup over these cost elements (a) and (b). Costs of facility build-out and/or expansion of Theraclone’s
or a Third-Party contract manufacturer’s facility shall be allocated to worldwide supply of products over a period of years
as described in the foregoing sentence, but, notwithstanding the first sentence of this Section 2.2(a), the [***]
markup over FBMC to arrive at the Purchase Price shall be calculated excluding the particular cost element described in this sentence,
and there shall be no markup over this cost element. FBMC and all of the foregoing elements of FBMC shall be calculated in accordance
with US generally accepted accounting principles consistently applied. Theraclone shall provide ZKC with details of such Fully
Burdened Manufacturing Cost upon request by ZKC. In establishing scale up commercial manufacturing process for bulk Supply Product,
Theraclone shall use Commercially Reasonable Efforts to achieve a commercially reasonable manufacturing cost for Supply Product.
If any non-conforming lot occurs, then the JSC or the JCC will discuss if the non-conformity is due to Theraclone’s willful
misconduct or negligence or not. If the JSC or JCC (as applicable) agrees that it is not due to Theraclone’s willful misconduct
or negligence, then the JSC or JCC (as applicable) shall also discuss reasonable measures to amortize or allocate the cost of such
non-conforming lot to the products for worldwide supply. (To avoid doubt, if due to willful misconduct or negligence, the costs
of the non-conforming lot shall not be included in whole or in part in FBMC.) If the JSC or JCC (as applicable) review reveals
reasonable measures that should be taken to avoid future failures and losses, then Theraclone shall implement such measures. If
the JSC or JCC (as applicable) cannot agree on the determination of Theraclone’s willful misconduct or negligence, then the
Chief Executive Officer (or his designee) of each of the parties shall enter into good faith discussion regarding the matter

 

*Confidential Treatment Requested..

 

    	3

    	 

    

 

Furthermore, if ZKC believes that there
has been a change that will have a material impact on the pricing of the Supply Products (for example, a material change in the
pricing policy established by the applicable Regulatory Authority in the Territory; a sharp exchange fluctuation for the Territory;
a material economic downturn within the Territory), then the parties agree to meet and engage in good faith discussions and negotiate
an agreement in good faith regarding a reasonable reduction to the [***] mark-up
to Fully Burdened Manufacturing Cost above for Supply Products supplied by Theraclone under this Section. If the parties are unable
to conclude such agreement within sixty (60) days after the date ZKC first notifies Theraclone regarding the change, either party
shall be entitled to submit the matter to the dispute resolution process in Article 11 for final determination and implementation
of such discount in a reasonable amount. The standard to be applied is that the reduction shall equal the percentage of ZKC’s
lost profitability on the Supply Products due to such material change (e.g., if a material change in the pricing policy of the
Japanese government reduces ZKC’s profit on the Supply Product by [***], then
the mark-up to Fully Burdened Manufacturing Cost shall be reduced by [***] –
that is, the mark-up to Fully Burdened Manufacturing Cost will be [***]). When making
the determination in the immediately preceding sentence, the arbitrator(s) will review up to five (5) years of historical data
regarding ZKC’s profitability with respect to the Supply Product, or if five (5) years of historical data is not available,
then the arbitrator(s) will use whatever historical data is available and reasonable market projections for the Supply Product
in the Territory such that the available historical data and the market projections cover a five (5) year span (e.g., if three
(3) years of historical data is available, then the arbitrator(s) will combine that with market projections for the next two (2)
years). The arbitrator(s) under Article 11 (if arbitration becomes necessary) is hereby empowered to select the reduction based
on such criterion. This Section is not an “agreement to agree” for legal purposes and is intended to be fully enforceable
with the arbitrator(s) fully empowered to make the selection as to the appropriate reduction.

 

Theraclone agrees to allow an independent
auditing firm selected and paid for by ZKC (except as set forth otherwise in 2.2(b)) to audit Theraclone’s accounting records
pertaining to the manufacture of the Supply Product once per year. ZKC agrees that all information relating to accounting records
pertaining to the manufacture of Supply Product shall be treated as Confidential Information under Article 10 hereof. Such
examination shall occur only on reasonable prior notice during regular business hours during the term of this Supply Agreement
and for three (3) years thereafter, provided, however, that such examination shall not (i) be of such records for more than
the prior three (3) years, or (ii) cover any such records which date prior to the date of the last examination, and provided
further that such accountants shall only report to ZKC as to the accuracy of the price charged by Theraclone to ZKC for ZKC purchase
of Supply Product.

 

(b)              
In the event that the audit conducted under Section 2.2(a) shows that ZKC has overpaid Theraclone (which may
include a finding that Theraclone’s Fully Burdened Manufacturing Cost has been miscalculated), and Theraclone does not dispute
the results of such audit with reasonable written evidences, then Theraclone shall pay back the amount of such overpayment immediately
upon request of ZKC. In the case that such overpayment is more than [***] of the
amounts otherwise due for the audited period, Theraclone shall reimburse ZKC for the expense of the audit.

 

*Confidential Treatment Requested.

 

    	4

    	 

    

 

(c)               
Theraclone shall invoice ZKC at the time of or after each shipment of the Supply Product and shall receive from ZKC
payment of such invoice within forty-five (45) days of ZKC’s receipt of the invoice.

 

2.3             
Forecast and Orders.

 

(a)               
Within sixty (60) days after the Effective Date (or such other date as may be agreed upon by the parties), ZKC shall
furnish to Theraclone a forecast (the “Initial Forecast”) of ZKC’s requirements for the Supply Product
for each of the calendar quarters within the period starting with the first full calendar quarter that starts six (6) months after
such Initial Forecast is due and ending with the calendar quarter that ends on September 30. Such Initial Forecast will contain
information sufficient for Theraclone to determine ZKC’s requirements for Supply Product for the period covered by the Initial
Forecast. By no later than March 31 of each year (the “Forecast Date”) following the due date of the Initial
Forecast, ZKC shall provide Theraclone with a forecast (a “Firm Forecast”) of ZKC’s requirements for the
Supply Product for each calendar quarter during the twelve-month period commencing on October 1 of the same calendar year
as the Forecast Date and ending twelve (12) months later (i.e., on September 30 of the next calendar year). To be clear, on
each anniversary of the Forecast Date during the term of this Supply Agreement, ZKC shall deliver to Theraclone additional Firm
Forecasts covering the twelve month period commencing where the prior Firm Forecast ended (i.e., commencing on October 1 of
the applicable year). The Initial Forecast shall be included within the meaning of “Firm Forecast.”

 

(b)              
The amount of Supply Product forecast in each Firm Forecast shall automatically be ZKC’s firm and binding purchase
order therefor and ZKC shall be obligated to purchase the amount provided therein. To be clear, except as set forth otherwise in
this Supply Agreement or as otherwise agreed to by the parties, ZKC shall be obligated to purchase not less than [***]
of the amount of Supply Product forecasted in each Firm Forecast. If, at any time, ZKC reasonably believes that the amount of Supply
Product it will require pursuant to a future Forecast will increase to more than [***]
or decrease to less than [***] of the quantities provided in the prior Firm Forecast,
ZKC shall inform Theraclone in writing promptly and provide Theraclone with an estimate of such anticipated future requirements.
Such estimate of anticipated future requirements shall be non-binding and is intended to aid Theraclone in planning; provided,
however, that in the event ZKC issues a purchase order for an amount in excess of the amount provided in the Firm Forecast, Theraclone
shall be obligated to deliver the amounts specified in such purchase order if such quantity falls within Theraclone’s production
capacities after taking into account Theraclone’s and its other licensees’ requirements. Notwithstanding anything implied
above that could be read to limit ZKC’s order for its trial or sales requirements, ZKC may include in the Firm Forecasts
(and Theraclone shall provide) amounts of Supply Product that will go into or are for ZKC’s safety stock.

 

*Confidential Treatment Requested.

 

    	5

    	 

    

 

Notwithstanding the foregoing, ZKC shall
be entitled to request to increase the amount of ordered Supply Product upon written notice to Theraclone at least six (6) months
in advance of the applicable delivery date. Theraclone will use Commercially Reasonable Efforts to accept and fulfill ZKC’s
request to change the amount of ordered Supply Product, but, with respect to any such requests to increase the amount of Supply
Product, it shall not in and of itself be considered a Supply Failure if Theraclone does not accept such request, and, if Theraclone
accepts such request, the increased amount over the quantity of the initially ordered amounts shall not be taken into account for
purposes of the “Supply Failure” definition.

 

In the event Theraclone is not able to meet
its and all of its licensees’ (meaning ZKC’s and those of any other licensee(s) for the Retained Territory) requirements
for Supply Products, then the Supply Product shall be reasonably allocated by Theraclone among ZKC, Theraclone, and Theraclone’s
other licensees in proportion to their relative demands and market size as determined by each entity’s average binding purchase
orders for Supply Product for the prior eighteen (18) months; provided, however, in no event shall ZKC be at a supply disadvantage
compared to Theraclone and its other licensees. In the event that any of the involved parties are not satisfied with Theraclone’s
allocation, then the CEOs of the involved parties will meet and will attempt to reach agreement on a reasonable, good faith allocation.

 

2.4             
Delivery. Theraclone will deliver the amounts specified in the Initial Firm Forecast and each Firm Forecast
in the calendar quarter specified therein. Delivery terms shall be FCA (Incoterms 2000) (as modified by this Section) at Theraclone’s
facility in Seattle, Washington, USA or such other facility as may be designated by Theraclone. To be clear, title to quantities
of Supply Product supplied under this Supply Agreement shall pass to ZKC and risk of loss of the quantities of Supply Product supplied
under this Supply Agreement shall pass to ZKC when the goods have been delivered to the carrier at the named place (i.e., in this
case, after Theraclone loads the goods onto the carrier at the facility designated by Theraclone). ZKC shall be responsible for
arranging and managing clearance through customs, and Theraclone shall provide all information needed to support this. Theraclone
shall use its reasonable commercial efforts to assist ZKC in arranging any desired insurance (in amounts that ZKC shall determine)
and transportation, via air freight unless otherwise specified in writing, to any destinations specified in writing from time-to-time
by ZKC. All customs, duties, costs, taxes, insurance premiums, and other expenses relating to such transportation and delivery,
shall be at ZKC’s expense. All shipment of the Supply Product shall be under appropriate storage conditions. Without limiting
Section 2.11, the terms and conditions of this Supply Agreement shall control as to a particular purchase order unless otherwise
agreed to in writing by the parties.

 

2.5             
Safety Stock. Promptly after the first BLA filing for Supply Product in the Territory), Theraclone and
ZKC shall, via the Joint Steering Committee, discuss and agree upon an appropriate amount of safety stock of Supply Product for
ZKC to hold (provided, however, if the Joint Steering Committee cannot agree, ZKC shall be entitled in any event to purchase the
amount of safety stock that ZKC deems necessary or appropriate). Such discussions shall take into account the shelf life and stability
of the Supply Product. Such safety stock shall be paid for by ZKC (under the terms set forth herein) and will be managed by ZKC.
For clarity, all purchases of safety stock shall be made pursuant to the forecasting and ordering mechanism set forth in Section 2.3
above.

 

    	6

    	 

    

 

2.6             
Payment Instructions. All payments due hereunder shall be made in US dollars by wire transfer of immediately
available funds to an account specified by Theraclone.

 

2.7             
Past Due Amounts. Any past due payments under this Supply Agreement shall accrue interest until paid at
the greater of (i) [***] or (ii) [***].
Notwithstanding the foregoing, if such rate is greater than the maximum rate permitted by law, then such rate will be reduced to
the maximum rate permitted by law.

 

2.8             
Foreign Currency. Currency conversions to US Dollars, if any shall be translated on a monthly basis from
Japanese Yen to US Dollars by using an average rate of exchange of such month. This average shall be computed using the closing
Telegraphic Transfer Selling (TTS) Rate of exchange quoted by the Tokyo-Mitsubishi Bank in Tokyo (or if it no longer exists its
successor, or if no successor to it exists then a similarly reputable financial institution) as of the end of such month plus the
rate as of the end of the prior month and dividing by two (2). A similar exchange mechanism shall be used for sales in other countries
in the Territory.

 

2.9             
Import Fees and Packaging. ZKC shall be responsible for obtaining all necessary import and/or export licenses
or permits and for the payment of all import and/or export fees, taxes or duties, and the like, in connection with the purchase
and/or delivery of Supply Product to ZKC. Other than filling into unlabelled vials with respect to quantities that ZKC orders to
be provided in that form, ZKC shall be responsible for finish packaging of Supply Product at its expense, including without limitation,
all packaging and labeling for commercial sales of the Supply Product.

 

2.10         
Permitted Uses. ZKC shall use the Supply Product supplied by Theraclone hereunder only for the purposes
of exercising ZKC’s license granted under the License Agreement. ZKC shall use the Supply Product in compliance with this
Supply Agreement, the License Agreement and with all applicable federal, state and local laws and regulations. Except as set forth
in Section 5.4, no rights or licenses are, or are intended to be, conveyed hereunder by implication, estoppel or otherwise
and no transfer of ownership of intellectual property rights is granted herein. Except as set forth in Section 5.4, all terms
related to licenses and ownership of intellectual property rights are covered in the License Agreement. ZKC shall not transfer
the Supply Product or any related information to any person who is not under the immediate and direct supervision of ZKC, except
as may otherwise expressly be provided in this Supply Agreement or the License Agreement, and specifically excluding: Sublicensees,
distributors, and others who are under contracts with ZKC which contracts are not prohibited under the License Agreement.

 

2.11         
No Change In Terms Through Purchase Orders. Only a formal writing signed by an officer of each party and
explicitly stating that it is an amendment to this Supply Agreement, can amend this Supply Agreement. No forecast (including the
Forecasts), purchase order, purchase order acceptance, document confirming or enclosed with a shipment, or other document shall
alter or amend the terms of this Supply Agreement. If there is a conflict or any inconsistency between such documents and this
Supply Agreement, the terms of this Supply Agreement shall control. Any such conflict or inconsistency is hereby expressly rejected.

 

*Confidential Treatment Requested.

 

    	7

    	 

    

 

3.                 
PRODUCT MANUFACTURE.

 

3.1             
Incoming Specifications. The parties will in good faith cooperate (via the Joint Steering Committee) with
one another to develop the Specifications, which shall be acceptable to both parties and in any event in compliance with cGMP and
any and all requirements of the Regulatory Authority in the Territory. The Specifications shall be agreed upon in writing by the
parties and attached hereto and incorporated into this Supply Agreement as Exhibit B. To avoid doubt, with respect
to any detailed aspects of the manufacturing process for Supply Product that are not explicitly stated in the agreed-upon Specifications,
initially such detailed aspects are subject to mutual agreement by the parties (after which such detailed aspects shall be deemed
included within the Specifications) and shall only be changed or amended in accordance with the process to amend the Specifications
set forth in this Section. The Specifications may be amended from time-to-time by mutual written agreement of the parties and as
set forth in this Section with respect to changes required to meet regulatory requirements in the Territory. Each of the parties
acknowledges and agrees that it is each of their intentions for the Specifications to be the same in the Territory and in the Retained
Territory, and they each agree to work together in good faith toward that intention. Notwithstanding the foregoing, the parties
each agree that any change to the Specifications required to meet regulatory requirements in the Territory shall be deemed mutually
agreed upon and the Specifications shall be deemed amended to incorporate such required change. ZKC shall notify Theraclone of
such required changes and the regulatory requirements requiring them. Any costs of such required change to the Specifications (after
the initial Specifications have been mutually agreed by the parties) shall be borne by ZKC. In addition, if ZKC requires (i) that
the Specifications for Supply Product (including, without limitation, a combination product) to be used in the Territory are different
from the specifications for the corresponding product in the Retained Territory and/or (ii) different Specifications because
ZKC requires a Supply Product that is different from the product(s) being developed and/or commercialized in the Retained Territory,
then [***] of all costs and expenses associated with developing such different Specifications
for the Territory shall be ZKC’s responsibility, including (without limitation) all process development, manufacturing development,
formulation, pre-clinical testing and clinical testing. If Theraclone requests any change to the agreed upon Specifications (including
without limitation any change required to meet regulatory requirements in the Retained Territory after the initial Specifications
have been mutually agreed by the parties), then [***] of all costs and expenses associated
with developing such different Specifications shall be Theraclone’s responsibility, including (without limitation) all process
development, manufacturing development, formulation, pre-clinical testing and clinical testing. The Specifications shall be considered
Confidential Information of both parties pursuant to Article 10 hereof.

 

3.2             
Manufacturing Process.

 

(a)               
Theraclone shall manufacture the Supply Product in accordance in all respects with cGMP and the Specifications and
any applicable regulations.

 

(b)              
Theraclone shall retain all manufacturing records for the period mutually agreed (including records relevant to the
accounting records described in Section 2.2(a)) and not discard them without the prior approval of ZKC, which approval will
not be unreasonably withheld or delayed. At a minimum, Theraclone shall retain all of the foregoing records at least for the minimum
period required by any law or regulation of the Territory.

 

*Confidential Treatment Requested.

 

    	8

    	 

    

 

(c)               
Theraclone shall not modify the processes nor change the facilities for manufacturing, testing, filling, or storage
for Supply Product for use in the Territory without the prior approval of ZKC, which approval will not be unreasonably withheld
or unreasonably delayed. To avoid doubt, it shall not be an unreasonable delay for ZKC to delay approval if ZKC is waiting for
a full reply from the applicable regulatory authority in the Territory or if ZKC requires the timing of the change to be delayed
so that there will be no interruption of legally-saleable-in-the-Territory Supply Product to ZKC pending regulatory review. In
addition, if Theraclone makes a change under this Section, then Theraclone shall be responsible for ZKC’s internal and external
regulatory costs.

 

3.3             
Testing of Supply Product.

 

(a)               
Theraclone shall test or cause to be tested each batch of Supply Product manufactured pursuant to this Supply Agreement
before delivery to ZKC. Each test shall test for, among other things, manufacture in accordance with the Specifications and all
applicable regulatory requirements, including cGMP. Each test shall set forth the Specifications, the items tested, and test results
in a certificate of analysis for each batch delivered. Theraclone shall send or cause to be sent such certificates to ZKC along
with delivery of Supply Product. Notwithstanding the foregoing, in no event shall Theraclone be required to perform tests that
are unique to ZKC (i.e., Theraclone will perform the same tests for all Supply Product regardless of whether such Supply Product
is being purchased by ZKC, an Other Licensee, or is being retained for use by Theraclone).

 

(b)              
ZKC may, in accordance with regulatory requirements in the Territory, test the Supply Product supplied by Theraclone.
Theraclone shall provide ZKC with biological materials, reference standards, assay information and any other in-house reagents
at reasonable cost in order for ZKC to test the conformity of the Supply Product supplied by Theraclone to Specifications. Notwithstanding
the foregoing, other than any tests requested or required (orally or in writing) by Regulatory Authorities or otherwise required
to comply with applicable regulations in the Territory, in no event will ZKC perform testing on the Supply Product that could result
in failed production units (i.e., lot failures) in the Retained Territory after such production units have been released by Theraclone;
provided, however, that the parties understand and agree that it is their mutual intent that Theraclone shall be entitled to manufacture
quantities of Supply Product under this Supply Agreement as separate batches from those that it manufactures for the Retained Territory
such that testing by Zenyaku pursuant to this Section will not jeopardize the release of quantities of Supply Product manufactured
for the Retained Territory.

 

4.                 
QUALITY ASSURANCE AND INSPECTION.

 

4.1             
Rejected Goods/Shortages.

 

(a)               
ZKC shall notify Theraclone in writing of any claim that any Supply Product does not conform to the Specifications
or any shortage in quantity of any shipment of Supply Product within [***] of delivery
(in accordance with Section 2.4) of such shipment, or, with respect to any claim that Supply Product did not conform to the
Specifications at the time of delivery (in accordance with Section 2.4), which claim could not be discovered upon reasonable
inspection of the Supply Product (including the testing of Supply Product set forth in Section 3.3 above and routine visual
inspection during such [***]) (a “Latent Defect”), within [***]
after becoming aware of or receiving notice of such claim. Upon confirming any such nonconformance or shortage (other than Latent
Defects, dealt with separately below in Section 4.1(d), Theraclone shall replace the Supply Product or make up the shortage
within [***] of receiving such notice, provided that Theraclone has sufficient conforming
Supply Product in its inventory to do so (subject to Section 4.1(c) below), and shall make arrangements with ZKC for the return
or destruction of any rejected Supply Product, with any reasonable return shipping charges or costs of destruction to be paid by
Theraclone.

 

*Confidential Treatment Requested.

 

    	9

    	 

    

 

 

(b)              
In the event of a conflict regarding any nonconforming Supply Product which Theraclone and ZKC are unable to resolve,
a sample of such Supply Product shall be submitted by ZKC to an independent laboratory reasonably acceptable to both parties for
testing against the Specifications, and the test results obtained by such laboratory shall be final and binding upon the parties.
The test results shall be considered Confidential Information pursuant to Article 10 hereof. The fees and expenses of such laboratory
testing shall be borne entirely by the party against whom such laboratory’s findings are made. In the event the test results
indicate that the Supply Product in question does not conform to the Specifications, Theraclone shall replace such Supply Product
with conforming Supply Product within [***] after receipt of such results, provided
that Theraclone has sufficient conforming Supply Product in its inventory to do so (subject to Section 4.1(c) below).

 

(c)               
If sufficient conforming Supply Product is not available for purposes of Sections 4.1(a) or (b), Theraclone
shall use its best efforts to replace the nonconforming Supply Product with conforming Supply Product as soon as possible, but
in no event shall the replacement time exceed [***]. For the avoidance of doubt,
such replacement set forth herein shall not relieve Theraclone from the liability arising from its delay of the delivery of Supply
Product, including liability in the form of the consequences provided for in Article 5.

 

(d)              
The remedy for Latent Defects shall be replacement as in subsection (a) if elected in writing by ZKC, and otherwise
shall be liability in the form of the consequences provided for in Article 5. The foregoing shall not limit ZKC’s rights
and Theraclone’s obligations under Section 8.

 

4.2             
Regulatory.

 

(a)               
In the event that any change to the Specifications is required by the applicable regulatory authority in the Territory
for Supply Product, Theraclone will ensure that such change is met. Such changes to the Specifications will be implemented as amendments
to the Specifications as set forth in Section 3.1.

 

(b)              
ZKC shall provide updates to Theraclone of (i) the progress of clinical development of Supply Product, (ii) the
fact of any investigational new drug application or BLA submissions relating to Supply Product, and (iii) copies of the applicable
sections of any ZKC regulatory filings which reference Theraclone, the Supply Product or Theraclone activities. The applicable
sections of such ZKC regulatory filings shall be delivered to Theraclone prior to submission of such regulatory filings, and Theraclone
shall have thirty (30) days to review and comment prior to their submission. ZKC shall also provide to Theraclone reasonable advance
notice of any regulatory submission containing information or data provided by Theraclone to ZKC that ZKC intends and is permitted
to disclose to regulatory agencies under this Supply Agreement or the License Agreement. Theraclone shall cooperate with ZKC and
provide reasonable assistance to make registration filings for Supply Product as set forth in Section 2.10 of the License
Agreement.

 

*Confidential Treatment Requested.

 

    	10

    	 

    

 

(c)               
Each party shall keep the other informed of any formal or informal inquiry by any regulatory agency of any state
or national government or supranational authority relating to Supply Product supplied hereunder.

 

(d)              
Theraclone shall permit representatives of any regulatory agency having jurisdiction over the manufacture and/or
marketing of the Supply Product or of any diagnostic assay or other product in which the Supply Product is incorporated (or that
is used in conjunction with Supply Product), to inspect its facilities in conjunction with the manufacture, testing, packaging,
storage, handling and shipping of the Supply Product. Further, Theraclone shall advise ZKC immediately if Theraclone receives notice
of an impending inspection or if an authorized agent of the FDA or other governmental agency visits any of Theraclone’s manufacturing
facilities concerning the Supply Product. Theraclone shall furnish to ZKC any report including any FDA Form 483 notices (or comparable
notices of other agencies), regulatory letters or similar documents received from such agency and the application of such report
to the Supply Product, if any, within seven (7) days of Theraclone’s receipt of such report.

 

(e)               
In the case that Theraclone engages a Third Party manufacturer (subject to ZKC’s prior approval as set forth
in Section 2.1) in connection with the supply of Supply Product hereunder, then Theraclone will require that such Third Party
manufacturer allow inspections by the Japanese and other Territory regulatory authorities (as well as those of the Retained Territory
upon whom Japanese or other Territory regulatory authorities rely) of those portions of its facilities where the Supply Products
are manufactured, tested, packaged, stored, handled and shipped and where the manufacturing records for the Supply Product are
stored, all on terms at least commensurate with those applicable to Theraclone’s manufacturing facilities in Section 4.2(d)
above.

 

(f)               
The parties agree that within [***] after the Effective Date ZKC shall
provide Theraclone a draft quality agreement for further discussion between the parties prior to its finalization as an agreement
acceptable to Theraclone, ZKC, and Third Party licensees of the Supply Product. Such quality agreement shall be finalized in any
event prior to Regulatory Approval of the Supply Product. Such quality agreement shall be fully consistent with and not change
the terms of this Supply Agreement or of the License Agreement, and shall be sufficiently detailed to comply with applicable regulatory
requirements. To avoid doubt, any terms of such quality agreement that are required by the Regulatory Authority in the Territory
need not be acceptable to Theraclone, ZKC and Third Party licensees of the Supply Product (and their consent to such terms as acceptable
shall not be required by this Section or it is deemed automatically granted). The out-of-pocket cost of preparing such quality
agreement (including Theraclone’s and Zenyaku’s out-of-pocket, reasonable and documented costs) shall be equally shared
by Theraclone and ZKC.

 

*Confidential Treatment Requested.

 

    	11

    	 

    

 

4.3             
Inspection by ZKC.

 

(a)               
Notwithstanding Theraclone’s obligation to provide the certificate set forth in Section 3.3, Theraclone
shall permit ZKC upon reasonable prior notice, but not less than thirty (30) days, and during regular business hours, at least
once per year and at any other time reasonably requested by ZKC and at ZKC’s expense, access to (a) those areas of Theraclone’s
manufacturing facilities where the Supply Product are manufactured, tested, packaged, stored, handled and shipped, and (b) the
manufacturing records for the Supply Product manufactured for ZKC.

 

(b)              
In the case that Theraclone engages a Third Party with regard to any of its obligations concerning the Supply Product
under this Supply Agreement (subject to ZKC’s prior approval as set forth in Section 2.1), notwithstanding Theraclone’s
obligation to provide the certificate set forth in Section 3.3, Theraclone shall use commercially reasonable efforts to require
such Third Party to permit ZKC to have the same inspection, access and audit rights that Theraclone has under Theraclone’s
agreement with such Third Party; provided, however, that in the event that such Third Party will not allow ZKC such access to its
facilities and records, then Theraclone will undertake to conduct an inspection and audit on ZKC’s behalf and in accordance
with ZKC’s instructions.

 

4.4             
Recalls, Product Withdrawals and Field Corrections. If either party becomes aware of any facts or circumstances
that suggest a recall, product withdrawal or field correction of a quantity of Supply Product supplied under this Supply Agreement,
it shall promptly notify the other party in writing. If there is a recall, product withdrawal or field correction of Supply Product
for the Territory, it will be executed in accordance with ZKC’s Supply Product recall procedures or other applicable SOP.
ZKC shall have the sole right (subject to any instructions from the applicable regulatory authority) to determine whether to implement
any recall, product withdrawal or field correction, and Theraclone will provide ZKC with all reasonable assistance. The costs of
such recall, product withdrawal or field correction shall be paid by the party whose activity, error, negligence or breach of contract
caused such recall, product withdrawal or field correction, or, if neither party’s activity, error, negligence or breach
of contract occasioned such recall, product withdrawal or field correction, then by ZKC.

 

5.                 
FAILURE TO SUPPLY; ESTABLISHMENT OF ALTERNATE SOURCES.

 

5.1             
Establishment and Maintenance of Second Source. As of the Effective Date, Theraclone’s intended
initial manufacturing facility for the Supply Product is [***]. In addition to this
facility (or its replacement), no later than twelve (12) months after the Effective Date, Theraclone will submit at least two (2)
potential candidates (who are not Other Licensees of Theraclone) to be the second source manufacturers of Supply Product to the
JSC and the JSC shall rank order such potential second source manufacturers. No later than twelve (12) months after Regulatory
Approval in the Territory (or such other date as may be agreed upon by the parties), Theraclone shall: (a) establish manufacture
of the Supply Product at a second facility that is fully accredited by the Regulatory Authority in the Territory, either through
contract with a Third Party approved in advance by ZKC (including with respect to the terms of Theraclone’s agreement with
such Third Party) or through a facility owned by Theraclone or its Affiliate and (b) qualify and validate such manufacture
at such facility by no later than twenty four (24) months after Regulatory Approval in the United States so that ZKC may legally
sell in the Territory quantities of Supply Product manufactured at such second facility. Such second facility shall have the capacity
available and devoted to Supply Product supply to supply (and such second facility shall supply to ZKC) a percentage of worldwide
requirements, which percentage shall be agreed upon by the JSC. For purposes of clarity, such second source manufacturer shall
be in addition to any of Theraclone’s Other Licensees who may be a manufacturing source and shall not be an Other Licensee.
For purposes of further clarity, Theraclone may propose the possibility that such second source manufacturer be an Other Licensee,
and Zenyaku shall discuss the possibility with Theraclone if requested. Zenyaku may in its sole discretion consent at any time
to such second source manufacturer being an Other Licensee. However, Zenyaku shall not be required to give such consent and may
withdraw such consent (subject to a reasonable transition period) once given. In any case and without limiting the foregoing, if
Zenyaku consents to such second source manufacturer being an Other Licensee, such consent is at all times contingent upon Zenyaku’s
continued satisfaction with the performance of the Other Licensee. All costs and expenses related to the activities described in
this Section 5.1 shall be borne by ZKC except as set forth in the following sentence (i.e., ZKC shall bear all such costs
and expenses only if such second source manufacturer is dedicated to supply the Supply Product for ZKC and its Affiliates and Sublicensees
only, and not for Theraclone or its Affiliates and Other Licensees). In the event that Theraclone, its Affiliate or an Other Licensee
wishes to have a manufacturer or second source manufacturer for Supply Product that is the same second source manufacturer chosen
by the parties pursuant to this Section 5.1, then Theraclone shall (and shall require such Affiliate or Other Licensee to)
share in the costs and expenses described in this Section 5.1, and sharing will be based on the anticipated or actual amounts
of Supply Product ordered by on the one hand ZKC and on the other hand Theraclone, its Affiliate or such Other Licensee (as the
case may be) and determined by the JSC. For purpose of clarity, any Supply Product sourced from such second source manufacturer
shall be subject to the pricing set forth in Section 2.2 above.

 

*Confidential Treatment Requested.

 

    	12

    	 

    

 

5.2             
Failure. Subject to the force majeure provision set forth below in Section 12.1, in the event that
Theraclone (i) fails to supply quantities of Supply Product properly ordered in accordance with this Supply Agreement for
a period of ninety (90) days beyond the delivery date for such Supply Product, or (ii) fails to supply at least [***]
of quantities of Supply Product properly ordered in accordance with this Supply Agreement for delivery for any two (2) consecutive
calendar quarters (each of such events, a “Supply Failure”), then the following subsections (a) and (b) shall
apply:

 

(a)               
Within sixty (60) days after a Supply Failure has occurred, ZKC shall notify Theraclone in writing of the Supply
Failure having occurred and with respect to: (1) whether or not Zenyaku desires for Theraclone to provide all amounts of Supply
Product that if Theraclone had supplied would have prevented the Supply Failure from occurring (and if Zenyaku does so desire,
then Theraclone will use Commercially Reasonable Efforts to do so and Zenyaku will be obligated to purchase such amounts requested
by Zenyaku to the extent delivered by Theraclone); and (2) whether or not Zenyaku desires to decrease the amount of ordered
Supply Product in the then-current Firm Forecast (and if Zenyaku does so desire, the amount of ordered Supply Product in the then-
current Firm Forecast will be deemed reduced as set forth in Zenyaku’s notice and Zenyaku will be obligated to purchase such
amounts requested by Zenyaku to the extent delivered by Theraclone). In addition, if within such 60-day period a new Firm Forecast
is due pursuant to Section 2.3(a), then, notwithstanding anything to the contrary in Section 2.3(a), Zenyaku shall have
until the end of such 60-day period to deliver such new Firm Forecast.

 

 

 *Confidential
Treatment Requested.

 

    	13

    	 

    

 

(b)              
Within six (6) months after a Supply Failure has occurred, Zenyaku shall notify Theraclone in writing whether Zenyaku
elects to manufacture or have manufactured Supply Products itself or by the second source manufacturer of Section 5.1 or other
Third Party designated by ZKC (“Manufacturing Step-In Rights”). If Zenyaku elects to exercise its Manufacturing
Step-In Rights, then such Supply Failure shall be deemed an uncured material breach of this Supply Agreement by Theraclone and
ZKC shall be deemed to have terminated this Supply Agreement pursuant to Section 6.4 below. To be clear, if ZKC elects to
exercise its Manufacturing Step-In Rights, thereafter ZKC shall be released from its covenant not to practice its manufacture and
have manufactured rights set forth in Section 5.4; ZKC shall be excused from its obligations under Section 2.1 to satisfy
all of its Requirements through Theraclone; and ZKC, in its sole discretion, may choose whether or not to continue to receive from
Theraclone all or any portion of ZKC’s requirements for Supply Products under this Supply Agreement during the ZKC Termination
Period (as defined below in Section 6.6(e)) and any such portions of ZKC’s requirements for Supply Products that ZKC
does choose to receive from Theraclone shall be subject to the terms governing forecasts and orders set forth in Section 2.3.
If ZKC elects to exercise its Manufacturing Step-In Rights, Theraclone will provide ZKC and/or any such Third Party manufacturer
with technology transfer consisting of all reasonably necessary information, rights, and cooperation (including site visits) to
enable ZKC or such Third Party to manufacture the Supply Product in accordance with the Specifications, and expenses thereof will
be equally shared by Theraclone and ZKC.

 

If ZKC decides to continue to receive any
quantities of Supply Products from Theraclone after a Supply Failure, such continuation shall not be construed as reinstating the
entire requirements obligations in Section 2.1 and shall not have any impact on ZKC’s right and ability to manufacture
or have a Third Party manufacture Supply Products. For purposes of clarification, Theraclone’s obligations under this Supply
Agreement shall continue in full force after a Supply Failure.

 

5.3             
Escrow of Cell Line. Within ninety (90) days after Zenyaku’s request, Theraclone shall deposit with
a Third Party escrow agent mutually agreeable to the parties at least [***] to establish
working cell banks, together with all reasonable documentation relating to such cell lines (including an SOP for healthy reculture
of such cell lines from the frozen sample form in which they will be stored in the escrow) (collectively, the “Cell Line
Materials”). The foregoing documentation shall also include master batch records for Supply Product manufacture. ZKC
shall be responsible for the costs associated with setting up this cell line escrow and for the storage of the Cell Line Materials.
The Third Party shall be in privity of contract with Theraclone and ZKC, and ZKC shall be the beneficiary under such contract.
If the deposited Cell Line Materials are destroyed, lost or in any way diminished, upon ZKC’s request, Theraclone shall provide
additional quantities of the Cell Line Materials in order to restore them to the initial deposit level contemplated by this Supply
Agreement at ZKC’s cost. If any updates or changes to the documentation relating to the cell lines that produce the Supply
Product are created and/or if there are any updates or changes to any of the cell lines used in manufacturing the Supply Product,
Theraclone shall promptly deposit them with the escrow agent as part of the Cell Line Materials. Without limiting ZKC’s rights
under Section 5.2, upon the occurrence of any Supply Failure, the escrow agent shall have full authority and be empowered
to (and shall) release the Cell Line Materials to ZKC upon ZKC’s request; provided, however, if a Supply Failure has not
occurred and ZKC requests such release, such request shall be deemed a material breach of this Supply Agreement and the License
Agreement. ZKC shall notify Theraclone if ZKC requests the release of the Cell Line Materials.

 

*Confidential Treatment Requested.

 

    	14

    	 

    

 

5.4             
License. Subject to the terms and conditions of this Supply Agreement, including but not limited to the
covenant and commitment in the next paragraph, Theraclone hereby grants to ZKC an exclusive license (with the right to grant sublicenses
through one or multiple tiers in accordance with Section 4.3 of the License Agreement) under the Theraclone Patents, Theraclone
Know-How and Theraclone’s interest in the Joint Patents to make and have made (a) Licensed Antibodies and Licensed Products
in or for the Territory for the Licensed Therapeutic/Prophylactic Field, (b) Clinical-and-Beyond Licensed Antibodies and Diagnostic
Products containing them in the Territory for Therapeutic Drug Monitoring and General Diagnostics; and (c) Other Licensed
Antibodies and Diagnostic Products containing them in the Territory for Therapeutic Drug Monitoring. Notwithstanding the above,
the foregoing license grant is subject to the limitations, conditions, and covenants set forth in the second and fifth paragraph
of Section 4.1(a) of the License Agreement. To be clear, the foregoing license may be exercised outside the Territory for
the manufacture of Licensed Antibodies and Licensed Products that are exclusively for use or sale in the Territory.

 

ZKC shall not, and hereby covenants and commits
that it and its Affiliates and Sublicensees shall not, exercise ZKC’s right to make and have made Licensed Antibodies and/or
Licensed Product, other than (x) having Theraclone and the designated Third Party second source manufacturer in Section 5.1
manufacture and supply Supply Product under this Supply Agreement, (y) formulating, filling and finishing Supply Product using
bulk drug substance or bulk formulated drug substance provided by Theraclone under this Supply Agreement, or (z) obtaining
approval or validation of a second source of supply in accordance with Section 5.1 above, in each case unless and until there
has been a Supply Failure in accordance with Section 5.2 above or ZKC is otherwise released from this covenant and commitment
pursuant to this Supply Agreement or the License Agreement.

 

To avoid doubt, the foregoing paragraph applies
only to the manufacture of bulk Licensed Antibody and bulk Licensed Product; it does not apply to any other part of the manufacture
of Supply Product; ZKC has at all times during the term of this Supply Agreement the right to vial and otherwise finish Supply
Product using bulk Supply Product provided by Theraclone, and reserves the right to undertake at its cost any downstream manufacturing
required by applicable laws or regulations (e.g., filling, labeling, packaging, etc.) after importation of bulk or vialed Supply
Product (as do its Sublicensees).

 

    	15

    	 

    

 

6.                 
TERM/TERMINATION.

 

6.1             
Term and Expiration. This Supply Agreement shall commence on the Effective Date and shall continue until
fifteen (15) years after Supply Product Regulatory Approval in Japan unless (a) earlier terminated by mutual agreement of
the parties or in accordance with this Article 6, (b) ZKC elects to continue this Supply Agreement in accordance with
Section 15.9 of the License Agreement and this Supply Agreement would naturally expire before the expiration of the three
(3) year period after the effective date of such termination (in which case this Supply Agreement shall continue until such period
expires (unless earlier terminated in accordance with this Article 6)), or (c) renewed one or more times according to
the following. No later than two (2) years prior to the scheduled expiration date of this Supply Agreement, either party may notify
the other party in writing that it wishes to extend the term of this Supply Agreement for an additional three (3) years beyond
such scheduled expiration date. If the other party wishes to renew this Supply Agreement for such additional period, it shall respond
in writing to this effect within three (3) months and this Supply Agreement shall be extended for such additional period. This
Supply Agreement may be extended one or more times.

 

6.2             
Cross-Termination with License Agreement; Expiration of License Agreement. This Supply Agreement shall
automatically terminate (a) upon any termination of the License Agreement that results in ZKC’s loss of its licenses
under the License Agreement pursuant to Section 15.8 of the License Agreement (which provides for the automatic termination
of this Supply Agreement) or (b) if ZKC elects to terminate this Supply Agreement pursuant to Section 15.9 of the License
Agreement. Upon expiration of the License Agreement under Section 15.2 of the License Agreement, ZKC may at its option elect
to terminate this Supply Agreement or allow this Supply Agreement to continue for its then-current term; provided, however, if
ZKC elects to allow this Supply Agreement to continue, thereafter ZKC may terminate this Supply Agreement at its option by providing
two (2) years prior written notice at any time to Theraclone unless the parties agree otherwise in writing. To be clear, this Supply
Agreement shall not terminate upon termination of the License Agreement not resulting in ZKC’s loss of its licenses under
the License Agreement, unless this Supply Agreement expires or is terminated under the other Sections of this Article 6.

 

6.3             
Theraclone Cessation of Manufacturing. In the event Theraclone intends to terminate this Supply Agreement
prior to the expiration of the term hereof, Theraclone shall notify ZKC in writing accordingly no less than three (3) years prior
to the intended date of termination. Upon the earlier of: expiry of such three (3) year notice period, or such time as ZKC has
fully validated an alternate source of Supply Product through which ZKC can legally sell in the Territory, this Supply Agreement
shall terminate; provided, however, if earlier occurring, this Supply Agreement shall terminate upon the assignment to ZKC (upon
ZKC’s request) of Theraclone’s rights and obligations with respect to the manufacture and supply of Supply Products
under Theraclone’s agreement therefor with the second source manufacturer described in Section 5.1 above. Theraclone
shall continue to supply Supply Products under this Supply Agreement up until the effective date of such termination. Without limiting
Theraclone’s foregoing obligation to continue to supply Supply Products, Theraclone shall, promptly after notifying ZKC of
Theraclone’s intention to terminate under this Section, provide ZKC with technology transfer as described in Section 5.2
at Theraclone’s cost.

 

    	16

    	 

    

 

6.4             
Termination With Cause. Upon any material breach of any material provision of this Supply Agreement by
either party, the non-breaching party may terminate this Supply Agreement upon sixty (60) days (or in the case of non-payment of
undisputed amounts, thirty (30) days) written notice to the breaching party. The notice shall detail the alleged breach and state
explicitly that it is a notice under this Section 6.4. The termination shall become effective at the end of such sixty (60)
day (or in the case of non-payment, thirty (30) day) period unless the breaching party shall have cured such breach within such
period. Furthermore, termination under this Section 6.4, if disputed by the non-terminating party, shall not be effective
until the dispute or contest is resolved under Article 11, and then only if the arbitrator finds that the termination is proper.
Termination by Zenyaku under this Section shall be subject to Section 6.6 and in particular Section 6.6(e).

 

6.5             
Termination for Insolvency. Either party may terminate this Supply Agreement upon written notice to the
other in the event of (a) insolvency of the other party, or the appointment of a receiver by the other party for all or any
substantial part of its properties, provided that such receiver is not discharged within sixty (60) days of its appointment, (b) the
adjudication of the other party as a bankrupt, (c) the admission by the other party in writing of its inability to pay its
debts as they become due, (d) the execution by the other party of an assignment for the benefit of its creditors or (e) the
filing by the other party of a petition to be adjudged as a bankrupt, or a petition or answer admitting the material allegations
of a petition filed against the other party in any bankruptcy proceeding, or the acts of the other party to any other judicial
proceeding intended to effect a discharge of the debts of the other party, in whole or in part. Termination by Zenyaku under this
Section shall be subject to Section 6.6 and in particular Section 6.6(e).

 

6.6             
Consequences of Expiration or Early Termination. Upon the expiration or termination of this Supply Agreement:

 

(a)               
Each party shall return or destroy, and certify to such destruction of, all Confidential Information that is Confidential
Information solely of the other party provided or obtained pursuant to this Supply Agreement, except that each party may maintain
one (1) copy for archival purposes solely to confirm compliance with the provisions of Article 10 hereof and except that ZKC
may retain Confidential Information of Theraclone for so long as ZKC retains any of its licenses under the License Agreement and/or
any surviving right to manufacture;

 

(b)              
In ZKC’s sole discretion, ZKC may purchase the safety stock inventory held by Theraclone for ZKC, if any; and

 

(c)               
ZKC may dispose of, by sale or otherwise, any remaining inventory of Supply Product that ZKC may have in its possession
on the date of expiration or early termination of this Supply Agreement (and if ZKC has lost its licenses under the License Agreement,
the licenses granted to ZKC under the License Agreement shall survive solely for this purpose).

 

(d)              
If this Supply Agreement is terminated by Theraclone pursuant to Section 6.3 or if this Supply Agreement is
terminated by ZKC pursuant to Section 6.4 or Section 6.5: (i) the licenses granted to ZKC in Section 5.4 shall
survive and shall be coterminous with (i.e., remain in effect during the same period of time as) the licenses granted to ZKC under
the License Agreement; and (ii) upon the effective date of such termination of this Supply Agreement, ZKC shall be released
from its covenant not to practice its manufacture and have manufactured rights set forth in Section 5.4.

 

    	17

    	 

    

 

(e)               
Notwithstanding anything to the contrary in this Supply Agreement, no termination of this Supply Agreement by Zenyaku
under Section 6.4 or Section 6.5 shall be effective prior to the earlier of: (i) all of the following have been
achieved: the establishment, qualification and validation of a Third Party contract manufacturer for Supply Product designated
by ZKC or of a Zenyaku facility to do so; in the former case, ZKC and such Third Party contract manufacturer having entered into
a supply agreement prior to the effective date of the Theraclone termination of this Supply Agreement; and ZKC may legally sell
in the Territory quantities of Supply Product manufactured by such Third Party contract manufacturer or at Zenyaku’s facility
(i.e., ZKC being able to manufacture or have manufactured Supply Product with no discontinuity vis à vis Theraclone’s
supply hereunder) or (ii) thirty-six (36) months from the notice of breach under Section 6.4 or insolvency under Section 6.5.
It is understood and agreed by the parties that subsection (i) shall be deemed satisfied upon the assignment to ZKC (upon
ZKC’s request) of Theraclone’s rights and obligations with respect to the manufacture and supply of Supply Products
under Theraclone’s agreement therefor with the second source manufacturer (whether or not an Other Licensee) described in
Section 5.1. The period from the end of the specified cure period for the breach or notice of insolvency (as applicable) until
the effective date of termination shall be the “ZKC Termination Period.” During the ZKC Termination Period,
ZKC is not required to obtain any or its full requirements from Theraclone under this Supply Agreement, except those amounts of
Supply Products that are subject to a Firm Forecast in effect immediately prior to the commencement of the ZKC Termination Period,
and ZKC shall be released from its covenant not to practice its manufacture and have manufactured rights set forth in Section 5.4.

 

6.7             
Inclusive Remedy. Except as otherwise provided in this Supply Agreement, each party shall have the rights
and remedies set forth herein in addition to any other remedies which it may have under applicable statutory or common law. Each
party shall have the sole discretion to determine which of its rights and remedies, if any, it shall pursue and such party shall
not be required to exhaust any of its other rights or remedies before pursuing any one of the rights and remedies set forth in
this Supply Agreement.

 

6.8             
Survival. Expiration or early termination of this Supply Agreement shall not relieve either party of its
obligations incurred prior to expiration or early termination. The obligations under Sections 2.2 (with respect to audit rights);
2.7 and 2.8 (with respect to payments due for sales during the term of this Supply Agreement); 4.4 (with respect to Supply Product
sold during the term of this Supply Agreement); 6.6; 6.7; and 6.8; and Articles 7, 8, 9, 10, 11 and 12 shall survive any expiration
or termination of this Supply Agreement.

 

    	18

    	 

    

 

7.                 
REPRESENTATIONS AND WARRANTIES.

 

7.1             
By Theraclone. Theraclone hereby represents and warrants to ZKC that:

 

(a)               
it has full right to enter into and perform Theraclone’s obligations under this Supply Agreement and to supply
the Supply Product;

 

(b)              
the execution, delivery, and performance of this Supply Agreement does not conflict with, violate or breach any agreement
to which Theraclone is a party;

 

(c)               
to the best of its knowledge as of the Effective Date, the Supply Product does not infringe any Third Party’s
right, including without limitation any intellectual property right;

 

(d)              
each of the Supply Products manufactured by or for Theraclone shall be manufactured in accordance with the Specifications
(including, to avoid doubt, the manufacturing methods and processes and assay procedures specified in the Specifications or otherwise
agreed by the parties whether or not explicitly stated in the Specifications) and all applicable regulatory requirements, including
cGMP;

 

(e)               
each of the Supply Products manufactured by or for Theraclone shall, upon delivery, meet the Specifications and all
applicable regulatory requirements, including cGMP, and shall not have been misused, contaminated, tampered with or otherwise altered
or mishandled prior to the time of delivery; and

 

(f)               
it has not engaged, and does not (and Theraclone hereby covenants that it shall not) engage, any employee, consultant
or other personnel that has been debarred or disqualified by the FDA or other regulatory authority, or, to the best of its knowledge,
that is the subject of debarment or disqualification proceedings by the FDA or other regulatory authority; Theraclone hereby covenants
that if Theraclone becomes aware of or receives notice of the debarment or disqualification of (or any proceedings regarding the
debarment or disqualification of) any person providing services to Theraclone which relate to services being provided under this
Supply Agreement, Theraclone shall notify ZKC immediately and address the issue as reasonably directed by ZKC.

 

Theraclone hereby covenants that it shall
obtain these same representations, warranties and covenants ((a) - (f)) from any Third Party manufacturer that it may engage, subject
to ZKC’s prior approval as set forth in Section 2.1.

 

7.2             
By ZKC. ZKC hereby represents and warrants to Theraclone that:

 

(a)               
it has the full right to enter into and perform ZKC’s obligations under this Supply Agreement; and

 

(b)              
the execution, delivery and performance of this Supply Agreement does not conflict with, violate or breach any agreement
to which ZKC is a party.

 

    	19

    	 

    

 

7.3             
Extent of Warranties. EXCEPT AS SPECIFICALLY PROVIDED IN THIS SUPPLY AGREEMENT, THE SUPPLY PRODUCT IS
SUPPLIED “AS IS” AND THERACLONE HEREBY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND WITH REGARD
TO THE SUPPLY PRODUCT, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE OR USE, AND ANY OTHER STATUTORY WARRANTIES.

 

8.                 
INDEMNIFICATION.

 

The parties’ obligations with respect
to indemnification are set forth in the License Agreement.

 

9.                 
LIMITATION OF LIABILITY.

 

EXCEPT WITH RESPECT TO A PARTY’S INDEMNIFICATION
OBLIGATIONS UNDER THIS SUPPLY AGREEMENT OR BREACH OF THE CONFIDENTIALITY OBLIGATIONS IN ARTICLE 10, IN NO EVENT WILL EITHER
PARTY HERETO BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES SUFFERED BY THE OTHER PARTY ARISING IN ANY
WAY OUT OF THIS SUPPLY AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN IF THE PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

 

10.             
CONFIDENTIALITY; PUBLICITY; PUBLICATIONS.

 

10.1         
Sections 11.3 through 11.7 of the License Agreement shall apply to this Supply Agreement as if set forth
fully within this Supply Agreement.

 

11.             
GOVERNING LAW; ARBITRATION.

 

11.1         
Article 12 of the License Agreement shall apply to this Supply Agreement as if set forth fully within this
Supply Agreement.

 

12.             
GENERAL PROVISIONS.

 

12.1         
Miscellaneous. Section 17.1 (Force Majeure), Section 17.2 (Severability), Section 17.4
(Notices), Section 17.5 (Independent Contractors), Section 17.6 (Unenforceable Provisions), Section 17.7 (Waiver),
Section 17.8 (Construction), Section 17.9 (Headings) and Section 17.10 (Counterparts) of the License Agreement shall
apply to this Supply Agreement as if set forth fully within this Supply Agreement.

 

12.2         
Entire Agreement. This Supply Agreement and all Exhibits hereto, entered into as of the date first written
above, together with the License Agreement, constitutes the entire agreement between the parties relating to the subject matter
hereof and supersedes all previous writings and understandings. No terms or provisions of this Supply Agreement shall be varied
or modified by any prior or subsequent statement, conduct or act of either of the parties, except that the parties may mutually
amend this Supply Agreement by written instruments specifically referring to and executed in the same manner as this Supply Agreement.

 

    	20

    	 

    

 

12.3         
Assignment. Neither this Supply Agreement nor any interest hereunder shall be assignable by either party
without the written consent of the other (which consent will not be unreasonably withheld or delayed); provided, however,
that either party may assign this Supply Agreement to any of such party’s Affiliates (for so long as such Affiliate remains
Affiliated with such party) or to any corporation or other entity with which such party may merge or consolidate (regardless of
who is the surviving entity of such merger or consolidation), and/or to any corporation or other entity to which such party may
transfer all or substantially all of such party’s assets to which this Supply Agreement relates or all or substantially all
of such party’s stock, without obtaining the consent of the other party. Transfer in contravention of this Section shall
be considered a material breach of this Supply Agreement pursuant to Section 6.4. Subject to other provisions of this Section,
all rights and obligations under this Supply Agreement and the licenses herein granted shall be binding upon and inure to the benefit
of the successors in interest of the respective parties. Any assignment in violation of the foregoing shall be null and void.

 

To avoid doubt, this Section shall not limit ZKC’s ability
to require delivery of Supply Products directly to ZKC’s Affiliates and Sublicensees for use in the Territory. The foregoing
sentence shall not be interpreted to deem such Affiliates and Sublicensees third party beneficiaries of this Supply Agreement.

 

12.4         
Costs and Expenses. For purpose of clarity, where in this Supply Agreement a cost and/or expenses is allocated
to one of the parties hereto, unless such cost or expense is specifically stated to be included in the calculation of Fully Burdened
Manufacturing Cost, such cost or expense shall be billed or invoiced to the responsible party by the receiving party and the responsible
party shall pay such bill or invoice within thirty (30) days or receipt thereof.

 

[Signature page follows.]

 

    	21

    	 

    

 

IN WITNESS WHEREOF, each of the parties hereto has caused this
Supply Agreement to be executed by its duly authorized officer as of the date first Written above.

 

 

	 	THERACLONE SCIENCES, INC.
	 	 
	 	By:	 
	 	 	 
	 	 	 
	 	 	 
	 	ZENYAKU KOGYO CO., LTD.
	 	 
	 	By:	 
	 	 	 
	 	 	 

 

 

    	22

    	 

    

 

EXHIBIT A 

 

SUPPLY PRODUCTS

 

    	23

    	 

    

 

EXHIBIT B

 

SPECIFICATIONS

 

    	24

    	 

    

  

EXHIBIT G

 

EXISTING THERACLONE IN-LICENSES

 

With reference to Section 14.2(vii):

[***]

 

With reference to Section 14.2(viii):

[***]

 

*Confidential Treatment Requested.

 

    	25Exhibit 10.66

  

 

		[***]	Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

 

 

 

RESEARCH COLLABORATION AND LICENSE AGREEMENT

 

by and between

 

PFIZER INC.

 

and

 

COVX TECHNOLOGIES IRELAND LIMITED

 

and

 

THERACLONE SCIENCES, INC.

 

December 17, 2010

 

    	 

    	 

    

RESEARCH COLLABORATION AND LICENSE
AGREEMENT

 

This Research Collaboration
and License Agreement (the “Agreement”) is entered into as of December 17, 2010 (the “Execution Date”),
by and, between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business
at 235 East 42nd St., New York, NY 10017 CovX Technologies Ireland Limited, an Affiliate corporation of Pfizer,
organized and existing under the laws of Ireland and having a place of business at 122 Ranelagh, Dublin 6, Ireland (individually
and collectively “Pfizer”) and Theraclone Sciences, Inc., a corporation organized and existing under the laws of Delaware
and having a principal place of business at 1124 Columbia Street, Suite 300, Seattle, WA 98104, USA (“Collaborator”).
Pfizer and Collaborator may each be referred to herein individually as a “Party” and collectively as the “Parties.”

 

WHEREAS, Collaborator
owns or otherwise controls certain patents, patent applications, technology, know-how, scientific and technical information and
other proprietary rights and information relating to the identification, research and development of Antibodies (as defined below);

 

WHEREAS, Pfizer has
extensive experience and expertise in the development and commercialization of pharmaceutical products, and desires to acquire
an exclusive license in the Territory (as defined below) under Collaborator’s patents, patent applications, technology, know-how,
scientific and technical information and other proprietary rights and information relating to Antibodies;

 

WHEREAS, Pfizer and
Collaborator wish to engage in collaborative research ‘regarding Antibodies and potential Products (as defined below); and

 

WHEREAS, subject to
the terms of this Agreement, Collaborator wishes to grant to Pfizer, and Pfizer wishes to receive from Collaborator, an exclusive
license in the Territory to use, research, develop, manufacture and commercialize Antibodies and Products.

 

NOW THEREFORE, in consideration
of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the Parties hereby agree as follows:

 

		1.	DEFINITIONS AND INTERPRETATION.

 

1.1.Defined
Terms. Capitalized terms not otherwise defined herein shall have the meanings set forth in Exhibit A.

 

		2.	LICENSE GRANTS AND TECHNOLOGY TRANSFER.

 

2.1.Exclusive
License from Collaborator to Pfizer. Effective as of the Effective Date, Collaborator hereby grants to Pfizer an exclusive
license (exclusive even as to Collaborator), with the right to sublicense, under the Collaborator Technology, to use, have used,
Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Antibodies and Products in the Territory.

‘

    	1

    	 

    

2.2.Reciprocal
Non-Exclusive Research License for Disclosed Know-How and Confidential Information. Subject to any preexisting exclusive license
grants to Third Parties, and without limiting any other license granted to either Party under this Agreement:

 

2.2.1.Pfizer
hereby grants to Collaborator a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license, with the
right to sublicense to Collaborator Affiliates, to use for research purposes all Pfizer Know-How or Pfizer Confidential Information
that is disclosed to Collaborator during the Term.

 

2.2.2.Collaborator
hereby grants to Pfizer a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license, with the right
to sublicense to Pfizer Affiliates, to use for research purposes all Collaborator Know-How or Collaborator Confidential Information
that is disclosed to Pfizer during the Term.

 

2.3.No
Implied Rights. Except as expressly provided in this Agreement, neither Party shall be deemed to have granted the other Party
(by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual property,
Know-How or information Controlled by such Party.

 

		3.	PAYMENTS BY PFIZER TO COLLABORATOR.

 

3.1.Initial
Research Payment. Within forty-five (45) days of receipt of invoice from Collaborator following the Effective Date, Pfizer
shall pay Collaborator a payment of [***].

 

3.2.Additional
Target Option Payment. In the event the parties agree on a fourth Target, within forty-five (45) days of receipt of invoice
from Collaborator following the identification of the fourth Target, Pfizer shall pay Collaborator a payment of [***].

 

3.3.Research
Funding. Pfizer will make the following one-time payments (each a “Preclinical Milestone Payment”) to Collaborator
within forty-five (45) days of receipt of invoice from Collaborator upon the first achievement of the applicable event listed below
for the Research Plans for each Infectious Disease Target (each, a “Preclinical Milestone Event”).

 

	[***]	[***]
	[***] 	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

 

 

*Confidential Treatment
Requested.

    	2

    	 

    

 

Pfizer will make the following one-time
Preclinical Milestone Payments to Collaborator within forty-five (45) days of receipt of invoice from Collaborator upon the first
achievement of the applicable Preclinical Milestone Event listed below for the Research Plans for each cancer Target.

 

	[***]	[***]
	[***] 	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

Collaborator shall be solely responsible
for all expenses it incurs in performing its obligations under the Research Program; provided, however, that if Pfizer requests
changes or additions to the Research Plan that cause additional fees or expenses (including but not limited to cost of labor) to
be incurred by Collaborator, then the Parties shall agree in advance on the amount of such additional fees and expenses and Pfizer
shall pay Collaborator for such additional fees and expenses within forty-five (45) days following Pfizer’s receipt of an
invoice therefor. Upon completion of a Preclinical Milestone Event, Collaborator will submit an invoice which shall be accompanied
by reasonable supporting documentation evidencing achievement of the Preclinical Milestone Event and Pfizer will pay Collaborator
within forty-five (45) days following Pfizer’s receipt of each such properly documented invoice.

 

3.4.Development
Payments. Pfizer shall notify Collaborator within fifteen (15) days of achievement of a Development Event and pay Collaborator
the amounts set forth below within forty-five (45) days of receipt of invoice from Collaborator following the first occurrence
of each event described below for the first Product to achieve such event against each Target (each, a “Development Payment”).

 

	 	Development Event	Development Payment
	(i)	[***]	[***]
	(ii)	[***]	[***]
	(iii)	[***]	[***]
	(iv)	[***]	[***]
	(v)	[***]	[***]

 

Each of the Development Payments set forth
above shall be payable one time only for each Target, regardless of the number of Products that target the same Target. For clarification,
if one Product replaces another Product in Development, then such replacement Product shall only be subject to Development Payments
that have not previously been triggered by one or more prior Products. The maximum amount payable by Pfizer in respect of Development
Payments if all Development Events occur for any Target shall be [***].

 

*Confidential Treatment
Requested.

 

    	3

    	 

    

 

3.5.Sales
Milestone Payments. Pfizer shall pay Collaborator the following one-time payments for each Target (each, a “Sales Milestone
Payment”) when Net Sales of Product for each Target in a Pfizer Year in the Territory (the “Total Annual Net Sales”)
first reach the respective thresholds indicated below:

 

	Total Annual Net Sales	Sales Milestone Payment
	[***]	[***]
	[***]	[***]

 

Pfizer shall make any Sales Milestone Payment
payable with respect to a Pfizer Year within 60 days after the end of the applicable Pfizer Year. For the avoidance of doubt, each
of the Sales Milestone Payments set forth above shall be payable one time only for each Target, regardless of the number of times
the corresponding Total Annual Net Sales levels are achieved.

 

3.6.Royalty
Payments.

 

3.6.1.Royalties.
Subject to the provisions of Section 3.6.3, Pfizer shall pay Collaborator royalties in the amount of the Marginal Royalty Rates
(set forth below) of the aggregate Net Sales resulting from the sale of Products, on a Product-by-Product basis, in the Territory
during each Pfizer Year of the applicable Royalty Term for each Product (each, the “Per Product Annual Net Sales”):

 

	Per Product Annual Net Sales	Marginal Royalty Rate

(% of Per Product Annual Net

Sales)
	[***]	[***]
	[***]	[***]
	[***]	[***]

Each Marginal Royalty Rate set
forth in the table above shall apply only to that portion of the Net Sales of a given Product in the Territory during a given Pfizer
Year that falls within the indicated range.

 

3.6.2.Fully
Paid-Up, Royalty Free License. Following expiration of the Royalty Term for any Product in a given country, no further royalties
shall be payable in respect of sales of such Product in such country and, thereafter the licenses granted to Pfizer with respect
to such Product in such country shall automatically become fully paid-up, perpetual, irrevocable and royalty-free.

 

3.6.3.Royalty
Adjustments. The following adjustments shall be made, on a Product-by-Product and country-by-country basis, to the royalties
payable pursuant to Section 3.6:

 

 

*Confidential Treatment
Requested.

    	4

    	 

    

 

(a)Third
Party Patents. If it is necessary or desirable for Pfizer to license one or more Patent Rights from one or more Third Parties
in order to Develop, Manufacture, Commercialize or use any Product, whether directly or through any Pfizer Affiliate or Sublicensee,
then Pfizer may, in its sole discretion, negotiate and obtain a license under such Patent Right(s) (each such Third Party license
referred to herein as an “Additional Third Party License”). Any royalty otherwise payable to Collaborator under this
Agreement with respect to Net Sales of any Product by Pfizer, its Affiliates or Sublicensees shall be reduced by [***]
of the amounts payable to Third Parties pursuant to any Additional Third Party Licenses, such reduction to continue until all such
amounts have been expended, provided however that in no event shall the total royalty payable to Collaborator for any Product
be less than [***] of the royalty amounts otherwise payable for such Product.

 

(b)No
Adjustment for Collaborator Third Party Agreements. Collaborator shall be solely responsible for (i) all obligations (including
any royalty or other obligations that relate to the Collaborator Technology or Collaborator Platform Technology) under its agreements
with Third Parties that are in effect as of the Effective Date or that Collaborator enters into during the Term and (ii) all payments
to inventors (other than inventors that are Representatives of Pfizer) of Collaborator Technology, Collaborator Platform Technology,
or Sponsored Research Technology, including payments under inventorship compensation Laws.

 

(c)Biosimilar
Entry. Any royalty otherwise payable to Collaborator under this Agreement with respect to Net Sales of a given Product in a
given country in the Territory will be reduced by [***] for so long as third party
Biosimilar versions of such Product become available and are being sold in such country and have at least [***]
of the total market in such country. “Biosimilar Version” of a Product means

 

(i)a
pharmaceutical product containing as the sole active ingredient(s) an antibody (or antibodies) having the same primary sequence
as the Antibody(ies) in such Product, and which can be commercially sold without infringing a Valid Claim in a patent in the Collaborator
Technology and/or Sponsored Research Technology, or

 

(ii)a biological product
that, through reference to a Product that has already received regulatory approval from the applicable Regulatory Authority (with
respect to such Product, a “Reference Product”), is eligible for Regulatory Approval in a country or jurisdiction pursuant
to the least restrictive abbreviated follow-on biological approval pathway established by the Regulatory Authority in such country
or jurisdiction pursuant to laws (as may be amended, or any subsequent or superseding law) or otherwise is approved or eligible
for Regulatory Approval in reliance, in whole or in part, on the prior Regulatory Approval of a Reference Product or on the safety
and efficacy data generated for the prior Regulatory Approval of a Reference Product, including any biological product that (a)
has been approved or would be eligible for approval as a biosimilar or interchangeable product by the FDA pursuant to Section 351(k)
of the Public Health Service Act (42 U.S.C. 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation,
(b) has been approved or would be eligible for approval as a similar biological medicine product by EMA as described in CHMP/437/04,
issued 30 October 2005, as may be amended, or any subsequent or superseding law, statute or regulation or (c) has otherwise obtained
Regulatory Approval from a Regulatory Authority analogous to those regulatory approvals described in clauses (a) and (b) in this
paragraph, including the FDA’s approval of any ANDA or Section 505(b)(2) Application.

 

 

*Confidential Treatment
Requested.

    	5

    	 

    

 

3.7.Reports
and Payments.

 

3.7.1.Cumulative
Royalties. The obligation to pay royalties under this Agreement shall be imposed only once with respect to any sale of any
Product.

 

3.7.2.Royalty
Statements and Payments. Within 60 days of the end of each Calendar Quarter, Pfizer shall deliver to Collaborator a report
setting forth, for the most recent Pfizer Quarter ending during such Calendar Quarter, the following information, on a Product-by-Product,
country-by-country and Territory-wide basis: (a) Net Sales of each Product, (b) the basis for any adjustments to the royalty payable
for the sale of any such Product and (c) the royalty due hereunder for the sale of each such Product. The total royalty due for
the sale of all such Products during such Pfizer Quarter shall be remitted at the time such report is made.

 

3.7.3.Taxes
and Withholding. It is understood and agreed between the Parties that any payments made by Pfizer under this Agreement are
inclusive of any value added or similar tax imposed upon such payments. In addition, in the event any payments made by Pfizer pursuant
to this Agreement become subject to withholding taxes under the Laws or regulations of any jurisdiction or Governmental Authority,
Pfizer shall deduct and withhold the amount of such taxes for the account of Collaborator to the extent required by applicable
Laws or regulations; such amounts payable to Collaborator shall be reduced by the amount of taxes deducted and withheld; and Pfizer
shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and transmit to Collaborator an official
tax certificate or other evidence of such tax obligations together with proof of payment from the relevant Governmental Authority
of all amounts deducted and withheld sufficient to enable Collaborator to claim such payment of taxes. Any such withholding taxes
required under applicable Laws or regulations to be paid or withheld shall be an expense of, and borne solely by, Collaborator.
Pfizer will provide Collaborator with reasonable assistance to enable Collaborator to recover such taxes as permitted by applicable
Laws or regulations.

 

3.7.4.Currency.
All amounts payable and calculations under this Agreement shall be in United States dollars. As applicable, Net Sales and any royalty
deductions shall be translated into United States dollars at the exchange rate used by Pfizer for public financial accounting purposes.

 

3.7.5.Method
of Payment. Each payment shall be made by electronic transfer in immediately available funds via either a bank wire transfer,
an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Pfizer’s election, to such
bank account as the Collaborator shall designate in writing to Pfizer.

 

    	6

    	 

    

 

3.7.6.Record
Keeping. Pfizer shall keep and shall cause its Affiliates and Sublicensees to keep books and accounts of record in connection
with the sale of Products in sufficient detail to permit accurate determination of all figures necessary for verification of royalties
and Sales Milestone Payments to be paid hereunder. Pfizer and its Affiliates shall maintain such records for a period of at least
3 years after the end of the Pfizer Quarter in which they were generated.

 

3.7.7.Audits.
Upon 30 days prior notice from Collaborator, Pfizer shall permit an independent certified public accounting firm of nationally
recognized standing selected by Collaborator and reasonably acceptable to Pfizer, to examine, at Collaborator’s sole expense,
the relevant books and records of Pfizer and its Affiliates as may be reasonably necessary to verify the amounts reported by Pfizer
in accordance with Section 3.7.2 and the payment of royalties and Sales Milestone Payments hereunder. An examination shall occur
not more than once in any Calendar Year and shall be limited to the pertinent books and records for any Calendar Year ending not
more than three 3 years before the date of the request. The accounting firm shall be provided access to such books and records
at Pfizer’s or its Affiliates’ facility(ies) where such books and records are normally kept and such examination shall
be conducted during Pfizer’s normal business hours. Pfizer may require the accounting firm to sign a reasonably acceptable
non-disclosure agreement before providing the accounting firm with access to Pfizer’s or its Affiliates’ facilities
or records. Upon completion of the audit, the accounting firm shall provide both Pfizer and Collaborator a written report disclosing
any discrepancies in the reports submitted by Pfizer or the royalties or Sales Milestone Payments paid by Pfizer, and, in each
case, the specific details concerning any discrepancies. No other information shall be provided to Collaborator.

 

3.7.8.Underpayments/Overpayments.
If such accounting firm concludes that additional royalties or Sales Milestone Payments were due to Collaborator, then Pfizer will
pay to Collaborator the additional royalties or Sales Milestone Payments within (60) days of the date Pfizer receives such accountant’s
written report. Further, if the amount of such underpayments exceeds more than 5% of the amount that was properly payable to Collaborator,
then Pfizer shall reimburse Collaborator for Collaborator’s out-of-pocket costs in connection with the audit. If such accounting
firm concludes that Pfizer overpaid royalties or Sales Milestone Payments to Collaborator, then Collaborator will refund such overpayments
to Pfizer, within 60 days of the date Collaborator receives such accountant’s report.

 

3.7.9.Confidentiality.
Notwithstanding any provision of this Agreement to the contrary (a) all reports and financial information of Pfizer, its Affiliates
or its Sublicensees which are provided to Collaborator shall be deemed to be Pfizer’s Confidential Information and subject
to the provisions of Section 7.

 

3.8.No
Guarantee of Success. Pfizer and Collaborator agree that payments to Collaborator pursuant to Section 3 are solely intended
to allocate amounts that may be achieved upon successful Development or Commercialization of a Product or Product, and are not
intended to be used as a measure of damages if this Agreement is terminated for any reason, including pursuant to Pfizer’s
right to terminate at for convenience. Pfizer and Collaborator agree that nothing in this Agreement will be construed as representing
any estimate or projection of the anticipated sales or the actual value of any Products that may be successfully Developed or Commercialized
under this Agreement or the damages, if any, that may be payable if this Agreement is terminated for any reason. Pfizer makes no
representation, warranty or covenant, either express or implied, that it will successfully Develop, Manufacture, Commercialize
or continue to Develop, Manufacture or Commercialize any Product in any country, or if Commercialized, that any Product will achieve
any particular sales level, whether in any individual country or cumulatively throughout the Territory.

 

    	7

    	 

    

 

3.9.Non-Refundable.
Except as specifically set forth in Section 3.7.8, all payments made under this Section 3 are non-refundable and non-creditable.

 

3.10.Past
Due Amounts. Any amount owed by Pfizer to Collaborator under this Agreement that is not paid within the applicable time period
set forth herein will accrue interest until paid at the annual rate of [***] above
the then-applicable short-term three-month London Interbank Offered Rate (LIBOR) as quoted in the Wall Street Journal, New York
Edition (or if it no longer exists, a similarly authoritative source) calculated on a daily basis, or, if lower, the highest rate
permitted under applicable law.

 

3.11.Obligation
to Make Payments. For purpose of clarity, in the event that Pfizer sublicenses, assigns, or transfers any of its rights hereunder
(including, without limitation its rights to any Antibodies or Products) or effects any similar transaction, Pfizer shall remain
obligated to make any and all payments owed to Collaborator as set forth in this Section 3.

 

		4.	RESEARCH PROGRAM.

 

4.1.Scope
of Research and Targets. Beginning on the Effective Date of the Agreement and ending on the third anniversary thereof (the
“Research Term”), Pfizer and Collaborator would collaborate to conduct research to identify, screen and evaluate Antibodies
against up to four Targets in accordance with a Research Plan, a template of which attached as Exhibit C for [***]
Targets and Exhibit D for [***] Targets. Pfizer and Collaborator have agreed that
the first and second Targets will be [***] and [***].
For the second [***] Target and fourth Target, Pfizer will propose the Target and
unless Collaborator has licensed another Person to exclusively develop and commercialize the proposed Target, the parties will
draft a specific Research Plan, which Research Plan must be agreeable to both Parties, for the second Target. During the Research
Term, Collaborator will work exclusively with Pfizer to identify Products to the Targets. Pfizer hereby agrees that Collaborator’s
existing programs in the fields of [***] preclude such disease indications from being
Targets.

 

 

*Confidential Treatment
Requested.

    	8

    	 

    

 

4.2.Research
Plan. All research conducted in connection with the Research Program will be performed by the Parties in accordance with the
Research Plan. The parties may agree to modify the Research Plan.

 

4.3.Allocation
of Responsibilities.

 

4.3.1.General.
Each Party shall use Commercially Reasonable Efforts to perform its obligations under the Research Plan in a professional and timely
manner.

 

4.3.2.Collaborator
Research Obligations. During the Research Term, Collaborator shall devote the resources necessary to achieve the Preclinical
Milestone Events.

 

4.3.3.Pfizer
Oversight of Research Activities. Pfizer will oversee and retain final decision making authority with respect to all research
activities performed under this Agreement. Without limiting the foregoing, Pfizer shall oversee the evaluation of all Antibodies
identified by the Collaborator and will provide feedback and guidance to Collaborator and the Qualified Researchers regarding such
Antibodies.

 

4.4.Research
Program Governance.

 

4.4.1.Collaboration
Management. Each Party shall appoint a single individual to act as the primary point of contact between the Parties to support
the Research Program (the “Alliance Managers”). Each Party may change its designated Alliance Manager at any time upon
written notice to the other Party. The Alliance Managers shall: (i) use good faith efforts to attend (either in person or by telecommunications)
all meetings of the JRC, but shall be non-voting members at such meetings; and (ii) be the first point of referral for all matters
of conflict resolution, and bring disputes to the attention of the JRC in a timely manner.

 

4.4.2.Joint
Research Committee.

 

(a)Composition.
The Parties shall establish a Joint Research Committee, comprised of three representatives of Collaborator and three representatives
of Pfizer. Each Party may replace its representatives to the JRC at any time upon notice to the other Party. Each Party may invite
non-voting employees and consultants to attend meetings of the JRC.

 

(b)Committee
Chair. The JRC shall be chaired by a Pfizer JRC member (the “JRC Chair”). Pfizer may replace the JRC Chair at any
time upon notice to Collaborator.

 

(c)Meetings.
During the Research Term, the JRC shall meet on a Calendar Quarter basis, either in-person or by audio or video teleconference.
Meetings of the JRC will only occur if at least one representative of each Party is present at the meeting or participating by
teleconference or videoconference. The Parties will take turns running the meetings. The Party running the meeting shall: (i) to
notify the other Party at least 30 days in advance of each JRC meeting; (ii) collect and organize agenda items for each JRC meeting;
and (iii) prepare the written minutes of each JRC meeting and circulate such minutes for review and approval by the Parties, and
identify action items to be carried out by the Parties. Each Party shall be responsible for all of its own expenses of participating
in such JRC meetings. The Parties shall endeavor to schedule meetings of the JRC at least three months in advance. The Parties
shall agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JRC.

 

    	9

    	 

    

 

(d)Responsibilities.
The JRC shall oversee and supervise the overall performance of the Research Plan and within such scope shall: (i) review the efforts
of the Parties under the Research Plan and allocate resources of each Party to perform the activities; (ii) revise and approve
any revised Research Plan; (iii) identify potential Product candidates; and (iv) attempt to resolve any disputes relating to the
Research Program on an informal basis.

 

(e)Decision-making.
In spite of the number of Pfizer JRC members or Collaborator JRC members, each Party shall have one vote, and the JRC shall make
decisions by consensus. If the JRC is unable to reach consensus, Pfizer shall have the right to make the final decision. In the
event of a dispute between the Parties with regard to the performance of the Research Program, the matter shall be first referred
to the Alliance Managers for resolution, and if not resolved, then shall be further escalated and resolved in accordance with the
provisions of Section 11.11.

 

(f)Limits
on JRC Authority. Notwithstanding any provision of this Section 4.4 to the contrary, each Party shall retain the rights, powers
and discretion granted to it under this Agreement and no such rights, powers, or discretion shall be delegated to the JRC unless
expressly provided for in this Agreement. The JRC shall not have the power to amend this Agreement or otherwise modify or waive
compliance with this Agreement in any manner

 

(g)Term.
The JRC shall be dissolved immediately upon expiration of the Research Term, unless the Parties otherwise agree in writing.

 

4.5.Research
Term Extension. The parties may extend the Research Term by mutual agreement.

 

4.6.Research
Program Expenses. Except as expressly set forth in Section 3.3, each Party shall bear all costs and expenses it incurs in connection
with its activities under the Research Program.

 

4.7.Transfer
of Materials from Pfizer to Collaborator.

 

4.7.1.Transfer.
From time to time during the Research Term, Pfizer may, in its sole discretion, provide Collaborator with tangible chemical or
biological materials (the “Pfizer Materials”). Pfizer represents and warrants to Collaborator that Pfizer has the right
to provide the Pfizer Materials to Collaborator. Except as expressly set forth in the preceding sentence, the Pfizer Materials
are provided by Pfizer on an “as-is” basis without any representation or warranty of any type, express or implied,
including any representation or warranty of merchantability, non-infringement, title or fitness for a particular purpose, each
of which is hereby expressly disclaimed by Pfizer.

 

    	10

    	 

    

 

4.7.2.Permitted
Use of Pfizer Materials. Collaborator shall use the Pfizer Materials solely in connection with conducting the activities specified
in the Research Plan (the “Permitted Activities”). Except in the performance of the Permitted Activities, Collaborator
shall not (a) make or attempt to make any analogues, progeny or derivatives of, or modifications to, the Pfizer Materials or (b)
use the Pfizer Materials for its own benefit or for the benefit of any of its Affiliates or any Third Party. Collaborator shall
retain possession over the Pfizer Materials and not provide any Pfizer Materials to any of its Affiliates or to any Third Party
without Pfizer’s prior written consent, which consent may be withheld in Pfizer’s sole discretion.

 

4.7.3.Unauthorized
Use of Pfizer Materials. If Collaborator uses any Pfizer Material in any manner other than in the performance of the Permitted
Activities, then any and all results of such unauthorized use, whether patentable or not, shall belong solely and exclusively to
Pfizer. Collaborator, on behalf of itself and its Affiliates, hereby assigns and agrees to assign to Pfizer all of Collaborator’s
and its Affiliates’ right, title and interest in and to all such discoveries and inventions. Collaborator further agrees
to cooperate with Pfizer to execute and deliver any and all documents that Pfizer deems reasonably necessary to perfect and enforce
Pfizer’s rights under this Section.

 

4.7.4.Title
to Pfizer Materials. All right, title and interest in and to the Pfizer Materials shall remain the sole and exclusive property
of Pfizer notwithstanding the transfer to and use by Collaborator.

 

4.7.5.Return
of Pfizer Materials. At the end of the Research Term (or such earlier time as Pfizer may request in writing), Collaborator
shall either destroy or return to Pfizer, at Pfizer’s sole discretion, all unused Pfizer Materials.

 

4.7.6.Ownership
of Material Improvements. “Pfizer Material Improvement” means any idea, concept, discovery, invention, Know-How,
trade secret, technique, methodology, modification, innovation, result, improvement, writing, documentation, data, research material
or right that (a) is conceived, discovered, invented, developed, created, made or reduced to practice or tangible medium by Collaborator
through the use of or otherwise involving or by reference to any Pfizer Material or (b) constitutes any improvement or enhancement
to, or a derivative or modification of, any Pfizer Material or any method of making or using any Pfizer Material. Collaborator,
on behalf of itself and its Affiliates, hereby assigns and agrees to assign to Pfizer all of Collaborator’s and its Affiliates’
right, title and interest in and to any and all Pfizer Material Improvements. Collaborator shall promptly notify Pfizer of any
Pfizer Material Improvement made by Collaborator or its Affiliates and shall cooperate fully in obtaining patent and other proprietary
protection for such Pfizer Material Improvement. Such protection shall be obtained in the name of Pfizer and at Pfizer’s
cost and expense, and Collaborator shall, and shall cause its Affiliates to, execute and deliver all requested applications, assignments
and other documents, and take such other actions as Pfizer may reasonably request, in order to perfect and enforce Pfizer’s
rights in any Pfizer Material Improvement.

 

    	11

    	 

    

 

		5.	PRODUCT DEVELOPMENT AND COMMERCIALIZATION.

 

5.1.General.
Subject to the provision of Section 4, Pfizer shall have sole authority over and control of the Development, Manufacture, Regulatory
Approval and Commercialization of Antibodies and Products.

 

5.2.Diligence.

 

5.2.1.Development
Diligence. Pfizer will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least one Product
in at least one indication in at least one Major Market Country for each Target. Pfizer will have no other diligence obligations
with respect to the Development or Regulatory Approval of Products under this Agreement.

 

5.2.2.Commercial
Diligence. Pfizer will use Commercially Reasonable Efforts to Commercialize a given Product in each Major Market Country in
the Territory where Pfizer or its designated Affiliates or Sublicensees seek and receive Regulatory Approval for such Product.
Pfizer will have no other diligence obligations with respect to the Commercialization of Products under this Agreement.

 

5.2.3.Exceptions
to Diligence Obligations. Notwithstanding any provision of this Agreement to the contrary, Pfizer will be relieved of all Pfizer
Diligence Obligations to the extent that:

 

(a)Pfizer
or Collaborator receives or generates any safety, tolerability or other data reasonably indicating, as measured by Pfizer’s
safety and efficacy evaluation criteria and methodology, or signaling that a Product has or would have an unacceptable risk-benefit
profile or is otherwise not reasonably suitable for initiation or continuation of Clinical Trials;

 

(b)Pfizer
or Collaborator receive any notice, information or correspondence from any applicable Regulatory Authority, or any applicable Regulatory
Authority takes any action, that reasonably indicates that a Product is unlikely to receive Regulatory Approval;

 

(c)Collaborator
fails to fulfill its obligations under the Research Plan or this Agreement and such failure prevents Pfizer from fulfilling the
Pfizer Diligence Obligations.

 

5.2.4.Deemed
Satisfaction of Pfizer Diligence Obligations. Without in any way expanding Pfizer’s obligations under this Agreement,
Pfizer’s achievement of any Development Event entitling Collaborator to receive a specific Development Payment described
in Section 3.4 will be conclusive evidence that Pfizer has satisfied all Pfizer Diligence Obligations under this Agreement up to
the date that such Development Event is achieved, as determined on a Target-by-Target basis.

 

5.2.5.Assertion
of Pfizer Diligence Obligation Claims. If Collaborator is, becomes or reasonably should be aware of facts that might form a
reasonable basis to allege that Pfizer has failed to meet any of its obligations under Section 5.2.1 or Section 5.2.2, then Collaborator
will promptly notify Pfizer in writing of such potential alleged performance failure (each such potential alleged performance failure,
a “Diligence Issue”). Promptly upon Pfizer’s receipt of any notice of a Diligence Issue pursuant to this Section
5.2.5, the Pfizer Alliance Manager will contact the Collaborator Alliance Manager to discuss the specific nature of such Diligence
Issue and seek to identify an appropriate corrective course of action. If, no later than 30 days after Pfizer’s receipt of
such a notice, (a) the Parties have not reached consensus regarding whether Pfizer has failed to satisfy its obligations pursuant
to Section 5.2.1 or Section 5.2.2 and (b) the Parties’ respective Alliance Managers have not agreed upon an appropriate corrective
course of action for such Diligence Issue, then such Diligence Issue will be escalated and resolved pursuant to the dispute resolution
provisions set forth in Section 11.11. If Collaborator fails to notify Pfizer of a Diligence Issue pursuant to this Section 5.2.5
within 90 days after the date that Collaborator first discovers or based on the information provided by Pfizer, reasonably should
have discovered such Diligence Issue, then Pfizer will be deemed to have satisfied its obligations under Section 5.2.1 and Section
5.2.2 with respect to such Diligence Issue.

 

    	12

    	 

    

 

5.2.6.Remedies
for Breach of Pfizer Diligence Obligations. If Pfizer materially breaches any Pfizer Diligence Obligation and fails to remedy
such breach within 90 days of Pfizer’s receipt of notice of such breach from Collaborator, then Collaborator may, in its
sole discretion, elect to terminate this Agreement pursuant to the provisions of Section 9.7.1(a) on a Product-by-Product and country-by-country
basis, but only to the extent that a Product in a given country in the Territory is directly and adversely impacted by such uncured
material breach.

 

5.3.Regulatory
Approvals. Pfizer or its designated Affiliate(s) shall have the sole authority to file applications for Regulatory Approval
for Products, including communicating with any Regulatory Authority both prior to and following Regulatory Approval.

 

5.4.Commercialization
Activities. Pfizer shall have sole and exclusive control over all matters relating to the Commercialization of Products, including
sole and exclusive control over (a) pricing of Products and (b) the negotiation of Product pricing with Regulatory Authorities
and other Third Parties.

 

5.5.Manufacturing.
Pfizer shall have the exclusive right to Manufacture Products itself or through one or more Affiliates or Third Parties selected
by Pfizer in its sole discretion. For clarity, Pfizer shall have no diligence obligations with respect to the Manufacture of Products
except to the extent necessary to fulfill its obligations under Section 5.2.1 or Section 5.2.2.

 

5.6.Progress
Reporting. Pfizer shall, within thirty (30) days of a written request from Collaborator, provide Collaborator with annual written
reports summarizing Pfizer’s activities to Develop and Commercialize Products. Any information or written report provided
by Pfizer to Collaborator pursuant to this Section 5.6 shall be deemed to be Pfizer’s Confidential Information and subject
to the provisions of Section 7.

 

5.7.Other
Pfizer Programs. Collaborator understands and acknowledges that Pfizer may have present or future initiatives or opportunities,
including initiatives or opportunities with its Affiliates or Third Parties, involving products, programs, technologies or processes
that are similar to, and in some instances may compete with a Product covered by this Agreement. Collaborator acknowledges and
agrees that nothing in this Agreement will be construed as a representation, warranty, covenant or inference that Pfizer will not
itself Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third Parties
to Develop, Manufacture or Commercialize products, programs, technologies or processes that are similar to or that may compete
with any product, program, technology or process covered by this Agreement, provided that, for clarity, Pfizer will not
use Collaborator’s Confidential Information in breach of this Agreement.

 

    	13

    	 

    

 

		6.	INTELLECTUAL PROPERTY.

 

6.1.Ownership
of Intellectual Property.

 

6.1.1.Ownership
of Inventions. Except as otherwise expressly set forth in this Agreement, each Party shall own all right, title and interest
in and to: (a) any and all Know-How, Antibodies and Products made solely by or on behalf of such Party or its Representatives in
connection with their activities under this Agreement and (b) any and all Patent Rights claiming any such Know-How, Antibodies
or Products described in clause (a) of this Section 6.1.1. Inventorship shall be determined in accordance with United States patent
laws.

 

6.1.2.Ownership
of Sponsored Research Technology. Notwithstanding any provision of Section 6.1.1 to the contrary and subject to Section 6.1.3,
Pfizer shall own all right, title and interest in and to: (a) any and all Know-How, Antibodies and Products, whether or not patentable,
made solely by or on behalf of Collaborator or its Representatives in connection with the Research Program or made jointly by or
on behalf of (i) Collaborator or its Representatives and (ii) Pfizer or its Representatives in connection with the Research Program
(“Sponsored Research Know-How”) and (b) any and all Patent Rights claiming or disclosing any invention included in
Sponsored Research Know-How (“Sponsored Research Patent Rights”). Collaborator agrees to assign and hereby perpetually
and irrevocably assigns and agrees to assign, and shall cause its Representatives to assign, to Pfizer all right, title and interest
throughout the world in and to any and all Sponsored Research Technology. Further, Collaborator shall, and shall cause its Representatives
to, execute any and all assignments, applications for domestic and foreign patents and other documents and to do such other acts
(including the execution and delivery of instruments of further assurance or confirmation) reasonably requested by Pfizer to assign
the Sponsored Research Technology to Pfizer and to permit Pfizer to practice and enforce the Sponsored Research Technology.

 

6.1.3.Ownership
of Collaborator Platform and Collaborator Platform Technology. Collaborator shall own all right, title and interest in and
to the Collaborator Platform and all Collaborator Platform Technology. Collaborator will use its Collaborator Platform to generate
Antibodies for Pfizer. In the course of conducting this work, Collaborator may develop enhancements or improvements to its own
Collaborator Platform that are generally applicable to the Collaborator Platform. Collaborator will own such enhancements or improvements.
During collaborative work conducted between Collaborator and Pfizer, Pfizer may provide know-how or information that generally
improves Collaborator Platform. Collaborator may use such enhancements or improvements to further develop its Collaborator Platform
and with its other collaborators provided that Collaborator may not provide information or know how to its other collaborators
that is related to the Pfizer Target or Antibodies.

 

    	14

    	 

    

 

6.2.Patent
Rights.

 

6.2.1.Filing,
Prosecution and Maintenance of Patent Rights.

 

(a)Collaborator
Patent Rights. Collaborator shall prepare, file, prosecute and maintain any Collaborator Patent Rights in all countries requested
by Pfizer (the “Designated Countries”). For purposes of this section 6.2 Collaborator Patent Rights do not include
Collaborator Platform Patent Rights. Collaborator shall keep Pfizer advised on the status of the preparation, filing, prosecution,
and maintenance of all patent applications included within the Collaborator Patent Rights and the maintenance of any issued patents
included within the Collaborator Patent Rights. Further, Collaborator shall consult and reasonably cooperate with Pfizer with respect
to the preparation, filing, prosecution and maintenance of all Collaborator Patent Rights, including: (i) allowing Pfizer a reasonable
opportunity and reasonable time to review and comment regarding relevant communications to Collaborator and drafts of any responses
or other proposed filings by Collaborator before any applicable filings are submitted to any relevant patent office or Governmental
Authority and (ii) reflecting any reasonable comments offered by Pfizer in any final filings submitted by Collaborator to any relevant
patent office or Governmental Authority. Pfizer shall promptly (within 45 days of receipt of invoice) reimburse Collaborator for
all out of pocket fees and expenses incurred as a result of Collaborator’s obligations with respect to such Designated Countries
as set forth in this Section 6.2.1. If Collaborator elects not to file a patent application included in the Collaborator Patent
Rights in any Designated Country or elects to cease the prosecution or maintenance of any Collaborator Patent Right in any Designated
Country, Collaborator shall provide Pfizer with written notice immediately, but not less than 30 days before any action
is required, upon the decision to not file or continue the prosecution of such patent application or maintenance of such patent.
In such event, Collaborator shall permit Pfizer, in Pfizer’s sole discretion, to file or continue prosecution or maintenance
of any such Collaborator Patent Right in such country on Collaborator’s behalf and at Pfizer’s expense. If Pfizer elects
to continue such prosecution or maintenance, (A) Collaborator shall execute such documents and perform such acts, at Pfizer’s
expense, as may be reasonably necessary to assign to Pfizer all right, title and interest in and to such Collaborator Patent Right
in such country, (B) such Patent Right shall no longer be a Collaborator Patent Right, and (C) any revenues generated by the sale
of any Product claimed by such Collaborator Patent Right in such country shall not be included in the calculation of Net Sales
for any purpose. Pfizer’s rights under this Section 6.2.1(a) shall be in addition to any other rights and remedies which
Pfizer may have as a result of Collaborator’s failure to satisfy its obligations hereunder.

 

(b)Pfizer
Patent Rights and Sponsored Research Patent Rights. Pfizer shall have the sole right, but no obligation, to file, prosecute
and maintain the Patent Rights that it owns or to which it otherwise has Control of prosecution rights, including the Pfizer Patent
Rights and Sponsored Research Patent Rights in its sole discretion.

 

    	15

    	 

    

 

6.2.2.Enforcement
and Defense of Patent Rights.

 

(a)Enforcement
of Collaborator Patent Rights. Each Party will promptly notify the other in the event of any actual, potential or suspected
infringement of a patent under the Collaborator Patent Rights by any Third Party. As between Pfizer and Collaborator, Pfizer shall
have the first right, except as otherwise provided in this Section 6.2.2, but not the obligation, to institute litigation or take
other steps to remedy infringement in connection therewith, and any such litigation or steps shall be at Pfizer’s expense,
subject to Collaborator’s obligation to indemnify Pfizer for such expenses pursuant to Section 10; provided that any
recoveries resulting from such litigation or steps relating to a claim of Third Party infringement, after deducting Pfizer’s
out of pocket expenses (including counsel fees and expenses) in pursuing such claim, will be deemed Net Sales. Pfizer shall not,
without the prior written consent of Collaborator, enter into any compromise or settlement relating to such litigation that (i)
admits the invalidity or unenforceability of any Collaborator Patent Right or (ii) requires Pfizer to abandon any Collaborator
Patent Right. In order to establish standing, Collaborator, upon request of Pfizer, agrees to timely commence or to join in any
such litigation, at Pfizer’s expense, and in any event to cooperate with Pfizer in such litigation or steps at Pfizer’s
expense. Collaborator will have the right to consult with Pfizer about such litigation and to participate in and be represented
by independent counsel in such litigation at Collaborator’s own expense. If Pfizer fails to institute such litigation or
otherwise take steps to remedy the infringement of a Collaborator Patent Right within 120 days of its receipt of notice thereof
in the case of a Collaborator Patent Right, then Collaborator shall have the right, but not the obligation, upon 20 days’
prior notice to Pfizer, at Collaborator’s expense, to institute any such litigation; provided further that any recoveries
resulting from such litigation or steps relating to a claim of Third Party infringement, will belong to Collaborator. Pfizer shall
have no obligation to cooperate with Collaborator in any such litigation. Neither Party shall incur any liability to the other
Party as a consequence of any litigation initiated or pursued pursuant to this Section 6.2.2(a) or any unfavorable decision resulting
therefrom, including any decision holding any Collaborator Patent Right invalid or unenforceable.

 

(b)Enforcement
of Pfizer Patent Rights and Sponsored Research Patent Rights. Pfizer shall have the sole right, but no obligation, to take
action to obtain a discontinuance of infringement or bring suit against a Third Party infringing or challenging the validity or
enforceability of any Pfizer Patent Right or any Sponsored Research Patent Right.

 

6.2.3.Allegations
of Infringement and Right to Seek Third Party Licenses.

 

(a)Notice.
If the Development, Manufacture, Commercialization or use of any Antibody or Product, the practice of any Collaborator Technology,
or the exercise of any other right granted by Collaborator to Pfizer hereunder (collectively, the “Licensed Activities”)
by Pfizer or any of its Affiliates or Sublicensees is alleged by a Third Party to infringe, misappropriate or otherwise violate
such Third Party’s Patent Rights or other intellectual property rights, Collaborator shall, promptly upon becoming aware
of such allegation, notify Pfizer in writing. Additionally, if Collaborator determines that, based upon the review of any Third
Party Patent Right or other Third Party intellectual property rights, it may be desirable to obtain a license from such Third Party
with respect thereto so as to avoid any potential claim of infringement by such Third Party against either Party or their respective
Affiliates or Sublicensees, then Collaborator shall promptly notify Pfizer of such determination.

 

    	16

    	 

    

 

(b)Pfizer
Option to Negotiate. If Pfizer determines, in its sole discretion, that, in order for Pfizer, its Affiliates or Sublicensees
to engage in the Licensed Activities, it is necessary or desirable to obtain a license under one or more Patent Rights or other
intellectual property rights Controlled by a Third Party (collectively, “Third Party IP Rights”), then Pfizer shall
have the sole right, but not the obligation, to negotiate and enter into a license or other agreement with such Third Party. All
amounts payable under any such license or agreement with a Third Party shall reduce Pfizer’s royalty obligations under this
Agreement as and to the extent provided in Section 3.6.3(a).

 

6.2.4.Third
Party Infringement Suits. Each of the Parties shall promptly notify the other in the event that any Third Party files any suit
or brings any other action alleging patent infringement by Pfizer or Collaborator or any of their respective Affiliates or Sublicensees
with respect to the Development, Manufacture, Commercialization or use of any Antibody or Product or the practice of any Collaborator
Technology (any such suit or other action referred to herein as an “Infringement Claim”). In the case of any Infringement
Claim against Pfizer (including its Affiliates or Sublicensees) alone or against both Pfizer and Collaborator (including its Affiliates),
Pfizer shall have the right, but not the obligation, to control the defense of such Infringement Claim, including control over
any related litigation, settlement, appeal or other disposition arising in connection therewith. Collaborator, upon request of
Pfizer, agrees to join in any litigation associated with any Infringement Claim at Pfizer’s expense and in any event to cooperate
with Pfizer at Pfizer’s expense. Collaborator will have the right to consult with Pfizer concerning any Infringement Claim
and to participate in and be represented by independent counsel in any associated litigation in which Collaborator is a party at
Collaborator’s own expense. If Pfizer elects to control the defense of any Infringement Claim and Collaborator is obligated
under Section 10.3 to indemnify Pfizer (including any Pfizer Indemnified Party) with respect to such Infringement Claim, then (a)
Pfizer will bear 50% of its own attorneys’ fees incurred in investigating, preparing or defending such Infringement Claim
notwithstanding the provisions of Section 10.3 and (b) Collaborator will otherwise indemnify Pfizer and any applicable Pfizer Indemnified
Parties to the full extent provided for under Section 10.3. In the case of any Infringement Claim against Collaborator alone, Pfizer
shall have the right to consult with Collaborator concerning such Infringement Claim and Pfizer, upon request of Collaborator,
will reasonably cooperate with Collaborator at Collaborator’s expense (but Pfizer shall have no obligation to join any Infringement
Claim or associated litigation).

 

6.2.5.Other
Actions by Third Parties. Each Party shall promptly notify the other Party in the event of any legal or administrative action
by any Third Party involving any Collaborator Patent Right of which it becomes aware, including any nullity, revocation, interference,
reexamination or compulsory license proceeding. Pfizer shall have the first right, but no obligation, to defend against any such
action involving any Collaborator Patent Right, in its own name (to the extent permitted by applicable Law), and any such defense
shall be at Pfizer’s expense, subject to Collaborator’s indemnification obligations under Section 10. Collaborator,
upon Pfizer’s request, agrees to join in any such action at Pfizer’s expense and in any event to cooperate with Pfizer
at Pfizer’s expense. If Pfizer fails to defend against any such action involving a Collaborator Patent Right, then Collaborator
shall have the right to defend such action, in its own name, and any such defense shall be at Collaborator’s expense. In
such event, Pfizer, upon Collaborator’s request, shall reasonably cooperate with Collaborator in any such action at Collaborator’s
expense.

 

    	17

    	 

    

 

6.2.6.Orange
Book Type Information. Pfizer shall be responsible for all submissions of patent information pertaining to each Product pursuant
to 21 U.S.C. § 355(b)(1)(G) (or any amendment or successor statute thereto), the Biologics Price Competition and Innovation
Act of 2009, or any similar statutory or regulatory requirement in any non-United States country or other regulatory jurisdiction

 

6.2.7.Biosimilar
Applications. Each Party shall immediately give written notice to the other of any notice received from a Third Party of an
application for FDA approval under the Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute
thereto) of a biosimilar (including any Biosimilar Version) referencing a Product or any certification under a similar statutory
or regulatory requirement in any non-United States country in the Territory claiming that a Collaborator Patent Right or Sponsored
Research Patent Right covering any Product is invalid or that infringement will not arise from the Development, Manufacture or
Commercialization of a proposed biosimilar (including any Biosimilar Version) by a Third Party. Upon the giving or receipt of such
notice, Pfizer shall have the first right (or the sole right, in the case of a Sponsored Research Patent Right) but not the obligation,
to bring an infringement action against such Third Party in connection with such certification. In the case of a Collaborator Patent
Right, Pfizer shall notify Collaborator at least ten (10) days prior to the date set forth by statute or regulation of its intent
to exercise, or not exercise, this right. Any infringement action against a Third Party arising under this Section shall
be governed by the provisions of Section 6.2.2.

 

6.2.8.Patent
Term Restoration and Extension. Pfizer shall have the exclusive right, but not the obligation, to seek, in Collaborator’s
name if so required, patent term extensions, and supplemental protection certificates and the like available under Law, including
35 U.S.C. § 156 and applicable foreign counterparts, in any country in the Territory in relation to the Collaborator Patent
Rights. Collaborator and Pfizer shall cooperate in connection with all such activities. Pfizer, its agents and attorneys will give
due consideration to all suggestions and comments of Collaborator regarding any such activities, but in the event of a disagreement
between the Parties, Pfizer will have the final decision-making authority; provided, however, that Pfizer shall seek (or allow
Collaborator to seek) to extend any Collaborator Patent Right at Collaborator’s request, including through the use of supplemental
protection certificates and the like, unless in Pfizer’s reasonable legal determination such Collaborator Patent Right may
not be extended under Law without limiting Pfizer’s right to extend any other Patent Right.

 

6.3.Recording.
If Pfizer deems it necessary or desirable to register or record this Agreement or evidence of this Agreement with any patent office
or other appropriate Governmental Authority(ies) in one or more jurisdictions in the Territory, Collaborator shall reasonably cooperate
to execute and deliver to Pfizer any documents accurately reflecting or evidencing this Agreement that are necessary or desirable,
in Pfizer’s reasonable judgment, to complete such registration or recordation. Pfizer shall reimburse Collaborator for all
reasonable out-of-pocket expenses, including attorneys’ fees, incurred by Collaborator in complying with the provisions of
this Section.

 

    	18

    	 

    

 

		7.	CONFIDENTIALITY.

 

7.1.Confidentiality.
Except to the extent expressly authorized by this Agreement, the Parties agree that, during the Term and for five years thereafter,
each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing
Party”) hereunder shall: (a) keep the Disclosing Party’s Confidential Information confidential; (b) not disclose, or
permit the disclosure of, the Disclosing Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing
Party’s Confidential Information for any purpose other than as expressly permitted under the terms of this Agreement.

 

7.2.Authorized
Disclosure.

 

7.2.1.Disclosure
to Party Representatives. Notwithstanding the foregoing provisions of Section 7.1, the Receiving Party may disclose Confidential
Information belonging to the Disclosing Party to the Receiving Party’s Representatives who (a) have a need to know such Confidential
Information in connection with the performance of the Receiving Party’s obligations or the exercise of the Receiving Party’s
rights under this Agreement and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential
Information that are at least as restrictive as those set forth in this Section 7.

 

7.2.2.Disclosure
to Third Parties. Notwithstanding the foregoing provisions of Section 7.1, each Party may disclose Confidential Information
belonging to the other Party to the extent such disclosure is reasonably necessary:

 

(a)to
Governmental Authorities (i) to the extent desirable to obtain or maintain INDs or Regulatory Approvals for any Antibody or Product
within the Territory, and (ii) in order to respond to inquiries, requests or investigations relating to Antibodies, Products or
this Agreement;

 

(b)to
outside consultants, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in
each case to the extent desirable to develop, register or market any Antibody or Product; provided that the Receiving Party
shall obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own similar types of
confidential information;

 

(c)in
connection with filing or prosecuting Patent Rights or trademark rights as permitted by this Agreement,

 

(d)in
connection with prosecuting or defending litigation as permitted by this Agreement;

 

(e)subject
to the provisions of Section 7.5.2, in connection with or included in scientific presentations and publications relating to Antibodies
or Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical
trials to clincialtrials.gov or PhRMA websites;

 

(f)to
the extent necessary or desirable in order to enforce its rights under this Agreement; and

 

    	19

    	 

    

 

(g)to
members of its board of directors, to its investors, and to bona fide prospective investors provided that the Receiving
Party shall obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own similar types
of confidential information outside.

 

If a Party deems it
reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to this Section 7.2.2, then the
disclosing Party shall to the extent possible give reasonable advance written notice of such disclosure to the other Party and
take such measures to ensure confidential treatment of such information as is reasonably required by the other Party, at the other
Party’s expense.

 

7.3.SEC
Filings and Other Disclosures. Either Party may disclose the terms of this Agreement to the extent required, in the reasonable
opinion of such Party’s legal counsel, to comply with applicable Law, including the rules and regulations promulgated by
the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory. Before
disclosing this Agreement or any of the terms hereof pursuant to this Section 7.3, the Parties will consult with one another on
the terms of this Agreement to be redacted in making any such disclosure, with the disclosing Party providing as much advanced
notice as is feasible under the circumstances, and giving consideration to the comments of the other Party. Further, if a Party
discloses this Agreement or any of the terms hereof in accordance with this Section 7.3, such Party shall, at its own expense,
seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested
by the other Party.

 

7.4.[Intentionally
Omitted]

 

7.5.Public
Announcements; Publications.

 

7.5.1.Announcements.
Except as may be expressly permitted under Section 7.3, neither Party will make any public announcement regarding this Agreement
without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement shall prevent Pfizer
from making any scientific publication or public announcement with respect to any Product under this Agreement; provided, however,
that, except as permitted under Section 7.2, Pfizer shall not disclose any of Collaborator’s Confidential Information in
any such publication or announcement without obtaining Collaborator’s prior written consent to do so. The Parties agree that
Collaborator may release the announcement attached hereto as Schedule 7.5.1 regarding the signing of this Agreement following the
Effective Date.

 

7.5.2.Publications.
Each Party shall submit to the other Party (the “Non-Disclosing Party”) for review and approval any proposed academic,
scientific and medical publication or public presentation which contains the Non-Disclosing Party’s Confidential Information.
In addition, Collaborator shall submit to Pfizer for review and approval any proposed publication or public presentation relating
to the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value
of the Collaborator Technology, the Pfizer Technology, the Sponsored Research Technology and the rights granted to Pfizer hereunder
and determining whether any portion of the proposed publication or presentation containing the Non-Disclosing Party’s Confidential
Information should be modified or deleted. Written copies of such proposed publication shall be submitted to the Non-Disclosing
Party no later than 60 days before submission for publication or presentation (the “Review Period”). The Non-Disclosing
Party shall provide its comments with respect to such publications and presentations within 30 days of its receipt of such written
copy. The Review Period may be extended for an additional 30 days in the event the Non-Disclosing Party can, within ten days of
receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent
applications. Collaborator and Pfizer will each comply with standard academic practice regarding authorship of scientific publications
and recognition of contribution of other parties in any publication governed by this Section 7.5.2. For the sake of clarity, Pfizer’s
obligation to submit any publication to Collaborator for review and approval under this Section 7.5.2 shall not apply to any publication
which does not contain Collaborator’s Confidential Information.

 

    	20

    	 

    

 

7.6.Obligations
in Connection with Change of Control. If Collaborator is subject to a Change of Control, Collaborator will, and it will cause
its Representatives to, ensure that no Confidential Information of Pfizer is released to any Affiliate of Collaborator that becomes
an Affiliate as a result of the Change of Control unless such Affiliate or its representatives of the Affiliate have signed individual
confidentiality agreements which include equivalent obligations to those set out in this Section 7. If any Change of Control of
Collaborator occurs, Collaborator shall promptly notify Pfizer, share with Pfizer the procedures it plans to implement in order
to protect the confidentiality of Pfizer’s Confidential Information prior to such implementation and make any adjustments
to such procedures that are reasonably requested by Pfizer.

 

		8.	REPRESENTATIONS AND WARRANTIES.

 

8.1.Mutual
Representations and Warranties. Each of Collaborator and Pfizer hereby represents and warrants to the other Party that:

 

8.1.1.it
is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization;

 

8.1.2.the
execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action under the
provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its
shareholders or other holders of its voting securities or voting interests;

 

8.1.3.it
has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder

 

8.1.4.this
Agreement has been duly executed and is a legal, valid and binding obligation on each Party, enforceable against such Party in
accordance with its terms; and

 

8.1.5.the
execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does
not and will not conflict with or result in a breach of or default under any binding obligation existing as of the Execution Date.

 

    	21

    	 

    

 

8.2.Mutual
Covenants. Each of Collaborator and Pfizer hereby covenants to the other Party that, from the Execution Date until expiration
or termination of this Agreement, it will perform its obligations under this Agreement in compliance with applicable Laws.

 

8.3.Representations
and Warranties of Collaborator. Collaborator hereby represents and warrants to Pfizer that:

 

8.3.1.except
as expressly disclosed in Schedule 8.3.1, Collaborator is the sole and exclusive owner of the Collaborator Technology and the Collaborator
Platform Technology, all of which is free and clear of any claims, liens, charges or encumbrances;

 

8.3.2.it
has and will have the full right, power and authority to grant all of the right, title and interest in the licenses and other rights
granted or to be granted to Pfizer, Pfizer’s Affiliates or Pfizer’s Sublicensees under this Agreement;

 

8.3.3.as
of the Execution Date (a) Exhibit B sets forth a true and complete list of any Patent Rights owned or otherwise Controlled by Collaborator
or its Affiliates that relate to the Antibodies or Products, (b) each such Patent Right remains in full force and effect and (c)
Collaborator or its Affiliates have timely paid all filing and renewal fees payable with respect to such Patent Rights;

 

8.3.4.as
of the Execution Date, Collaborator has disclosed to Pfizer all material scientific and technical information and all information
relating to safety and efficacy known to it or its Affiliates with respect to the Antibodies and Products;

 

8.3.5.it
has complied with all applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance
of the Collaborator Patent Rights and Collaborator Platform Patent Rights;

 

8.3.6.except
as expressly disclosed in Schedule 8.3.6, Collaborator has independently developed all Collaborator Know-How and Collaborator Platform
Know-How or otherwise has a valid right to use all Collaborator Know-How and Collaborator Platform Know-How, and to permit Pfizer,
Pfizer’s Affiliates and Pfizer’s Sublicensees to use, the Collaborator Know-How for all permitted purposes under this
Agreement;

 

8.3.7.no
Collaborator Technology existing as of the Effective Date is subject to any funding agreement with any government or Governmental
Authority;

 

8.3.8.except
as expressly disclosed in Schedule 8.3.8, neither Collaborator nor any of its Affiliates are party to or otherwise subject to any
agreement or arrangement which limits the ownership or licensed rights of Pfizer or its Affiliates with respect to, or limits the
ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in,
to or under, any intellectual property right or material (including any Patent Right, Know-How or other data or information), in
each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to Pfizer or its Affiliates
pursuant to this Agreement;

 

    	22

    	 

    

 

8.3.9.(a)
there are no Collaborator Third Party Agreements, other than the Collaborator Third Party Agreements expressly disclosed in Schedule
8.3.9 (each, a “Disclosed Third Party Agreement”), true and complete copies of which have been provided to Pfizer,
(b) except as provided in the Disclosed Third Party Agreements, no Third Party has any right, title or interest in or-to, or any
license under, any Collaborator Technology, (c) no rights granted by or to Collaborator or its Affiliates under any Disclosed Third
Party Agreement conflict with any right or license granted to Pfizer or its Affiliates hereunder and (d) Collaborator and its Affiliates
are in compliance in all material respects with all Disclosed Third Party Agreements;

 

8.3.10.there
is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal,
regulatory or otherwise, pending or, to the best knowledge of Collaborator, threatened against Collaborator or any of its Affiliates
or (b) judgment or settlement against or owed by Collaborator or any of its Affiliates, in each case in connection with the Collaborator
Technology, any Antibody or any Product or relating to the transactions contemplated by this Agreement; and

 

8.3.11.to
the best of its knowledge, the practice of the Collaborator Technology and the Collaborator Platform Technology to Develop any
Antibody or Product does not infringe or misappropriate any issued patent or other proprietary right owned or possessed by any
Third Party.

 

8.4.Collaborator
Covenants. Collaborator hereby covenants to Pfizer that, from the Execution Date until expiration or termination of this Agreement:

 

8.4.1.it
shall not, and shall cause its Affiliates not to license, sell, assign or otherwise transfer to any Person any Collaborator Technology,
or incur any other obligation that is or would be inconsistent with the licenses and other rights granted to Pfizer under this
Agreement;

 

8.4.2.it
will not take any action that diminishes the rights under the Collaborator Technology, Sponsored Research Technology granted to
Pfizer under this Agreement or fail to take any action that is reasonably necessary to avoid diminishing the rights under the Collaborator
Technology or Sponsored Research Technology granted to Pfizer under this Agreement;

 

8.4.3.it
will (a) not enter into any agreement that adversely affects the rights granted to Pfizer or Collaborator’s ability to fully
perform its obligations hereunder; (b) not amend or otherwise modify any Collaborator Third Party Agreement or consent or waive
rights with respect thereto in any manner that (i) adversely affects the rights granted to Pfizer or (ii) Collaborator’s
ability to fully perform its obligations hereunder; (c) remain, and cause its Affiliates to remain, in compliance in all material
respects with all Collaborator Third Party Agreements.

 

8.4.4.it
will maintain valid and enforceable agreements with all Persons acting by or on behalf of Collaborator or its Affiliates under
this Agreement which require such Persons to assign to Collaborator their entire right, title and interest in and to all Collaborator
Technology and Sponsored Research Technology.

 

    	23

    	 

    

 

8.5.Representation
by Legal Counsel. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement
and acknowledges that it has participated in the drafting hereof In interpreting and applying the terms and provisions of this
Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms and provisions.

 

8.6.Disclaimer.
THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL
OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED.

 

		9.	GOVERNMENT APPROVALS; TERM AND TERMINATION.

 

9.1.[Intentionally
Omitted]

 

9.2.[Intentionally
Omitted]

 

9.3.Government
Approvals. Each of Collaborator and Pfizer shall cooperate with the other Party and use Commercially Reasonable Efforts to
make all registrations, filings and applications, and to obtain as soon as practicable all governmental or other consents or approvals
necessary for the consummation of the transaction.

 

9.4.Term.
The term of this Agreement (the “Term”) will commence on the Effective Date and extend on a country-by-country basis
(in the Territory), unless this Agreement is terminated earlier in accordance with this Section 9, until the last to expire of
any Royalty Term for any Product in such country in the Territory.

 

9.5.Termination
by Collaborator. Collaborator may terminate this Agreement for cause, at any time during the Term, by giving written notice
to Pfizer in the event that Pfizer commits a material breach of its obligations under this Agreement and such material breach remains
uncured for ninety days, measured from the date written notice of such material breach is given to Pfizer; provided, however, that
if any breach is not reasonably curable within ninety days and if Pfizer is making a bona fide effort to cure such breach, such
termination shall be delayed for up to an additional ninety days in order to permit Pfizer a reasonable period of time to cure
such breach, and if not cured within such second ninety day period then this Agreement shall terminate at the end of such one hundred
and eighty day period.

 

9.6.Termination
by Pfizer.

 

9.6.1.Termination
for Convenience. Upon at least 60 days written notice, to Collaborator, Pfizer may terminate this Agreement on a Target-by-Target
or Product-by-Product and country-by-country basis, or in its entirety, without cause, for any or no reason.

 

    	24

    	 

    

 

9.6.2.Termination
for Cause. Pfizer may terminate this Agreement for cause with respect to one or more Targets or Products in one or more countries
in the Territory or may terminate this Agreement in its entirety, at any time during the Term, by giving written notice to Collaborator
in the event that Collaborator commits a material breach of its obligations under this Agreement with respect to such Target or
Product, and such material breach remains uncured for 90 days, measured from the date written notice of such material breach is
given to Collaborator; provided, however, that if any breach is not reasonably curable within 90 days and if Collaborator
is making a bona fide effort to cure such breach, such termination shall be delayed for a time period to be agreed by both Parties
in order to permit Collaborator a reasonable period of time to cure such breach.

 

9.7.Effects
of Termination.

 

9.7.1.Effect
of Termination.

 

(a)Termination
for Cause by Collaborator; Termination for Convenience by Pfizer. In the event that Collaborator terminates this Agreement
for cause pursuant to Section 9.5 or Pfizer terminates this Agreement with respect to the entire Agreement, or to a specific Target
without cause pursuant to Section 9.6.1, the following will apply:

 

(i)Except
as otherwise expressly provided herein, all rights and obligations of each Party hereunder shall cease except non-exclusive research
licenses granted in Section 3.2.

 

(ii)If
Collaborator provides written notice to Pfizer within 90 days following the effective date of termination, the Parties will negotiate
in good faith for a period not to exceed 90 days regarding:

 

    	25

    	 

    

 

(A)the
transfer or grant of a license by Pfizer to Collaborator of Pfizer Technology necessary to allow Collaborator to continue to Develop,
Commercialize and Manufacture any Antibody(ies) and Product(s) under Development or Commercialization by Pfizer under this Agreement
at the time of termination, in the form in which such Product then exists (a “Continuation Product”) including the
payment by Collaborator of royalty for sales of the Product;

 

(B)the
related transfer to Collaborator of development data and regulatory filings specifically relating to such Continuation Product
or the granting to Collaborator of rights of reference with respect to such data and filings; and

 

(C)the
provision by Pfizer to Collaborator of transitional supplies of such Continuation Product at a commercially reasonable supply price
for a commercially reasonable period of time.

 

(iii)Neither
Party will be obligated to enter into any transaction described in Section 9.7.1(a)(ii), and neither Party will have any liability
to the other for failure to do so.

 

(iv)If
the termination occurs prior to the completion of all of the Preclinical Milestone Events for a Target, and Collaborator is conducting
work on such Target, within forty-five (45) days of receipt of invoice from Collaborator Pfizer will pay Collaborator the Preclinical
Milestone Payment that corresponds to the next Preclinical Milestone Event.

 

(b)Termination
for Cause by Pfizer.

 

(i)Complete
Termination. In the event that Pfizer terminates this Agreement in its entirety pursuant to Section 9.6.2: (A) all licenses
granted under this Agreement by Collaborator to Pfizer shall become fully paid-up, perpetual, and irrevocable; (B) Collaborator
shall, for a period of 90 days following the effective date of termination, provide Pfizer with knowledge transfer assistance;
(C) any amounts payable by Pfizer to Collaborator pursuant to Section 3 shall be reduced to [***]
of the amount that would otherwise have been payable under the terms of the Agreement during its Term, and (D) except as otherwise
expressly provided herein, all other rights and obligations of each Party with respect to all Products throughout the Territory
shall cease.

 

9.7.2.Accrued
Rights. Expiration or termination of this Agreement for any reason shall be without prejudice to any right which shall have
accrued to the benefit of either Party prior to such termination, including damages arising from any breach under this Agreement.
Expiration or termination of this Agreement shall not relieve either Party from any obligation which is expressly indicated to
survive such expiration or termination.

 

9.7.3.Survival
Period. The following sections, together with any sections that expressly survive (including any perpetual licenses granted
hereunder), shall survive expiration or termination of this Agreement for any reason: Sections 1 (Definitions and Interpretation),
2.2 (Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information), 2.3 (No Implied Rights), 3.4
(Development Payments), 3.5 (Sales Milestone Payments), 3.6 (Royalty Payments), 3.7.1 through 3.7.5 (to the extent any Product(s)
are sold in the applicable time period), 3.7.6 (Record Keeping), 3.7.7 (Audits), 3.7.8 (Underpayments/Overpayments), 3.7.9 (Confidentiality),
3.9 (Non-Refundable), 3.10 (Past Due Amounts), 3.11 (Obligation to Make Payment), 4.7.2 (Permitted Use of Pfizer Materials), 4.7.3
(Unauthorized Use of Pfizer Materials), 4.7.4 (Title to Pfizer Materials), 4.7.5 (Return of Pfizer Materials), 4.7.6 (Ownership
of Material Improvements), 6.1 (Ownership of Intellectual Property), 7 (Confidentiality), 9.7 (Effects of Termination), 9.8 (Provision
for Insolvency), 10.1 (No Consequential Damages), 10.2 (Indemnification by Pfizer), 10.3 (Indemnification by Collaborator), 10.4
(Procedure), and 11 (Miscellaneous)

 

 

 

*Confidential Treatment
Requested.

    	26

    	 

    

 

9.8.Provision
for Insolvency.

 

9.8.1.Termination
Right. Collaborator shall be deemed a “Debtor” under this Agreement if, at any time during the Term (a) a case
is commenced by or against Collaborator under the Bankruptcy Code, (b) Collaborator files for or is subject to the institution
of bankruptcy, reorganization, liquidation or receivership proceedings (other than a case under the Bankruptcy Code), (c) Collaborator
assigns all or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for Collaborator’s
business or (e) a substantial portion of Collaborator’s business is subject to attachment or similar process; provided,
however, that in the case of any involuntary case under the Bankruptcy Code, Collaborator shall not be deemed a Debtor if the
case is dismissed within 60 days after the commencement thereof If Collaborator is deemed a Debtor, then Pfizer may terminate this
Agreement by providing written notice to Collaborator.

 

If Pfizer terminates this Agreement
pursuant this Section 9.8.1, then: (i) all licenses granted to Pfizer under this Agreement shall become irrevocable and perpetual,
and Pfizer shall have no further obligations to Collaborator under this Agreement other than (A) those obligations that expressly
survive termination in accordance with Section 9.7.3 and (B) an obligation to pay royalties with respect to Net Sales of Products
in an amount equal to [***] of the amount that would otherwise have been payable
under this Agreement, such amount to be paid in accordance with and subject to the other terms of this Agreement governing the
payment of royalties; (ii) such termination shall not be construed to limit Collaborator’s right to receive payments that
accrued before the effective date of such termination; (iii) Pfizer shall have the right to offset, against any payment owing to
Collaborator as provided for under clause (i), above, any damages agreed by the Parties to be owed by Collaborator to Pfizer; and
(iv) Nothing in this Section 9.8.1 shall limit any other remedy Pfizer may have for any breach by Collaborator of this Agreement.

 

9.8.2.Rights
to Intellectual Property. All rights and licenses now or hereafter granted by Collaborator to Pfizer under or pursuant to any
Section of this Agreement, are rights to “intellectual property” (as defined in the Bankruptcy Code). The Parties acknowledge
and agree that all of the payments provided for under Sections 3 and all other payments by Pfizer to Collaborator hereunder, other
than royalty payments pursuant to Section 3.5 do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy
Code or relate to licenses of intellectual property hereunder. If (a) a case under the Bankruptcy Code is commenced by or against
Collaborator, (b) this Agreement is rejected as provided in the Bankruptcy Code and (c) Pfizer elects to retain its rights hereunder
as provided in Section 365(n) of the Bankruptcy Code, then Collaborator (in any capacity, including debtor-in-possession) and its
successors and assigns (including any trustee) shall provide to Pfizer all intellectual property licensed hereunder, and agrees
to grant and hereby grants to Pfizer and its Affiliates a right to access and to obtain possession of and to benefit from and,
in the case of any chemical or biological material or other tangible item of which there is a fixed or limited quantity, to obtain
a pro rata portion of, each of the following to the extent related to any Antibody or Product, or otherwise related to any right
or license granted under or pursuant to this Agreement: (i) copies of pre-clinical and clinical research data and results; (ii)
all of the following (to the extent that any of the following are so related): cell lines, antibodies, assays, reagents and other
biological materials; (iii) Product samples; (v) laboratory notes and notebooks; (vi) Product data or filings, and (vii) rights
of reference in respect of regulatory filings and approvals, all of which constitute “embodiments” of intellectual
property pursuant to Section 365(n) of the Bankruptcy Code, and (viii) all other embodiments of such intellectual property, whether
any of the foregoing are in Collaborator’s possession or control or in the possession and control of any Third Party but
which Collaborator has the right to access or benefit from and to make available to Pfizer; provided, however, that none of the
foregoing shall include rights to the Collaborator Platform or Collaborator Platform Technology except as expressly licensed under
this Agreement.

 

 

*Confidential Treatment
Requested.

    	27

    	 

    

 

Collaborator shall not interfere
with the exercise by Pfizer or its Affiliates of rights and licenses to intellectual property licensed hereunder and embodiments
thereof in accordance with this Agreement and agrees to use Commercially Reasonable Efforts to assist Pfizer and its Affiliates
to obtain such intellectual property and embodiments thereof in the possession or control of Third Parties as reasonably necessary
or desirable for Pfizer or its Affiliates or Sublicensees to exercise such rights and licenses in accordance with this Agreement.

 

9.8.3.No
Limitation of Rights. All rights, powers and remedies of Pfizer provided in this Section 9.8 are in addition to and not in
substitution for any and all other rights, powers and remedies now or hereafter existing at Law or in equity (including the Bankruptcy
Code) in the event of the commencement of a case under the Bankruptcy Code involving Collaborator.

 

		10.	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE.

 

10.1.No
Consequential Damages. Except with respect to liability arising from a breach of Section 6 or 7, from any willful misconduct
or intentionally wrongful act, or to the extent such Party may be required to indemnify the other Party under this Section 10,
in no event will either Party or its Representatives be liable under this Agreement for any special, indirect, incidental, consequential
or punitive damages, whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of profits
or revenue suffered by either Party or any of its Representatives. Without limiting the generality of the foregoing, “consequential
damages” will be deemed to include, and neither Party will be liable to the other Party or any of such other Party’s
Representatives or stockholders for any damages based on or measured by loss of projected or speculative future sales of the Products,
any Development Payment due upon any unachieved Development Event under Section 3.4, any Sales Milestone Payment due upon any unachieved
Total Annual Net Sales level under Section 3.5, any unearned royalties under Section 3.6 or any other unearned, speculative or
otherwise contingent payments provided for in this Agreement.

 

    	28

    	 

    

 

10.2.Indemnification
by Pfizer. Pfizer will indemnify, defend and hold harmless Collaborator, each of its Affiliates, and each of its and its Affiliates’
employees, officers, directors and agents (each, a “Collaborator Indemnified Party”) from and against any and all liability,
loss, damage, expense (including reasonable attorneys’ fees and expenses) and cost (collectively, a “Liability”)
that the Collaborator Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of:

 

(a)Development,
Manufacture, Commercialization or use of any Product by, on behalf of, or under the authority of, Pfizer (other than by any Collaborator
Indemnified Party), other than (i) claims by Third Parties relating to patent infringement arising out of the exercise of rights
under the Collaborator Patent Rights, (ii) claims by Third Parties relating misappropriation of trade secrets arising out of the
exercise of rights under the Collaborator Know-How, or (iii) claims for which Collaborator is required to indemnify Pfizer pursuant
to Section 10.3; or

 

(b)the
material breach by Pfizer of any of its representations, warranties or covenants set forth in Section 8.1;

 

except, in each case, to the extent caused
by the negligence, recklessness or intentional acts of Collaborator or any Collaborator Indemnified Party.

 

10.3.Indemnification
by Collaborator. Collaborator will indemnify, defend and hold harmless Pfizer, its Affiliates, Sublicensees, contractors, distributors
and each of its and their respective employees, officers, directors and agents (each, a “Pfizer Indemnified Party”)
from and against any and all Liabilities that the Pfizer Indemnified Party may be required to pay to one or more Third Parties
resulting from or arising out of the material breach by Collaborator of any of its representations, warranties or covenants set
forth in Section 8.1, Section 8.2, Section 8.3 or Section 8.4
except to the extent caused by the negligence, recklessness or intentional acts of Pfizer or any Pfizer Indemnified Party.

 

10.4.Procedure.

 

10.4.1.Notice.
Each Party will notify the other Party in writing in the event it becomes aware of a claim for which indemnification may be sought
hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with
respect to any matter for which a Party (the “Indemnified Party”) is entitled to indemnification hereunder (a “Third
Party Claim”), then the Indemnified Party shall promptly notify the Party obligated to indemnify the Indemnified Party (the
“Indemnifying Party”) thereof; provided, however, that no delay on the part of the Indemnified Party in notifying
the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that)
the Indemnifying Party is prejudiced thereby.

 

    	29

    	 

    

 

10.4.2.Control.
Subject to Pfizer’s right to control any actions described in Sections 6.2.2, 6.2.3, or 6.2.4. (even where Collaborator is
the Indemnifying Party), the Indemnifying Party shall have the right, exercisable by notice to the Indemnified Party within ten
Business Days after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim,
to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including
the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably
acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in the reasonable
judgment of the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is sought, (b) the Third Party Claim
seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party
and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge the Third Party Claim in full
(the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the “Litigation Conditions”).
Within ten Business Days after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to
defend a Third Party Claim, the Indemnified Party shall give notice to the Indemnifying Party of any objection thereto based upon
the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party shall continue to defend the Third
Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given,
or if any such objection is withdrawn, the Indemnifying Party shall be entitled, at its sole cost and expense, to assume direction
and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party.
During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate,
and shall cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of
the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery
proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying
Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party’s intent
to defend any Third Party Claim within ten Business Days after notice thereof; the Indemnified Party may (without further notice
to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party’s expense
(including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying
Party or the Indemnified Party, as the case may be, shall have the right to join in (including the right to conduct discovery,
interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense,
of any Third Party Claim that the other party is defending as provided in this Agreement.

 

    	30

    	 

    

 

10.4.3.Settlement.
The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement
that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party shall have the sole and exclusive
right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third
Party Claim involves equitable or other non-monetary relief, but shall not have the right to settle such Third Party Claim to the
extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the
Indemnifying Party and the Indemnified Party shall not make any admission of liability in respect of any Third Party Claim without
the prior written consent of the other party, and the Indemnified Party shall use reasonable efforts to mitigate Liabilities arising
from such Third Party Claim.

 

10.5.Insurance.
Each Party further agrees to obtain and maintain, during the Term, commercial general liability insurance, including products liability
insurance (which products liability insurance will be effective as of the commencement of the first Phase I Clinical Trial for
a Product), with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory
to the other Party) to cover its indemnification obligations under Section 10.2 or Section 10.3, as applicable, in each case with
limits of not less than [***] per occurrence and in the aggregate. Insurance shall
be procured with carriers having an A.M. Best Rating of A-VII or better.

 

		11.	MISCELLANEOUS.

 

11.1.Assignment.
Neither this Agreement nor any interest hereunder shall be assignable by a Party without the prior written consent of the other
Party, except as follows: (a) a Party may assign its rights and obligations under this Agreement by way of sale of itself or the
sale of the portion of its business to which this Agreement relates, through merger, sale of assets and/or sale of stock or ownership
interest, or (b) such Party may assign its rights and obligations under this Agreement to any of its Affiliates, provided that
such Party shall remain liable for all of its rights and obligations under this Agreement. In addition, Pfizer may assign its rights
and obligations under this Agreement to a Third Party where Pfizer or its Affiliate is required, or makes a good faith determination
based on advice of counsel, to divest a Product in order to comply with Law or the order of any Governmental Authority as a result
of a merger or acquisition. Each Party shall promptly notify the other Party of any assignment or transfer under the provisions
of this Section 11.1. This Agreement shall be binding upon the successors and permitted assigns of the Parties. Any assignment
not in accordance with this Section 11.1 shall be void.

 

11.2.Change
of Control of Collaborator. Collaborator shall notify Pfizer in writing promptly following the entering into of a definitive
agreement with respect to a Change of Control of Collaborator.

 

 

*Confidential Treatment
Requested.

    	31

    	 

    

 

11.3.Further
Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as
may be necessary or appropriate in order to carry out the purposes and intent of the Agreement.

 

11.4.Force
Majeure. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance
is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other
Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party
takes Commercially Reasonable Efforts to remove the condition. For purposes of this Agreement, “force majeure” shall
include conditions beyond the control of the Parties, including an act of God, voluntary or involuntary compliance with any regulation,
Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of
public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe.

 

11.5.Notices.
Any notice or notification required or permitted to be provided pursuant this Agreement shall be in writing and shall be deemed
given upon receipt if delivered by overnight delivery using a nationally recognized express courier service and specifying next
Business Day delivery (receipt verified), to the Parties at the following addresses:

 

All correspondence to Pfizer
shall be addressed as follows:

 

Pfizer Inc.

235 East 42nd Street

New York, New York 10017-5755

 

Attention:President, Worldwide
Research and Development

 

Copy to:Associate General Counsel,
Business Transactions

 

And

 

Stephen Murnaghan

Managing Director

CovX Technologies Ireland Limited

122 Ranelagh

Dublin 6

Ireland

 

All correspondence to Collaborator
shall be addressed as follows:

 

TheracloneSciences, Inc.

1124 Columbia Street, Suite 300

Seattle, WA 98104, USA

Attention: Chief Financial Officer

 

    	32

    	 

    

 

with a copy to:

 

Beacon Law Advisors, PLLC

801 2nd Ave., Suite
614

Seattle, WA 98104, USA

 

Attention: Noel Howe

 

11.6.Amendment.
No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.

 

11.7.Waiver.
No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by
an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver
by either of the Parties of any breach of any provision hereof by the other Party shall not be construed to be a waiver of any
succeeding breach of such provision or a waiver of the provision itself.

 

11.8.Severability.
If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall
not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such
fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement
shall be construed as if such clause had never been contained in this Agreement, and there shall be deemed substituted a provision
as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by applicable
Law.

 

11.9.Descriptive
Headings. The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing
or interpreting any of the provisions of this Agreement.

 

11.10.Export
Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from
the United States of America or other countries which may be imposed upon or related to Collaborator or Pfizer from time to time.
Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under
this Agreement or any products using such technical information to a location or in a manner that at the time of export requires
an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency
or other governmental entity.

 

11.11.Dispute
Resolution. If any dispute or disagreement arises between Pfizer and Collaborator in respect of this Agreement, the Pfizer
Alliance Manager and the Collaborator Alliance Manager shall meet and use their reasonable endeavors to resolve the dispute. If
the Alliance Managers are unable to resolve the dispute, then the Chief Scientific Officer and Vice President of Pfizer and the
Chief Executive Officer of Collaborator shall meet for the purpose of resolving such dispute. If, within a further period of 30
days, or if in any event within 90 days of initial notice of dispute, then the Parties agree that either Party may initiate litigation
to resolve the dispute.

 

    	33

    	 

    

 

Notwithstanding any provision of
this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction seeking
any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce
its rights under this Agreement. The provisions of this Section 11.11 will survive for five years from the date of termination
or expiration of this Agreement.

 

11.12.Governing
Law. This Agreement, and all claims arising under or in connection therewith, shall be governed by and interpreted in accordance
with the substantive laws of the State of New York, without regard to conflict of law principles thereof.

 

11.13.Consent
to Jurisdiction. Each Party to this Agreement hereby (a) irrevocably submits to the exclusive jurisdiction of the state courts
of the State of New York or the United States District Court for the Southern District of New York for the purpose of any and all
actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement.

 

11.14.Entire
Agreement. This Agreement constitutes and contains the complete, final and exclusive understanding and agreement of the Parties
and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written,
between the Parties respecting the subject matter hereof and thereof, including that certain Non-Disclosure Agreement between the
Parties dated April 7, 2010 which is hereby terminated effective as of the Execution Date, provided that such Non-Disclosure
Agreement will continue to govern the treatment of Confidential Information disclosed by the Parties prior to the Execution Date
in accordance with its terms.

 

11.15.Independent
Contractors. Both Parties are independent contractors under this Agreement. ‘Nothing herein contained shall be deemed
to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or
employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other
Party. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities
in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.

 

11.16.Counterparts.
This Agreement may be executed in three counterparts, each of which shall be an original and each of which shall constitute together
the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which shall be binding when received
by the applicable Party.

 

    	34

    	 

    

 

11.17.No
Third Party Rights or Obligations. No provision of this Agreement shall be deemed or construed in any way to result in the
creation of any rights or obligation in any Person not a Party to this Agreement. However, Pfizer may decide, in its sole discretion,
to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that Pfizer shall remain
liable hereunder for the performance by any such Affiliates of any such obligations.

 

(Signature page follows.)

 

    	35

    	 

    

IN WITNESS WHEREOF,
authorized representatives of the Parties have duly executed this Agreement as of the Execution Date to be effective as of the
Effective Date.

 

	PFIZER INC.	 	THERACLONE SCIENCES, INC.
	 	 	 
	 	 	 
	By 	/s/ Rodney Lappe	 	By 	/s/ Steven Gillis
	Name:Rodney Lappe	 	Name:Steven Gillis
	Title:  Sr Vice-President, WRD	 	Title:  Chairman, Acting CEO
	 	 	 
	 	 	 
	 	 	 
	COVX TECHNOLOGIES IRELAND 

LIMITED	 	 
	 	 	 
	 	 	 
	By 	/s/ Stephen Murnaghan	 	 
	Name:Stephen Murnaghan	 	 
	Title:  Managing Director	 	 

 

 

 

Signature Page to Research Collaboration
and License Agreement

    	36

    	 

    
 

Exhibit A

 

Defined Terms

 

“Affiliate”
means, with respect to any Person, any other Person that controls, is controlled by or is under common control with such Person.
(b) possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of any such Person
(whether through ownership of securities or other ownership interests, by contract or otherwise).

 

“Antibody”
means any antibody that targets a Target and either (a) is delivered by Collaborator to Pfizer under the Research Plan and meets
the specific criteria described in the Research Plan, or (b) is a fragment, variant, modification or derivative of any such antibody
described in (a) that is created, made or discovered by or on behalf of Pfizer or its Affiliate or sublicensee.

 

“Bankruptcy Code”
means Section 101(35A) of Title 11 of the United States Code, as amended.

 

“Biological License
Application” or “BLA” means a Biological License Application, or an New Drug Application submitted to the FDA
in the United States in accordance with the FD&C Act with respect to a biological products or any analogous application or
submission with any Regulatory Authority outside of the United States.

 

“Calendar Quarter”
means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31.

 

“Calendar Year”
means any calendar year.

 

“Change of Control”
means, with respect to a Party (a) the acquisition of beneficial ownership, directly or indirectly, by any Person of securities
or other voting interest of such Party representing a majority or more of the combined voting power of such Party’s then
outstanding securities or other voting interests, (b) any merger, reorganization, consolidation or business combination involving
such Party with a Third Party that results in the holders of beneficial ownership of the voting securities or other voting interests
of such Party immediately prior to such merger, reorganization, consolidation or business combination ceasing to hold beneficial
ownership of at least (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization,
consolidation or business combination, (c) any sale, lease, exchange, contribution or other transfer (in one transaction or a series
of related transactions) of all or substantially all of the assets of such Party to which this Agreement relates, other than a
sale or disposition of such assets to an Affiliate of such Party or (d) the approval of any plan or proposal for the liquidation
or dissolution of such Party (other than in circumstances where such Party is deemed a Debtor pursuant to Section 9.8).

 

“Clinical Trial”
means a human clinical study conducted on sufficient numbers of human subjects that is designed to (a) establish that a pharmaceutical
product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the pharmaceutical product for its
intended use, and to define warnings, precautions and adverse reactions that may be associated with the pharmaceutical product
in the dosage range to be prescribed or (c) support Regulatory Approval of such pharmaceutical product or label expansion of such
pharmaceutical product. Without limiting the foregoing, Clinical Trial includes any Phase I Clinical Trial, Phase II Clinical Trial
or Phase III Clinical Trial.

 

    	End Notes -1

    	 

    

 

“Collaborator
Know-How” means any Know-How that (a) is Controlled by Collaborator or any of its Affiliates as of the Effective Date or
that comes into the Control of Collaborator or any of its Affiliates during the Term (other than through the grant of a license
by Pfizer) and (b) relates to any Antibody or Product or to the Development, Manufacture, Commercialization or use of any of the
foregoing.

 

“Collaborator
Patent Right” means any Patent Right that (a) is Controlled by Collaborator or any of its Affiliates as of the Effective
Date (including the Collaborator Patent Rights listed in Exhibit B or comes into the Control of Collaborator or any of its Affiliates
during the Term (other than through the grant of a license by Pfizer) and (b) claims or discloses any (i) Antibody or Product (including
the composition of matter thereof), (ii) method of making any Antibody or Product or materials used in any method of making any
Antibody or Product, or (iii) methods of using any Antibody or Product.

 

“Collaborator
Platform” means Collaborator’s I-Startm platform technology and antibody repertoire array for the discovery
of antibodies.

 

“Collaborator
Platform Know-How” means any Know-How that relates to the Collaborator Platform.

 

“Collaborator
Platform Patent Right” means any Patent Right that claims or discloses the Collaborator Platform or any portion thereof,
or methods of using the Collaborator Platform.

 

“Collaborator
Platform Technology” means the Collaborator Platform Patent Rights and the Collaborator Platform Know-How.

 

“Collaborator
Technology” means the Collaborator Patent Rights and Collaborator Know-How.

 

“Collaborator
Third Party Agreement” means any agreement between Collaborator (or any of its Affiliates) and any Third Party that relates
to any of the Collaborator Technology.

 

“Combination
Product” means a Product containing an Antibody and one or more other therapeutically active ingredients.

 

“Commercialize”
or “Commercializing” means to market, promote, distribute, offer for sale, sell, have sold, import, have imported,
export, have exported or otherwise commercialize a compound or product. When used as a noun, “Commercialization” means
any and all activities involved in Commercializing.

 

“Commercially
Reasonable Efforts” means, with respect to the efforts to be expended by a Party with respect to any objective, those reasonable,
good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar
circumstances. With respect to any efforts relating to the Development, Regulatory Approval or Commercialization of a Antibody
or Product by a Party, generally or with respect to any particular country in the Territory, a Party will be deemed to have exercised
Commercially Reasonable Efforts if such Party has exercised those efforts normally used by such Party, in the relevant country,
with respect to a compound, product or product candidate, as applicable (a) of similar modality Controlled by such Party, or (b)
(i) to which such Party has similar rights, (ii) which is of similar market potential in such country, and (iii) which is at a
similar stage in its development or product life cycle, as the Antibody or Product, in each case, taking into account all Relevant
Factors in effect at the time such efforts are to be expended. Further, to the extent that the performance of a Party’s obligations
hereunder is adversely affected by the other Party’s failure to perform its obligations hereunder, the impact of such performance
failure will be taken into account in determining whether such Party has used its Commercially Reasonable Efforts to perform any
such affected obligations.

 

    	End Notes -2

    	 

    

 

“Confidential
Information” means, with respect to each Party, all Know-How or other information, including proprietary information and
materials (whether or not patentable) regarding or embodying such Party’s technology, products, business information or objectives,
that is communicated by or on behalf of the Disclosing Party to the Receiving Party or its permitted recipients. Confidential Information
does not include any Know-How or other information that (a) was already known by the Receiving Party (other than under an obligation
of confidentiality to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing Party, (b) was generally
available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party, (c) became
generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than
through any act or omission of the Receiving Party in breach of its obligations under this Agreement, (d) was disclosed to the
Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party
not to disclose such information to the Receiving Party or (e) was independently discovered or developed by or on behalf of the
Receiving Party without the use of any Confidential Information belonging to the Disclosing Party. The terms and conditions of
this Agreement shall be considered Confidential Information of both Parties.

 

“Control”
or “Controlled” means with respect to any intellectual property right or material (including any Patent Right, Know-How
or other data, information or material), the ability (whether by sole, joint or other ownership interest, license or otherwise,
other than pursuant to this Agreement) to, without violating the terms of any agreement with a Third Party, grant a license or
sublicense or provide or provide access or other right in, to or under such intellectual property right or material.

 

“Develop”
or “Developing” means to discover, research or otherwise develop a process, compound or product, including conducting
non-clinical and clinical research and development activities. When used as a noun, “Development” means any and all
activities involved in Developing.

 

“Development
Event” means each Development event listed in the table that appears in Section 3.4.

 

“Effective Date”
means the later of the Execution Date.

 

    	End Notes -3

    	 

    

 

“FD&C Act”
means the United States Federal Food, Drug, and Cosmetic Act, as amended; and the rules and regulations promulgated thereunder.

 

“FDA” means
the United States Food and Drug Administration or any successor agency thereto and any analogous agency or Regulatory Authority
outside of the United States.

 

“First Commercial
Sale” means, with respect to any Product and with respect to any country of the Territory, the first sale of such Product
by Pfizer or an Affiliate or Sublicensee of Pfizer to a Third Party in such country after such Product has been granted Regulatory
Approval by the appropriate Regulatory Authority(ies) for such country.

 

“GAAP”
means United States generally accepted accounting principles, consistently applied.

 

“Governmental
Authority” means any court, agency, department, authority or other instrumentality of any national, state, county, city or
other political subdivision.

 

[***]

 

“ND” means
an Investigational New Drug Application submitted under the FD&C Act, or an analogous application or submission with any analogous
agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct Clinical Trials.

 

“Joint Research
Committee” or “JRC” means the steering committee described in Section 4.4.2(a).

 

“Know-How”
means any proprietary invention, discovery, development, data, information, process, method, technique, material or other know-how,
whether or not patentable, and any physical embodiments of any of the foregoing.

 

“Law” means
any law, statute, rule, regulation, order, judgment or ordinance of any Governmental Authority.

 

“Major EU Market
Country” means any of France, Germany, Italy, Spain or the United Kingdom.

 

“Major Market
Country” means any Major EU Market Country, Japan or the United States.

 

“Manufacture”
or “Manufacturing” means to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance
testing, release, ship or store a compound or product or any component thereof. When used as a noun, “Manufacture”
or “Manufacturing” means any and all activities involved in Manufacturing a compound or product or any component thereof.

 

“Net Sales”
means: (a) with respect to a Product that is not a Combination Product, gross receipts from sales by Pfizer and its Affiliates
and Sublicensees of such Product to Third Parties in the Territory, less in each case (i) bad debts and (ii) sales returns and
allowances actually paid, granted or accrued, including trade, quantity and cash discounts and any other adjustments, including
those granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, ‘rebates,
chargeback rebates, reimbursements or similar payments granted or given to wholesalers or other distributors, buying groups, health
care insurance carriers, chain pharmacies, mass merchandisers, staff model HMO’s, pharmacy benefit managers or other institutions,
adjustments arising from consumer discount programs or other similar programs, customs or excise duties, sales tax, consumption
tax, value added tax, and other taxes (except income taxes) or duties relating to sales, any payment in respect of sales to the
United States government, any state government or any foreign government, or to any other Governmental Authority, or with respect
to any government-subsidized program or managed care organization, and freight and insurance (to the extent that Pfizer, its Affiliates
or its Sublicensees bear the cost of freight and insurance for the Product); and (b) with respect to a Product that is a Combination
Product, that percentage of the Net Sales of such Combination Product (as determined in accordance with clause (a)) as Pfizer may
reasonably determine based on the wholesale acquisition costs of the Antibody contained in a Product and the other active ingredient(s)
in such Combination Product when sold separately, or other similar approach. Net Sales shall be determined from books and records
maintained in accordance with GAAP, as consistently applied by Pfizer with respect to sales of the Product.

 

 

 

*Confidential Treatment
Requested.

    	End Notes -4

    	 

    

 

“Patent Rights”
means any and all (a) issued patents, (b) pending patent applications, including all provisional applications, substitutions, continuations,
continuations-in-part, divisions and renewals, and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations
and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent
term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) other
forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts
of any of the foregoing.

 

“Person”
means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization,
including a government or political subdivision or department or agency of a government.

 

“Pfizer Diligence
Obligations” means Pfizer’s Development and Regulatory Approval diligence obligations under Section 5.2.1 and Pfizer’s
Commercialization diligence obligations under Section 5.2.2.

 

“Pfizer Know-How”
means any Know-How, including all Sponsored Research Know- How that (a) is Controlled by Pfizer on the Effective Date or that comes
into the Control of Pfizer during the Term (other than through the grant of a license by Collaborator) and (b) relates to one or
more Antibodies or Products or the Development, Manufacture, Commercialization or use of any of the foregoing.

 

“Pfizer Patent
Right” means any Patent Right, including all Sponsored Research Patent Rights , that (a) is Controlled by Pfizer on the Effective
Date or that comes into the Control of Pfizer during the Term (other than through the grant of a license by Collaborator) and (b)
claims or discloses any (a) Antibody or Product (including the composition of matter thereof), (b) method of making any Antibody
or Product or (c) method of using any Antibody or Product.

 

    	End Notes -5

    	 

    

 

“Pfizer Quarter”
means each of the four (4) thirteen (13) week periods (a) with respect to the United States, commencing on January 1 of any Pfizer
Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer
Year.

 

“Pfizer Technology”
means the Pfizer Patent Rights and Pfizer Know-How.

 

“Pfizer Year”
means the twelve month fiscal periods observed by Pfizer (a) commencing on January 1 with respect to the United States and (b)
commencing on December 1 with respect to any country in the Territory other than the United States.

 

“Phase I Clinical
Trial” means a Clinical Trial that generally provides for the first introduction into humans of a pharmaceutical product
with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of such product,
in a manner that .is generally consistent with 21 CFR § 312.21(a), as amended (or its successor regulation), or similar clinical
study in a country other than the United States, provided, however, a Phase I Clinical Trial does not include any study
generally characterized by the FDA as an “exploratory IND study” in CDER’s Guidance for Industry, Investigators,
and Reviewers Exploratory IND Studies, January 2006, irrespective of whether or not such study is actually performed in the
United States or under an IND.

 

“Phase 2b Trial”
means, with respect to the US, the second phase of human clinical trials of a Licensed Product to gain evidence of the efficacy
in one or more indications and expanded evidence of the safety of such Licensed Product and an indication of the dosage regimen
required, as described in 21 C.F.R.§ 312.21(b), as may be amended, or, with respect to any other country or jurisdiction,
the equivalent of such a clinical trial in such other country or jurisdiction.

 

“Phase III Clinical
Trial” means a pivotal Clinical Trial with a defined dose or a set of defined doses of a pharmaceutical product designed
to ascertain efficacy and safety of such product, in a manner that is generally consistent with 21 CFR § 312.21(c), as amended
(or its successor regulation), for the purpose of enabling the preparation and submission of an BLA, or similar clinical study
in a country other than the United States.

 

“Price Approval”
means, in any country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical
products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement
authorization or pricing approval or determination (as the case may be).

 

“Product”
means any pharmaceutical product ‘containing one or more Antibodies whose manufacture, use, sale, offer for sale or importation
by Pfizer in a given country in the Territory is covered by a Valid Claim under a Collaborator Patent Right or Sponsored Research
Patent Right in such country.

 

“Regulatory Approval”
means all technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of BLAs,
supplements and amendments, pre- and post- approvals, pricing and third party reimbursement approvals, and labeling approvals)
of any Regulatory Authority, necessary for the use, Development, Manufacture, and Commercialization of a pharmaceutical product
in a regulatory jurisdiction. [***]

 

*Confidential Treatment
Requested.

    	End Notes -6

    	 

    

 

“Regulatory Authority”
means, with respect to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission,
the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau,
commission, council or other Governmental Authority involved in the granting of a Regulatory Approval.

 

“Relevant Factors”
means all relevant factors that may affect the Development, Regulatory Approval or Commercialization of a Antibody or Product,
including (as applicable): actual and potential issues of safety, efficacy or stability; product profile (including product modality,
category and mechanism of action); stage of development or life cycle status; actual and projected Development, Regulatory Approval,
Manufacturing, and Commercialization costs; any issues regarding the ability to Manufacture or have Manufactured any Antibody or
Product; the likelihood of obtaining Regulatory Approvals (including satisfactory Price Approvals); the timing of such approvals;
the current guidance and requirements for Regulatory Approval for the Product and similar products and the current and projected
regulatory status; labeling or anticipated labeling; the then-current competitive environment and the likely competitive environment
at the time of projected entry into the market; past performance of the Product or similar products; present and future market
potential; existing or projected pricing, sales, reimbursement and profitability; pricing or reimbursement changes in relevant
countries; proprietary position, strength and duration of patent protection and anticipated exclusivity; and other relevant scientific,
technical, operational and commercial factors.

 

“Representatives”
means (a) with respect to Pfizer, Pfizer, its Affiliates, its Sublicensees and each of their respective officers, directors, employees,
consultants, contractors and agents and (b) with respect to Consultant, Consultant, its Affiliates and each of their respective
officers, directors, employees, consultants, contractors and agents.

 

“Research Plan”
means the research plan attached hereto as Exhibit C or D, as it may be amended from time to time pursuant to Section 4.2.

 

“Research Term”
means the period of time beginning on the Effective Date and expiring on the third anniversary thereof or such later date as may
be established pursuant to Section 4.5, unless earlier terminated pursuant to the terms of this Agreement.

 

“Royalty Term”
means, with respect to any particular Product in any particular country in the Territory, the latter of (i) the period during which
the sale, offer for sale or importation of such Product in such country is covered by a Valid Claim of the Sponsored Research Patent
Rights or Collaborator Patent Rights covering such Product in such country, or (ii) 10 years from First Commercial Sale. For the
avoidance of doubt, the Royalty Term for a given Product in a given country in the Territory (a) will not begin until the First
Commercial Sale of such Product in such Country and (b) if not previously expired, will expire immediately upon expiration or termination
of this Agreement.

 

“Sponsored Research
Technology” means the Sponsored Research Patent Rights and Sponsored Research Know-How as those terms are defined in section
6.1.2 of this agreement.

    	End Notes -7

    	 

    

 

“Sublicensee”
means any Person to whom Pfizer grants or has granted, directly or indirectly, a sublicense of rights licensed by Collaborator
to Pfizer under this Agreement.

 

“Target”
means the therapeutic target [***]. In the event that a second [***]
Target or fourth Target (or both) is identified by Pfizer and the Parties discuss and mutually agree upon a research plan (in accordance
with Section 4.1) for such targets then, at such time, such target shall become a “Target”. “Territory”
means world-wide.

 

“Third Party”
means any Person other than Pfizer, Collaborator or their respective Affiliates.

 

“Trademark”
means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of
origin or ownership, including the goodwill and activities associated with each of the foregoing.

 

“Valid Claim”
means, with respect to a particular country, a claim of an issued and unexpired Collaborator Patent Right or Sponsored Research
Patent Right that (a) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other Governmental
Authority of competent jurisdiction, which decision is unappealed or unappealable within the time allowed for appeal and (b) has
not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise.

 

The following terms
are defined in the section of this Agreement listed opposite each term:

 

	Defined Term	Section in Agreement
	Additional Third Party License	3.6.3(a)
	Agreement	Preamble
	Alliance Managers	4.4.1
	Collaborator	Preamble
	Collaborator Alliance Manager	4.4.1
	Collaborator Indemnified Party	10.2
	Collaborator JRC Members	4.4.2(a)
	Continuation Product	9.7.1(a)(ii)(A)
	Debtor	9.8
	Designated Countries	6.2.1(a)
	Development Payment	3.4
	Diligence Issue	5.2.5
	Disclosed Third Party Agreement	8.3.9
	Disclosing Party	7.1
	[Execution Date]	Preamble
	Indemnified Party	10.4
	Indemnifying Party	10.4
	Infringement Claim	6.2.4

 

 

*Confidential Treatment
Requested.

    	End Notes -8

    	 

    

 

	JRC Chair	4.4.2(b)
	Liability	10.2
	Licensed Activities	6.2.3(a)
	Litigation Conditions	10.4.2
	Marginal Royalty Rate	3.6.1
	Non-Disclosing Party	7.5.2
	Party or Parties	Preamble
	Permitted Activities	4.7.2
	Per Product Annual Net Sales	3.6.1
	Pfizer	Preamble
	Pfizer Alliance Manager	4.4.1
	Pfizer Indemnified Party	10.3
	Pfizer JRC Members	4.4.2(a)
	Pfizer Material Improvements	4.7.6
	Pfizer Materials	4.7.1
	Receiving Party	7.1
	Research Program	4.1
	Review Period	7.5.2
	Sales Milestone Payment	3.5
	Sponsored Research Know-How	6.1.2
	Sponsored Research Patent Right	6.1.2
	Term	9.4
	Third Party Claim	10.4.1
	Third Party IP Rights	6.2.3(b)
	Total Annual Net Sales	3.5

 

    	End Notes -9

    	 

    

Exhibit B

 

Collaborator Patent Rights

 

None

 

    	End Notes -10

    	 

    

Exhibit C

 

[***]

 

 

 

 

*Confidential Treatment
Requested.

    	End Notes -11

    	 

    

Exhibit D

 

[***]

 

 

*Confidential Treatment
Requested.

    	End Notes -12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]